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ABSTRACT
Patients with renal failure react inappropriately to many drugs and have an increased
incidence of side effects which may be due to changes in drug absorption, distribu¬
tion, metabolism and excretion. Active or inactive polar drug metabolites which are
normally excreted in the urine will accumulate and patients with end stage disease
may depend completely on haemodialysis or continuous ambulatory peritoneal dialysis
(CAPD) for their elimination. Despite several single dose studies little information
exists about the disposition of paracetamol and frusemide during chronic dosing in
patients with renal failure including those maintained on dialysis and this has been
investigated further in the present study.
Six patients with end stage disease maintained on CAPD were given 1 g of oral para¬
cetamol. Absorption was normal but plasma concentrations of the glucuronide and
sulphate conjugates were greatly increased with little change during the observation
period. The extraction capacity of the peritoneal membrane was low and the perito¬
neal clearance was <7 ml.min"1 for paracetamol and these conjugates. The disposition
of paracetamol was then compared in 6 healthy volunteers and 6 conservatively
managed patients with chronic renal failure taking 1 g 3 times a day for 10 days. The
daily plasma concentrations of unchanged paracetamol were significantly higher in the
patients (3.1 +0.6 versus 1.1 +0.3 mg.l"1) suggesting enterohepatic recycling with
regeneration by hydrolysis of the conjugates and reabsorption of the parent compound.
There was marked accumulation of the glucuronide conjugate (87.0 ±69.0 versus
3.0+0.5 mg.1"1 in the volunteers) which was dependent on the severity of the renal
failure. The concentrations of the sulphate conjugate did not accumulate as predicted
(25.0 +19.0 mg.r1) possibly due to depletion of inorganic sulphate. Patients with end
stage renal failure maintained on haemodialysis were also treated with a similar
regime of paracetamol. Neither the glucuronide nor sulphate conjugate reached the
predicted mean plasma concentrations of 569 ± 150 and 434 ±92 mg.l"1 and extrac¬
tion ratios of paracetamol and its conjugates were less than 50 %.
The diuretic response of frusemide is related to urinary drug concentration with
marked interindividual variation. Single doses of oral and intravenous frusemide
(40 mg) were given to 8 healthy male volunteers and 11 patients with renal failure
maintained on CAPD (80 mg). In the volunteers, the absorption rate was variable and
the bioavailability was 53.6 ±21.3 %. Only one half of the intravenous dose and one
third of the oral dose was available for pharmacological action as judged by the uri¬
nary recovery. Absorption was markedly delayed (128 ±58 versus 90 ±16 min) but
more complete (70.1 ±13.1 %) in the patients. The drug was dependent on non-renal
clearance for elimination (61.9 ±20.4 ml.min"1) and the peritoneal clearance was
negligible. Ten conservatively managed patients with chronic renal failure received 80
to 500 mg frusemide . Despite the markedly reduced renal clearance (11.2 ±19.4
versus 76.5 ±18.0 ml.min"1 in the volunteers) no accumulation was observed and
absorption was normal. The urinary recovery of frusemide was dependent on residual
renal function. The non-renal clearance was also significantly reduced (43.8 ±12.2
versus 61.4 ±11.8 ml.min"1 in the volunteers) but the mechanisms are unknown.
Finally, the effects of paracetamol on the actions of frusemide which are thought to
depend on prostaglandin synthesis were studied in healthy female volunteers. Para¬
cetamol pretreatment significantly reduced the frusemide-induced increase in renal
excretion of vasodilator prostaglandins and the rise in plasma renin activity. There
was no significant effect on the natriuresis or diuresis.
Some changes in the disposition of paracetamol and frusemide in patients with chronic
renal failure were as predicted. However, findings such as the failure of predicted
accumulation of paracetamol conjugates, the increased plasma concentrations of
unchanged paracetamol, the delayed absorption of frusemide (but not paracetamol) in
patients on CAPD and the decreased non-renal clearance of frusemide in conservative¬
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Patients with impaired renal function often exhibit inappropriate responses to the usual
therapeutic doses of drugs and there is a higher incidence than expected of adverse
reactions in such patients (Smith et al., 1966 and Jick, 1977). Although the reasons
are probably multifactorial, a major determinant is thought to be the alteration in drug
disposition which occurs in chronic renal failure (Verbeeck et al., 1981 (a)). This may
necessitate a modification of dose (Bennett et al., 1983) particularly when the drug is
normally excreted unchanged to a significant extent. Furthermore, pharmacologically
active drug metabolites which are removed by urinary excretion will accumulate
during regular administration in chronic renal failure leading to a situation analogous
to the administration of another unknown drug (Drayer, 1977 and Verbeeck et al.,
1981 (a)).
The changes in disposition of drugs which may occur in chronic renal failure include
alterations in drug absorption, distribution, metabolism and/ or excretion. For exam¬
ple, gastrointestinal disturbances associated with renal failure such as nausea, vomit¬
ing, diarrhoea and oedema of the gastrointestinal tract may affect drug absorption
(Lee and Marbury, 1984). Despite this, little information is available regarding the
bioavailability of specific drugs in patients with renal failure (Turnheim, 1991). There
are reports however of decreased intestinal absorption of frusemide, pindolol and D-
xylose in patients with renal failure (Tilstone and Fine, 1978, Chau et al., 1977 and
Craig et al., 1983). Patients may be maintained on a variety of medication to treat not
only the renal failure but also other conditions. For example, antacids may be pre¬
scribed for gastrointestinal symptoms and to lower serum phosphate levels. They may
alter the absorption of other drugs by several mechanisms including delayed gastric
emptying, simple adsorption of the drug, complex formation between the metal cation
and drug and alteration of the gastrointestinal pH (Hurwitz, 1977).
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Drug distribution can also be altered significantly in patients with renal disease as a
result of reduced binding to plasma proteins (Gibaldi, 1977). For acidic drugs, it is
generally accepted that this can be explained by the combination of a decrease in
serum albumin concentrations and a decrease in the binding capacity of the albumin
due to a change in molecular configuration or to competition for binding by retained
anionic metabolites in uraemia (Gibaldi, 1977 and Reidenberg and Drayer, 1984).
Drugs that are organic bases may also have decreased binding to plasma proteins in
patients with renal disease (Reidenberg, 1977). Drugs which seem to bind normally
such as d-tubocurarine and indomethacin may have more than one protein binding site
(Ghoeneim et al., 1973 and Sjoholm et al., 1976) whereas others which have de¬
creased binding such as diazepam appear to bind to one only site on albumin (Sjoholm
et al., 1976). Decreased plasma protein binding of drugs in patients with chronic
renal failure may lead to a higher fraction of unbound drug available for pharmaco¬
logical action but may also lead to enhanced clearance since the rates of some elimina¬
tion processes are proportional to the unbound concentration of drug (Gibaldi, 1977).
The majority of drugs are not excreted unchanged but are transformed to metabolites
which are then excreted. Renal failure may alter the rate as well as the extent of this
biotransformation (Reidenberg, 1977) which often takes place in two phases. In phase
I reactions the parent drug is converted to a more polar metabolite by oxidation,
reduction or hydrolysis (Drayer, 1974). In phase II, the phase I metabolite or the drug
itself reacts with an endogenous substrate such as glucuronic acid, acetyl CoA, gly¬
cine or inorganic sulphate to yield a conjugated metabolite which is then excreted in
the urine and/or bile (Glauser, 1974).
oxidation
reduction conjugation
Drug Phase I Phase II metabolites
hydrolysis acetylation
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Most of these reactions are carried out in the liver by microsomal enzymes which are
located in the smooth endoplasmic reticulum of the hepatic cells and the more polar
metabolites are more easily excreted in the urine than the parent compounds. Drug
metabolites may be biologically active or inactive. The former may account for the
entire therapeutic activity and toxicity of the parent compound (Drayer, 1977).
The effect of renal failure on hepatic metabolism in animals has been studied by
several investigators. A decreased activity of the mixed-function oxidase activity in
liver microsomes of uraemic rats was found by Leber and Schiitterle (1972), and
Patterson and Cohn (1984). However, in man many drugs that are metabolised by
microsomal oxidation are eliminated normally in patients with chronic renal failure
(Reidenberg, 1977). Indeed, the microsomal oxidation of some drugs is accelerated in
uraemia and these include phenytoin (Letteri et al., 1971 and Odar-Cederlof and
Borg3, 1974), antipyrine (Lichter et al., 1973 and Maddocks et al., 1975) and pro¬
pranolol (Bianchetti et al., 1976). Although decreased plasma protein binding may
explain the increased clearance of phenytoin in uraemia, antipyrine is only slightly
bound under normal conditions and the binding of propranolol is unaffected by renal
disease (Reidenberg, 1977). Induction of oxidation by substances in the diet or other
drugs is possible (Reidenberg, 1977 and Loub et al., 1975).
Both reduction of Cortisol and hydrolysis of procaine appear to be slower in patients
with chronic renal failure (Englert et al., 1958 and Reidenberg et al., 1972) while
conjugation of paracetamol with glucuronide and sulphate is reported to be normal
(Lowenthal et al., 1976). Acetylation of p-aminosalicylate may be reduced in patients
with impaired renal function (Ogg et al., 1968).
Changes in renal drug metabolism must also be considered as the role of the kidneys
in drug metabolism is increasingly recognised (Anders, 1980 and Turnheim, 1991).
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For example, the osteodystrophy of chronic renal disease is probably a result of im¬
paired 1-hydroxylation of 25-hydroxycholecalciferol in the kidneys (Fraser and
Kodicek, 1970). Furthermore, the increased response of patients with renal insuffi¬
ciency to insulin is not only a result of reduced extrarenal insulin metabolism but also
of diminished renal metabolism of insulin (Rabkin et al., 1984).
Reduced renal function will lead to a reduction in the rate of excretion of many drugs
via the kidneys. Furthermore, marked accumulation of active or inactive metabolites
would be expected to occur under these circumstances (Verbeeck et al., 1981 (a)). For
example, allopurinol is rapidly metabolised to oxipurinol which has xanthine oxidase inhibitory
activity and significantly contributes to the therapeutic effect of allopurinol in man.
Patients with renal failure exhibit a higher incidence of side effects during allopurinol
therapy and it has been suggested that this may be due to accumulation of the active
metabolite (Elion et al., 1968). The hypothesis has been supported by the finding of
greatly elevated plasma concentrations of oxipurinol in patients with renal failure
(Hande and Stone, 1979).
Marked accumulation of normally inactive metabolites should also occur with regular
administration in patients with chronic renal failure. The consequences of such
accumulation are unknown (Prescott et al., 1989). Of particular importance in this
regard is glucuronidation which produces a highly polar metabolite which is excreted
in the urine and/or bile (Verbeeck et al., 1981 (a)). In renal failure the biliary route of
excretion may become more important and under these circumstances the possibility
exists for hydrolysis of the conjugate by the gastrointestinal flora with liberation of the
parent compound which can be then reabsorbed (Verbeeck et al., 1981 (a)). Oxaze¬
pam is eliminated in man almost entirely by formation of the glucuronide conjugate
which is normally eliminated in the urine (Alvdn and Odar-Cederlof, 1978). Enter-
ohepatic recycling has been proposed to explain the prolonged elimination half life of
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oxazepam which occurs during multiple dosing in patients with renal failure and in
support of this the faecal excretion of the glucuronide conjugate was markedly in¬
creased in such patients (Odar-Cederlof et al., 1977).
The disposition of drugs is further altered in patients with end-stage renal failure
maintained on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
Dialysis essentially involves the juxtaposition of a semipermeable membrane between
a flowing stream of blood and an appropriate rinsing solution (Maher, 1977). In
haemodialysis the semipermeable membrane is located in a dialysis machine and in
CAPD the patient's own peritoneal membrane is used. Waste products from the pa¬
tient's blood diffuse across the membrane and are eliminated in the dialysate (Gabriel,
1988). Drugs and drug metabolites can also be eliminated in this way (Lee and
Marbury, 1984 and Paton et al., 1985).
The extent of removal of a drug during haemodialysis may be sufficient to require a
dosage supplement to ensure adequate therapeutic efficacy (Lee and Marbury, 1984).
Numerous factors affect drug removal during haemodialysis and these include:
(1) Physiochemical properties of the drug such as the molecular weight and water
solubility.
(2) The mechanical properties of the dialysis system such as the surface area, porosity
and thickness of the dialyser membrane and the geometry of the membrane supports.
(3) The blood and dialysate flow rates.
(4) Pharmacokinetic factors such as volume of distribution, intrinsic metabolic clear¬
ance, protein binding and red blood cell partition (Lee and Marbury, 1984).
When patients undergo dialysis there may be depletion of drugs administered for
therapeutic purposes and dosage may have to be increased. Examples include amino-
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glycoside and cephalosporin antibiotics (Maher, 1977). If the intrinsic non-renal or
metabolic clearance of a drug is large, the contribution of haemodialysis to the total
clearance is likely to be much less and the effect on the overall rate of removal will be
minimal. Such drugs include the tricyclic antidepressants (Bickel, 1975).
CAPD is a commonly used alternative to haemodialysis in the treatment of end-stage
renal failure. Peritonitis is the most frequent complication of the procedure and the
need to administer intraperitoneal antibiotics to treat the condition has stimulated a
number of pharmacokinetic studies of these drugs (Keller et al., 1990). There have
been relatively few studies with other drugs particularly in relation to removal by the
peritoneal route (Keller et al., 1990). Factors which influence the peritoneal clearance
of drugs are the volume of distribution and the degree to which the drug is bound to
plasma proteins. Thus, prerequisites for rapid drug elimination during CAPD include
a small volume of distribution, low plasma protein binding and little non renal or
residual renal clearance (Paton et al., 1985 and Keller et al., 1985). The low effec¬
tive flow rate of the peritoneal effluent of approximately 7 ml.min"1 is an important
limiting factor (Keller et al., 1990).
Therefore drug disposition may be altered in many ways in patients with impaired
renal function. Two of the most commonly used medications in patients with chronic
renal failure are the analgesic paracetamol and the loop diuretic frusemide. Both drugs
are used frequently and often on a regular basis in such patients.
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Paracetamol
Paracetamol (acetaminophen, N-acetyl-para-aminophenol, 4-hydroxy-acetanilide, Fig.
1.1) is frequently recommended as a mild, relatively safe analgesic for patients with
chronic renal failure. It is available without prescription in many countries and there
has been a marked increase in its use in recent years with a corresponding decline in
the use of aspirin (Spooner and Harvey, 1976).
The antipyretic properties of the aniline derivatives were investigated following the
discovery in the late 19th century that acetanilide lowered the body temperature of
patients with fever. Acetanilde and phenacetin were introduced into clinical practice in
1886 and 1887 respectively and paracetamol was first used clinically as an anti¬
pyretic/analgesic by Von Mering in 1893. (Smith, 1958). Paracetamol attracted little
attention, however, until the discovery that it was the major metabolite of both aceta¬
nilide and phenacetin (Brodie and Axelrod, 1948 and 1949, Fig. 1.1) and that it had
similar analgesic potency (Flinn and Brodie, 1948). It was erroneously concluded that
the analgesic and antipyretic properties of acetanilide and phenacetin were mainly due
to their conversion to paracetamol (Fig 1.1).
Paracetamol has a molecular weight of 151.2 and it is a moderately water and lipid
soluble weak organic acid with a pKa of 9.5. It is thus largely un-ionised over the
physiological pH range (Forrest et al., 1982). Although it has antipyretic and analge¬
sic actions similar to aspirin it is said to have only a weak antiinflammatory action
(Beaver, 1965). Although most antipyretic analgesics are known to act by inhibition of
prostaglandins synthesis, paracetamol has been considered in the past to exert only a
weak inhibitory effect (Brune, 1983). The administration of paracetamol to healthy
female volunteers under conditions of controlled sodium intake, however, caused
significant reduction in PGE2 and sodium excretion similar to that induced by indome-












Fig 1.1. Chemical structure of aniline and its derivatives acetanilide, phenacetin and
paracetamol.
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In healthy volunteers paracetamol is rapidly absorbed from the gastrointestinal tract
but a variable proportion is lost through first-pass metabolism (Chiou, 1975, Perucca
and Richens, 1979, Rawlins et al., 1977). Oral bioavailability does not increase with
larger doses and is about 75 % (Clements et al., 1984). Absorption depends on the
rate of gastric emptying (Heading et al., 1973) and animal studies have shown that it
occurs rapidly from the small intestine (Bagnall et al., 1979). Mean maximum plasma
concentrations in fasting volunteers have been noted at 22 min (Nimmo et al., 1975),
20 min (McGilveray and Mattok, 1972), 21 min (Prescott et al., 1989), 60 min
(Dordoni et al., 1973) and 1.4 h (Heading et al., 1973) depending on the dosage form
and conditions. There may be as much as an 80 fold range in plasma concentrations
1 h after the ingestion of a therapeutic dose of tablets (Prescott, 1974) and the rate of
absorption from solid dosage forms may vary by up to 50 % from one occasion to
another (Richter and Smith, 1974).
Paracetamol distributes throughout most tissues and fluids reaching a tissue : plasma
concentration ratio of about unity in all tissues except fat and cerebrospinal fluid
(Brodie and Axelrod, 1949 and Gwilt et al., 1963). Under normal circumstances
paracetamol does not bind extensively to plasma proteins (Forrest et al., 1982) and
distribution is largely complete in 1 to 1.5 h. It is extensively metabolised in the liver
primarily to a glucuronide and sulphate conjugate. In addition a minor fraction is
converted by hepatic mixed function oxidases to a highly reactive alkylating metabo¬
lite, probably N-acetyl-p-benzo-quinoneimine (Miner and Kissenger, 1979). This
metabolite is normally inactivated by conjugation with reduced glutathione and is
eventually excreted in the urine as cysteine and mercapturic acid conjugates (Forrest
et al., 1982). Overdoses of paracetamol cause acute hepatic necrosis as a result of
depletion of glutathione and of covalent binding of the excess reactive metabolite to
vital cell constituents (Mitchell et al., 1973 and 1974).
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In young healthy subjects approximately 85 to 95 % of a therapeutic dose is excreted
in the urine within 24 h with about 4, 60, 30, 3 and 4 % appearing as unchanged
paracetamol and its glucuronide, sulphate, cysteine and mercapturate conjugates
respectively (Prescott et al., 1989). As paracetamol is a moderately lipid-soluble weak
organic acid it is likely to undergo glomerular filtration with subsequent passive
reabsorption and the renal clearance at normal urine flow rates is about 12 ml.min"1
(Forrest et al., 1982). The highly polar glucuronide and sulphate conjugates appear to
be both filtered at the glomerulus and actively secreted by the tubules since their renal
clearances are approximately 130 and 170 ml.min 1 (Forrest et al., 1983).
In patients with chronic renal failure, the absorption of paracetamol was normal but
from 8 to 24 h it disappeared from the plasma more slowly than in healthy volunteers
(Prescott et al., 1989). Furthermore, plasma concentrations of the glucuronide and
sulphate conjugate of paracetamol were greatly increased and were even higher in
patients with end-stage renal failure maintained on haemodialysis (Lowenthal et al.,
1976 and Prescott et al., 1989). Haemodialysis appeared to be the major route of
elimination of the metabolites (He et al., 1976). Marked accumulation of the polar
metabolites would therefore seem inevitable in patients with renal failure taking
paracetamol regularly (Prescott et al., 1989).
Paracetamol is normally a very safe drug but may produce acute centrilobular hepatic
necrosis when taken in overdose (Clark et al., 1973, Davidson and Eastham, 1966,
James et al., 1975, McJunkin et al., 1976 and Portmann et al., 1975). Hepatotoxicity
is related to the conversion of a small fraction of the dose to a highly reactive arylat-
ing metabolite which is normally inactivated by preferential conjugation with gluta¬
thione and excreted as cysteine and mercapturic acid conjugates (Mitchell et al., 1973
and 1974). Following a hepatotoxic dose, glutathione is depleted and the toxic meta¬
bolite binds covalently to vital proteins and enzymes causing cell damage and necrosis
11
(Jollow et al., 1973, Mitchell et al., 1973, Potter et al., 1973 and Prescott 1983).
Glutathione precursors and other sulfhydryl compounds prevent glutathione depletion,
covalent binding and liver damage, probably by facilitation of glutathione conjugation
(Mitchell et al., 1974, Prescott and Matthew, 1974 and Prescott et al., 1977).
Frusemide
Frusemide, (furosemide, (4-chloro-N-furfuryl-5-sulfamoyl-anthranilic acid or 5-
(aminosulfonyl)-4-chloro-2((2-furanylmethyl)amino) benzoic acid, Fig. 1.2) is a
potent loop diuretic used in the treatment of oedematous states associated with cardi¬
ac, hepatic and renal failure. Therapy is frequently complicated however by apparent¬
ly erratic systemic availability from the oral route and from unpredictable responses to
a given dose (Boles Ponto and Schoenwald, 1990). The extensive literature on fru¬
semide disposition is confusing and frequently conflicting.
The diuretic was first used clinically in 1963 (Kleinfelder, 1963). Early studies con¬
firmed that it was much more effective than the organomercurial agents in inducing a
water and sodium diuresis. It could be used orally and its diuretic action was inde¬
pendent of alterations in acid base balance (Goodwin and Gunton, 1965, Stewart and
Edwards, 1965 and Verel et al., 1964).
Frusemide is an anthranilic acid derivative with a molecular weight of 330.74. It is
practically insoluble in water, only slightly soluble in ether and chloroform, sparingly
soluble in alcohol and soluble in acetone, dimethylformamide, acetonitrile, solutions
of alkali hydroxides and methanol. The pKa is 3.9. Frusemide is available for both






Fig 1.2. Chemical structure of frusemide.
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The action of frusemide depends on inhibition of the active reabsorption of chloride at
the ascending loop of Henle (Odlind, 1979). At the cellular level, frusemide inhibits
the sodium-potassium-chloride cotransport system (Feig, 1986). with enhanced excre¬
tion of sodium, chloride, potassium, hydrogen, calcium, magnesium, ammonium,
bicarbonate and possibly phosphate. Frusemide is delivered to its site of action by
active secretion via the nonspecific organic acid pump (Odlind, 1979 and Odlind and
Beermann, 1980 (a)). Response is related to the concentration of the drug in the urine
rather than the plasma (Chennevasin et al., 1979) and also to the time course of deliv¬
ery of drug to the renal tubule (Kaojaren et al., 1982).
The administration of frusemide is associated with a marked increase in the excretion
of renal prostaglandins and it has been suggested that they mediate at least some of its
pharmacological actions (Abe et al., 1977 and Weber, et al., 1977). In keeping with
this the nonsteroidal anti-inflammatory drugs which inhibit prostaglandin synthesis
decrease the transient rise in renin activity induced by frusemide (Patak et al., 1975,
Rumpf et al., 1975, Frohlich et al., 1976 and Passmore et al., 1989) but their effects
on its natriuretic response are more controversial (Attalah, 1979).
The oral absorption of frusemide is erratic and variable and the reasons proposed
include inter- and intra-subject variability, the usage of different dosage forms and
study protocols, including whether the subjects were in a fasting or a non fasting state
(Boles Ponto and Schoenwald, 1990). The methods used to measure frusemide are
also a potential source of variability (Benet, 1979). In general, maximum plasma
concentrations of frusemide are achieved 60 to 90 min following an oral dose (Beer¬
mann et al., 1975, Branch et al., 1977, Kelly et al., 1974 and Waller et al., 1982) and
reported values for the bioavailability range from 20 to 100 % (Branch et al., 1977,
Hammarlund et al., 1984, Kelly et al., 1974, Rane et al., 1978, Smith et al., 1980
(a), Tilstone and Fine, 1978, Waller et al., 1982 and Zhu et al., 1987).
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Frusemide is highly bound to plasma proteins (>97 %), almost exclusively to albu¬
min (Zini et al., 1976 and Smith et al., 1980 (a)). This together with its limited lipid
solubility restricts its distribution throughout the body and the reported values of Vd
are 2 to 5 times the plasma volume which is 2.8 to 3.5 1 in a 70 kg man (Diem and
Letner, 1970).
At least 2 metabolites of frusemide have been reported, frusemide glucuronide and 4-
chloro-5-sulfamoylanthranilic acid (CSA). The glucuronide is an accepted metabolite
whereas the status of CSA as a metabolite is highly controversial (Smith et al., 1980
(a)). In healthy subjects about 14 % of an oral and intravenous dose of frusemide was
recovered in the urine as the glucuronide conjugate (Smith et al., 1980 (a)). The
exposure of frusemide to strong acid during the analytical procedure may result in its
degradation to CSA (Fig. 1.3) suggesting that the latter is an analytical artifact rather
than a metabolite of frusemide (Smith et al., 1980 (a)). The liver may not be the
primary site of frusemide metabolism as the non renal clearance of frusemide is not
reduced in patients with severe liver disease (Fuller et al., 1981 and Keller et al.,
1981).
Following intravenous administration in healthy volunteers frusemide is cleared both
by renal and non renal mechanisms in highly variable but often equivalent proportions
(Boles Ponto and Schoenwald, 1990). Reported values for total clearance and for the
contribution of the renal and non renal components vary enormously (Benet, 1979 and
Boles Ponto and Schoenwald, 1990). The fraction of the dose excreted unchanged in
the urine represents the amount available for pharmacological action (Brater, 1986).
This varies from 50 to 80 % with intravenous administration and from 20 to 55 %
with oral administration (Boles Ponto and Schoenwald, 1990).
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Fig 1.3. Chemical structure of the proposed metabolite of frusemide 4-chloro-5-
sulfamoylanthranilic acid (CSA). The status of this metabolite is highly controversial as it
may be produced by exposure of frusemide to strong acids during the analytical
procedure.
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One of the major advantages of frusemide is its ability to induce a diuresis even in
patients with advanced renal impairment (Allison and Kennedy, 1971). In patients
with chronic renal failure, however, endogenous organic acids accumulate and block
frusemide secretion to its site of action at the renal tubules (Rose et al., 1976). Larger
doses than normal are therefore required to cause a diuresis (Brater et al., 1986). The
disposition of frusemide has been extensively studied in patients with chronic renal
impairment but results have been variable and conflicting (Benet, 1979, and Boles
Ponto and Schoenwald, 1990). In some studies, the oral absorption of frusemide was
delayed in patients with renal failure (Huang et al., 1975, Beermann et al., 1977, Riva
et al., 1982 and Boutron et al., 1981). Furthermore the bioavailability was lower than
normal (Kelly et al., 1977, Rane et al., 1978 and Tilstone and Fine, 1978).
As expected the renal clearance of frusemide is much lower in patients with renal
impairment but the non-renal clearance has been reported to be both decreased (Rane
et al., 1978) and increased (Cutler et al., 1974). There has also been controversy over
the elimination half life of frusemide which has been reported to vary from normal
(1 h) or to as long as 24 h in these patients (Beermann et al., 1977). Although differ¬
ences may be partly due to differences in study protocols including the assays used to
measure frusemide and the nature and degree of renal impairment in the patients
studied, nonetheless, at least some of the variability is difficult to explain.
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Study objectives
The object of the present study was to elucidate the disposition of paracetamol and
frusemide in patients with varying degrees of chronic renal impairment. Both drugs
are frequently used in the treatment of patients with chronic renal failure and their
disposition in such patients has been investigated following single doses. However,
little information is available regarding the situation during multiple dosing in patients
with renal failure. As most patients usually take drugs regularly rather than on a once
off basis, multiple dose studies are of more relevance clinically.
1. The first objective was to develop a reliable HPLC method for the measurement of
frusemide in plasma, urine and dialysate. Paracetamol and its polar conjugates can be
reliably measured in plasma using high performance liquid chromatography but
frusemide is technically more difficult to measure partly due to its extensive binding
to plasma proteins. Inaccuracies may occur due to its sensitivity to light and its pro¬
posed instability in the presence of acid which may be required for extraction. Fur¬
thermore, it is unclear whether CSA is an analytical artifact or a true metabolite.
2. The disposition of paracetamol in healthy volunteers has been well established but
considerable controversy exists in relation to frusemide both in health and disease.
The next objective, therefore, was to establish the disposition of single doses of
frusemide in healthy drug-free volunteers before attempting to elucidate its disposition
in patients with impaired renal function.
3. Little information is available about the disposition of drugs in patients with end-
stage renal failure maintained on CAPD. Single doses studies with paracetamol and
frusemide were therefore performed in such patients to establish the absorption pattern
of both drugs. It was anticipated that abnormalities might exist partly due to the
severe renal failure but possibly also due to the presence of large volumes of dialysate
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in the peritoneal cavity. It was hoped to establish the effect of severe renal disease on
the metabolism of paracetamol to its polar conjugates and the degree to which these
metabolites accumulate in the presence of end-stage renal disease. Considerable con¬
troversy exists regarding the extent and site of the non-renal clearance of frusemide. It
was hoped to clarify the situation in these patients who provide a useful model for
non-renal clearance due to the minimal or absent contribution of the kidneys to total
clearance. Finally, the peritoneal clearance of frusemide, paracetamol and paraceta¬
mol conjugates was measured to find out to what extent this form of dialysis can
compensate for the minimal or absent renal clearance.
4. Little information is available regarding drug disposition during chronic dosing.
Conservatively managed patients often require large doses of frusemide to maintain an
effective diuresis and may be maintained on these doses chronically. A group of such
patients was studied to investigate whether the diuretic accumulates under these
circumstances, and to determine the absorption patterns of large doses of frusemide.
A crucial question was to establish the fraction of the daily doses which reaches its
site of action at the tubular lumen. Complementary intravenous studies were per¬
formed to establish bioavailability, distribution and the extent of total and non-renal
clearance.
5. The next objective was to determine the disposition of paracetamol during chronic
dosing in a similar group of patients. It was anticipated that marked accumulation of
the polar glucuronide and sulphate conjugates of paracetamol would occur due to
reduced renal elimination. In addition, biliary excretion of retained conjugates might
lead to regeneration of paracetamol in the gut with subsequent reabsorption of the
parent compound leading to persistent and higher concentrations in the blood. It was
hoped to determine whether increased production of the potentially toxic glutathione-
derived conjugates occurs during chronic dosing in patients with renal failure.
19
6. A further objective was to establish the disposition of paracetamol in haemodialysis
patients under similar conditions to determine the degree of accumulation of the polar
paracetamol conjugates in the presence of minimal renal function. It was expected that
such patients would be dependent on haemodialysis to eliminate the retained conju¬
gates and it was hoped to establish the adequacy of the procedure in preventing the
gross retention of metabolites that would otherwise seem inevitable.
7. The final objective was to investigate the possibility that the pharmacological ac¬
tions of frusemide including the rise in plasma renin activity, increased excretion of
urinary prostaglandins and natriuresis may be inhibited by concurrent treatment with
paracetamol due to inhibition of prostaglandin synthesis. Such an interaction might
mean that paracetamol is less suitable in patients with renal impairment than was






SECTION 2.1: VOLUNTEERS AND PATIENTS
Healthy volunteers
Healthy male and female volunteers between the ages of 18 to 55 yr were recruited by
advertisement or from the hospital staff and their acquaintances. They had no medical
illnesses and physical examination was normal. The volunteers were taking no regular
medication (apart from oral contraceptives in the case of the females) and they
claimed to drink less than 5 units of alcohol per week.
A 10 ml sample of venous blood was drawn from each volunteer for biochemical and
haematological screening and urinalysis was performed.
Patients with chronic renal failure
All patients with chronic renal failure who participated in the study were attending the
Medical Renal Unit, The Royal Infirmary, Edinburgh. Patients with moderate degrees
of renal impairment (i.e. creatinine clearance 10-60 ml.min"1) were managed conser¬
vatively and those with end-stage disease (creatinine clearance <5-10 ml.min"1) were
on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).
The patients were between the ages of 20 to 75 yr and the aetiology of the renal fail¬
ure included pyelonephritis, glomerulonephritis, polycystic kidney disease, diabetes
mellitus and hypertension. Details of the medical histories, medication and the find¬
ings on physical examination were noted. Venous blood was sampled to determine
current biochemical and haematological status and urine was collected for 24 h to
measure the creatinine clearances in the conservatively managed group.
Patients who were treated conservatively for more severe degrees of renal failure
were on a low protein diet of about 40 g per day. They were not allowed any added
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salt and they avoided foods containing large quantities of potassium. They were
encouraged to maintain a high fluid intake. Patients on haemodialysis or CAPD were
allowed to eat more protein (60 g per day) but their fluid intake was restricted to
about one 1 per day.
Renal replacement therapy
Haemodialysis
Haemodialysis is an intermittent treatment which is usually performed for 3-5 h, 2 or
3 times a week. During the procedure, the patient's blood is brought into apposition
with a dialysate solution in an artificial kidney machine (Fig. 2.1). The blood is
separated from the dialysate by a semi-permeable membrane in the dialyser. This has
a very large surface area and low molecular weight constituents of the blood such as
urea in high concentration pass across the semi-permeable membrane into the dialy¬
sate and are eliminated from the body (Allen, 1990 and Gabriel,1988).
Blood is pumped from the patient at about 150 to 200 ml.min"1 into the dialyser and a
bubble trap and then returned to the patient. Vascular access is usually by a fistula
created under the skin between an artery and a vein in the forearm (Fig. 2.1). The
vein increases in size as a result of the increased quantity of blood flowing through it,
allowing one wide bore needle to be inserted for blood flow to the machine (the
"arterial" line) and another for blood returning (the "venous" line).
The dialysate consists of reversed osmosis treated water mixed with a dialysate con¬
centrate in a ratio of 35:1 to give a buffered solution containing sodium 129, chloride
88.8, calcium 1.75, potassium 1.5, magnesium 0.75 and acetate 46.7 mmol.l"1, and
glucose 0.2% (w/v). It is heated to 37°C and de-aerated before passing through the





















Fig 2.1. A diagram of the basic flow paths of a dialysis machine. The "arterial" blood
line leads from the fistula in the arm via the blood pump through the fistula and back
to the "venous" line of the fistula. The dialysate pathway extends from the source of
dialysate in the machine through the dialyser and then to the drains (adapted from
Gabriel, 1980).
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The dialyser contains synthetic semi-permeable membranes based on cellulose which
allow blood to come into close proximity with the dialysate. If blood and dialysate
pass each other at low pressure, low molecular weight metabolites and excess electro¬
lytes pass from the blood to the dialysate and are hence removed from the body. If the
pressure across the semi-permeable membrane is raised either by increasing the pres¬
sure of the blood in the dialyser or increasing the osmotic effect of the dialysate or
both, water will be extracted from the patient. The dialysis machines used were
Gambro AK10 (Gambro, Hechingen, Federal Republic of Germany) or Fresenius
2008 (Fresenius, Bad Homburg, Federal Republic of Germany) with hollow Fibre
dialysers.
Continuous Ambulatory Peritoneal Dialysis
In CAPD, dialysis is performed continuously across the peritoneum which acts as a
naturally occurring semi-permeable membrane (Gabriel, 1988). Dialysate is intro¬
duced into the abdominal cavity and removed at regular intervals via a flexible
"Tenckhoff" catheter which may be left in situ permanently (Fig. 2.2).
The dialysate is similar to that used for haemodialysis except that it is made hyperton¬
ic by adding varying quantities of glucose which exert a "sucking" effect on the peri¬
toneum, drawing fluid out from the blood by osmosis. The greater the quantity of
glucose, the more fluid is removed. The dialysate comes in sealed bags of 2000 ml
and contains sodium 132, chloride 102, calcium 1.75, lactate 35, and magnesium 0.75
mmol.1"1 ("Dianeal" solution). The pH is 5.5 and the glucose content is 1.36, 2.27 or
3.86% depending on individual requirements. Some patients on an older system use
dialysate containing sodium 134 and chloride 103.5 mmol.l"1 with a glucose content of
1.5 or 2.3 %.
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Fig 2.2. A chronic peritoneal "Tenckhoff" dialysis catheter in place (adapted from
Gabriel, 1980).
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CAPD is performed by connecting a warmed bag of dialysate to the end of the
Tenckhoff catheter under sterile conditions . The bag is then hung up above the pa¬
tient and the dialysate flows into the abdominal cavity (Fig. 2.3). The empty bag is
clamped off, rolled up and put under the patient's clothing.
After a dwell time of 5 to 8 h, the first bag is unrolled and placed below the abdomi¬
nal cavity to drain the used dialysate out of the peritoneal cavity. Once this is com¬
plete the bag is disconnected and replaced by a fresh bag which is hung up to allow
the dialysate to run in as before.
Most patients perform 3 to 4 exchanges per day at approximately 08.00, 13.00, 18.00
and 23.00 h. The main complication of CAPD is bacterial peritonitis and therefore a
strict aseptic technique is essential (Gabriel, 1988).
Ethical approval and subject consent
All studies were approved by the local Ethics of Medical Research Committee and
healthy volunteers and patients with chronic renal failure gave their informed written
consent before participating in the studies.
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Fig 2.3. The technique of continuous ambulatory peritoneal dialysis (CAPD). A 2 1
bag of dialysate is hung up above the patient. The fluid flows down the transfer set
into the peritoneal cavity. The line is then clamped off and the bag is rolled up and put
into the patients pocket. After 5 h or more the bag is unrolled and placed below the
level of the patient's abdomen and the used dialysate flows out (adapted from Gabriel,
1980).
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SECTION 2.2: ANALYTICAL METHODS
Concentrations of paracetamol and frusemide were quantitated in plasma, urine and
dialysate by High Performance Liquid Chromatography (HPLC). In the case of para¬
cetamol the method had been previously established in our department and an assay
was developed for the measurement of frusemide as part of this work.
Assay of paracetamol and its conjugates in plasma, urine and dialysate by High
Performance Liquid Chromatography
Background
Samples were assayed for paracetamol and its glucuronide, sulphate, cysteine, and
mercapturate conjugates by HPLC with UV detection. The method is based on the
original method of Adriaenssens and Prescott, (1978). Electrochemical detection was
also used for low concentrations of the cysteine and mercapturic acid conjugates of
paracetamol in the presence of potentially interfering peaks (Clements et al., 1984).
Materials
Paracetamol, paracetamol glucuronide, paracetamol sulphate, paracetamol cysteine
and paracetamol mercapturic acid conjugates for reference standards were kindly
donated by Sterling-Winthrop Research and Development Division, Alnwick, Eng¬
land. Potassium dihydrogen phosphate, formic acid, isopropanol and acetic acid were
supplied by BDH Chemicals Limited, Poole, England. 60% perchloric acid and ethyl
acetate were supplied by Fisons, Loughborough, England and helium was obtained
from the British Oxygen Company.
The internal standard used was N-propionyl-4-aminophenol (NPA). This was synthe-
sised from 4-aminophenol and propionic anhydride (BDH Chemicals Limited) as
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described by Adriaenssens (1980).
Instrumentation
The HPLC system consisted of a Waters Associates liquid chromatograph comprising
a pump (Model 590) which delivered the mobile phase (degassed with helium prior to
use) to an automatic sample injection module (Waters Intelligent Sample Processor
710B, WISP). Before reaching the analytical column the solvent was passed through a
2n metal filter and a Waters "Guard-PAK" precolumn containing the same packing
material as the column.
The analytical column was an 8 mm x 10 cm Waters "Radial-PAK" cartridge contain¬
ing a reversed phase, 5 or 10ji, Clg bonded spherical silica support. The column was
housed in a Waters RCM-100 Radial Compression Module. The eluent passed into a
Waters Associate ultraviolet (UV) absorbance detector, Model 441. The UV detector
output was passed to an IBM-XT microcomputer running the JCL6000 (Jones
Chromatography, Clywd, Wales) programme for integration and full analysis of the
chromatogram. Results were printed on an Epson LX-800 printer. Electrochemical
detection (Model LC-4A, Bioanalytical Systems, Inc.) was also used to detect small
amounts of cysteine and mercapturate conjugates as described (Clements et al., 1984).
Collection and storage of samples
Venous blood samples were collected into 10 ml heparinised tubes, centrifuged at
1250 g for 15 min and the plasma transferred to glass tubes. Urinary volumes and pH
were recorded and 20 ml aliquots stored in universal containers. For patients on
CAPD, used bags of dialysate were weighed and their volumes measured. All samples
were stored at -20°C until assayed.
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Assay of plasma samples
Chromatographic conditions
Flow rate:
Mobile phase: 0.05 M potassium dihydrogen phosphate containing
0.1% formic acid:isopropanol (295:5 v/v)
3ml.min"1
Pressure: 1000 psi
Detector wavelength: 254 nm
Preparation of standards and test samples for plasma assay
For estimating concentrations of paracetamol and its metabolites, spiked plasma
samples containing known concentrations of paracetamol were prepared and run in
duplicate with the test samples. To 0.5 ml of plasma was added 50 /xl of 30 mg%
NPA in 30% w/v aqueous perchloric acid and the sample was then "whirlimixed"
(Whirlimixer, Jencons, Hertfordshire, England ) to precipitate the plasma proteins.
The tubes were centrifuged for 10 min at 1400 g and up to 30 /d of the clear superna¬
tant injected directly into the HPLC system.
Results of plasma assay
Concentrations were calculated in paracetamol equivalents from the peak area ratios
of paracetamol and paracetamol conjugates to the internal standard, NPA. The ratios
were then multiplied by a factor representing the reciprocal of the regression line for
the standards to give the paracetamol concentration in /xg.ml"1. Correction factors of
0.835 and 1.027 were used for the glucuronide and sulphate conjugates because only
authentic paracetamol standards were used. (Adriaenssens and Prescott, 1978).
If chromatograms of the blank samples contained peaks corresponding to paracetamol
or its glucuronide or sulphate conjugates 40 fxl of 8-glucuronidase and sulphatase
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(Sigma Chemical Co., Poole, Engla-d) was added to the sample and the mixture
incubted at 37°C overnight. These enzymes liberate free paracetamol from its glucu-
ronide and sulphate conjugate respectively. Therefore, a reduction in the size of these
peaks with an associated increase in the size of the paracetamol peak on the chromat-
ogram suggested that the samples already contained some paracetamol conjugates.
Allowance was made for this by taking into account the known rate of elimination of
paracetamol and its conjugates according to Equation 2.1:
Ct = C0e *•«
where C( is the plasma concentration at time "t" and represents the residual amount of
paracetamol or its conjugates at each time point when there is measurable amounts in
the blank sample.
CQ is the plasma concentration at time "0" in the blank sample.
K is the elimination rate constant of the drug or its conjugates
and "t" is the time of the sample
Using this equation a set of concentrations were calculated which represented the
residual concentrations at each time point. These were then subtracted from the
concentrations measured after the dose of paracetamol had been given to give the
corrected plasma concentrations of paracetamol or its conjugates.
The retention times of paracetamol glucuronide, paracetamol sulphate, paracetamol
and NPA were 2.7, 4.2, 6.3, and 12 min respectively. The system also separated the
cysteine (5.3 min) and mercapturate (15.0 min) conjugates of paracetamol with elec¬
trochemical detection. The limit of detection of each compound was less than
1 jig.ml ~l. The calibration plots for paracetamol were linear over a range of 5 to 50
jig.ml"1 and the coefficient of variation for repeated measurements was under 5%
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(Adriaenssens, 1980).
Assay of urine samples
The materials and instrumentation were the same as for the plasma assay.
Chromatographic conditions
Mobile phase: 1% acetic acid:ethyl acetate (99:0.5 v/v)
Flow rate: 3ml.min1
Pressure: 1000 psi
Detector wavelength: 254 nm
Preparation of standards and test samples for urine assay
For the estimation of paracetamol and its metabolites in urine, standard solutions of
paracetamol were prepared and run with the test samples. The urine was mixed with
NPA standard in different proportions according to the concentration of paracetamol
and its metabolites present and volumes up to 5 jzl were injected directly into the
HPLC system.
Results of urine assay
Concentrations of paracetamol and its glucuronide and sulphate metabolites were
calculated as described for the plasma assay using correction factors of 1.1 and 1.046
for the sulphate and glucuronide conjugates respectively. No correction factor was
used for the cysteine and mercapturate conjugate (Adriaenssens, 1980).
The retention times of paracetamol sulphate, paracetamol glucuronide, paracetamol,
NPA, cysteine and mercapturate were 0.9, 2.1, 4.8, 9.7, 11.1 and 12.5 min respec¬
tively. The limit of detection of the assay was dependent on the presence of interfering
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peaks from endogenous material present in the urine. The calibration plots for para¬
cetamol were linear over a range of 25 to 500 ng.ml1 and the coefficient of variation
was about 10 % (Adriaenssens, 1980).
Assay of dialysate samples
The same method was used as for the urine samples but because the samples were
very dilute larger volumes (10 - 30 jtl) were injected into the system.
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The measurement of frusemide in plasma, urine and dialysate by High Perform¬
ance Liquid Chromatography
Background
Many methods have been described for the measurement of frusemide in biological
fluids. Early techniques included the administration of the radiolabeled drug, fru-
semide-S35 (Calesnick et al., 1966, Kelly et al., 1974, Beerman et al., 1975 and
Honari et al., 1977), and a spectrofluorometric assay which was first developed by
Haussler and Hadju (1964), and subsequently modified by several other groups
(Cutler et al., 1974, Kelly et al., 1974, Andreason et al., 1978, Homeida et al., 1977
and Huang et al., 1975). Other assays have been developed with thin layer chroma¬
tography (Mikkelson & Andreason, 1977) and gas liquid chromatography (Lindstrom
and Molander, 1974). However, more sensitive methods involve the use of high
performance liquid chromatography (HPLC) and many different groups have pub¬
lished either their own methods (Lindstrom, 1974, Blair et al., 1975, Carr et al.,
1978, Nation et al., 1979, Andreason et al., 1981, Kerremans et al., 1982, Uchino et
al., 1984, Lovett et al., 1985, Sood et al., 1987 and Lin et al., 1979) or modifications
of these original methods (Smith et al., 1980 (a)) & 1981, Rapaka et al., 1982 and
Snedden et al., 1982).
There are particular problems associated with the measurement of frusemide in
plasma which partly explains why the relevant literature is extensive and at times
conflicting. Frusemide is extensively bound to plasma proteins under normal circum¬
stances (>97%) (Zini et al., 1976, Rane et al., 1978 and Andreason et al., 1978),
and it has to be separated from them in order to measure its concentration in the
plasma. The plasma is commonly acidified with hydrochloric acid (HCL) followed by
extraction of the frusemide into an organic solvent such as ether prior to its measure¬
ment by HPLC (Lindstrom, 1974, Carr et al., 1978 and Andreason et al., 1981). The
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organic phase is then evaporated and the residue dissolved in a suitable solvent before
injection into the HPLC system. However, exposure of frusemide to acid causes its
degradation to a split product 4-chloro-5-sulphamoylanthranilic acid (CSA) and
complete transformation to CSA is achieved by heating an acid solution of frusemide
to 70°C for 45 min (Hadju & Haussler, 1964). This has lead to the belief by some
authors that the use of HC1 before extraction is responsible for degradation of fru¬
semide during the analytical procedure with production of CSA as an artifact (Smith
et al., 1980 (a))). Kerremans et al., (1982) only recovered 50% of frusemide using
1.5 M HC1 and preferred acetic acid for acidification. Other authors have substituted
methylene chloride as the solvent for extraction because they found less interference
from endogenous substances removed from plasma with the frusemide (Uchino et al.,
1984, Lovett et al., 1985).
Another approach is precipitation of plasma proteins with acetonitrile in place of
extraction (Lin et al., 1979). The addition of acetonitrile to plasma results in the
precipitation of proteinaceous material while the frusemide remains in the organic
phase. The acetonitrile is then removed by evaporation and the reconstituted sample
injected into the HPLC system, thereby eliminating the need for the acidification of
the sample prior to analysis. However, a comparison of both methods showed that
with extraction the sensitivity was approximately five times greater than with acetoni¬
trile precipitation (Bauza et al., 1985). Furthermore, even though 6 M HC1 was used
to acidify the samples to pH less than or equal to 1, the recovery of frusemide was
essentially quantitative when extraction followed within 2 min. After 1 h 5-10% of
the frusemide was lost, presumably due to decomposition.
The story is further complicated by the methods used for the detection of frusemide in
the HPLC system. Several authors have used UV detection at a wavelength 280 nm
(Lindstrom, 1974, Blair et al., 1975, Andreason et al., 1981 and Lin et al., 1979) but
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fluorescence detection increases the sensitivity of the assay (Smith et al., 1980 (a)))
and it has been adopted by most authors (Carr et al., 1978, Nation et al., 1979,
Rapaka et al., 1982, Kerremans et al., 1982, Uchino et al., 1984, Lovett et al., 1985
and Sood et al., 1987). The difficulty arises from the fact that the fluorescence of
frusemide is greatest at acid pH but here it is unstable (Kerremans et al., 1982). If the
fluorescence of frusemide at pH 1.6 is taken as 100%, it is 97% at pH 2.5 and 81 % at
pH 4.6. There is no appreciable fluorescence at pH 5.6 or 6.6 (Rapaka et al., 1982).
Therefore, even if samples are not exposed to strong acids during extraction, most
authors use mobile phases which have been buffered to low pH in the range of 2.0 -
3.5 (Kerremans et al., 1982, Rapaka et al., 1982, Blair et al., 1985 and Lovett et al.,
1985). This raises the question of stability of the frusemide under these conditions.
Decomposition of frusemide may also occur when it is exposed to light (Moore and
Sithipitaks 1983), and exclusion of light is recommended during storage and analysis
(Blair et al., 1975, Carr et al., 1978, Kerremans et al., 1982, Uchino et al., 1984,
Sood et al., 1987 and Bauza et al., 1985). When solutions of frusemide were exposed
to light, there was rapid hydrolysis to at least 3 compounds and this process was
markedly accelerated by an acidic pH (Kerremans et al., 1982). However it has been
subsequently been claimed that special treatment to protect the samples from light is
unnecessary provided that frusemide is stable in each of the solvents used for the
assay upon exposure to normal fluorescent room lighting (Lovett et al., 1985).
Frusemide also remains stable when it is stored in frozen plasma for at least 4 months
(Kerremans et al., 1982 and Lovett et al., 1985).
The pharmacological activity of frusemide seems to correlate best with its urinary
excretion rate (Chennavasin et al., 1979) and most authors have included the estima¬
tion of urinary frusemide in their methods. What is puzzling is that these methods
often involve elaborate extraction procedures despite the fact that less than 100 mg
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protein is normally excreted per day in the urine (Lindstrom, 1974, Carr et al., 1975,
Kerremans et al., 1982, Uchino et al., 1984, Sneddon et al., 1982 and Bauza et al.,
1985). By contrast the concentration of proteins in the plasma is normally 60-80 g.l"1.
It seems unnecessary therefore to remove these small amounts urinary protein under
normal circumstances. Interference from endogenous substances may also have neces¬
sitated extraction although urine has been injected directly onto the HPLC column
(Lin et al., 1979). The same stability problems apply to frusemide in urine on expo¬
sure to light or acidic pH but samples can be stored frozen for 204 days (Bauza et al.,
1985).
On the basis of these reports precautions should be taken to minimise the exposure of
frusemide samples to acid or light during the analytical procedure.
Development of HPLC assays for the estimation of frusemide in plasma, urine
and dialysate.
Materials
A pure sample of frusemide was kindly donated by Hoechst UK Limited, Hounslow,
Middlesex, England. Acetic acid, acetonitrile, methanol, sodium acetate and the inter¬
nal standard (toluic acid) were all supplied by BDH Chemicals Limited. Helium and
nitrogen were obtained from The British Oxygen Company.
Instrumentation
The HPLC system consisted of a Waters Associates liquid chromatograph comprising
a pump which delivered the mobile phase (degassed with helium prior to use) to an
automatic sample injection module the Waters Intelligent Sample Processor 710B
(WISP). Before reaching the analytical column the solvent passed through a 2[x metal
filter and a pre-column containing the same packing material as the column.
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The column was a 8 x 100 mm Waters ^Bondapak Clg radial compression cartridge
containing ODS silica (10ji). From the column the eluent passed into an Waters
Associates ultraviolet (UV) absorbance detector, Model 440. The detector output was
passed to a Bryans 28000 single channel recorder (Bryans, Mitcham, England) or a
Shimadzu C-R1B reporting integrator (Dyson Instruments, Tyne and Wear, England)
to produce the chromatograms and integrated peak areas. Once the assay had been
fully standardised the detector output was passed to an IBM-XT microcomputer
running the JCL6000 (Jones Chromatography, Clywd, Wales) programme for integra¬
tion and full analysis of the chromatogram. Results were printed on an Epson LX-800
printer.
Collection and storage of samples
Samples were collected and stored as described for the paracetamol assay but were
protected from light at all times.
Chromatographic conditions








Detector wavelength: 280 nm
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Development of plasma assay
(a) Effects of pH on stability of frusemide.
A series of experiments was done with aqueous solutions of frusemide to establish the
effects of pH on the stability of frusemide.
A range of aqueous standards of 1, 5 and 10 mg.T1 frusemide were buffered to pH 2
to 7 and volumes of 10 to 30 y\ were injected into the system. Frusemide peaks were
sharp and well defined from pH 2 until pH 6. As the pH increased beyond 6.3, the
peaks of both the frusemide and internal standard became split and obliterated and
eventually no frusemide or toluic acid was detected at pH 7.0. Under these conditions
no obvious degradation of frusemide occurred under acidic conditions of pH as low as
2.0. The distortion seen at high pH was considered to be an analytical artifact due to
interaction with the column and both frusemide and the internal standard disappeared
progressively. The manufacturers of the ^tBondapak column advise using a pH range
of 2 to 8 and preferably an even narrower range of 3.5 - 6.5. At a pH of greater than
7.8 the ODS is stripped.
(b) Effects of light on stability of frusemide.
When aqueous samples of frusemide 1, 5 and 10 mg.l"1 were exposed to daylight and
analysed weekly over a period of 2 months there was a progressive reduction in the
size of the peak with development of a second, earlier peak.
(c) Removal of protein from plasma samples.
Plasma proteins were precipitated with acetonitrile as described by Benet et al.,
(1979). In this way, the need for acidification before extraction was avoided. Initial¬
ly, 400 y\ of acetonitrile was added to 200 y\ plasma containing frusemide and inter¬
nal standard. The sample was centrifuged and 10 to 30 y\ of the supernatant was in-
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jected directly into the HPLC system. However, the resultant chromatograms showed
a number of peaks which did not correspond to frusemide.
(d) Acidification after acetonitrile precipitation.
The chromatograms obtained after acetonitrile precipitation resembled the aqueous
standards made up in alkaline buffer. As the pH of plasma is normally 7.35 to 7.45 it
seemed reasonable to acidify the samples after acetonitrile precipitation to give good
resolution of the peaks. Acidification with 20 /xl citric acid (0.01 M) gave clean, sharp
reproducible peaks. Unfortunately this resulted in rapid deterioration in column effi¬
ciency with broadening of the peaks.
(e) Removal of acetonitrile.
It became apparent that it was acetonitrile itself rather than the pH of the sample that
was causing the apparent splitting and distortion of the chromatograms. If acetonitrile
was added to aqueous standards, a similar distortion of the shape and size of the fru¬
semide and toluic acid peaks occurred which could be rectified by the addition of
citric acid. It was therefore decided to remove the acetonitrile by evaporation with a
stream of nitrogen after precipitation and then reconstitute the pellet in de-ionised
water before injection into the HPLC system.
Final method for measuring frusemide in plasma by HPLC
Serial dilutions of a stock solution of frusemide in blank plasma (Blood Transfusion
Service) were prepared to give 2 sets of standards of concentrations 0.5 to 10 mg.l"1
and 0.1 to 0.5 mg.l"1. A blank sample of plasma was also included. To 200 /xl of each
standard was added 20 /xl toluic acid (1 mg.ml"1) and 400 /xl acetonitrile. The sample
was whirlimixed and then centrifuged at 1800 g for 10 min. The supernatant was
transferred to glass conical tubes and the acetonitrile evaporated off under a gentle
stream of nitrogen. The residue was reconstituted with 100 /xl of de-ionised water
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and 30-90 /xl injected into the HPLC system. For the low range of 0.2 to 0.5mg.r' the
mobile phase was changed to use a slightly less acetonitrile (62 ml). Using the peak
area ratios of frusemide to internal standard a factor was calculated which represented
the reciprocal of the slope of the regression line of the standards. This was then used
to calculate the concentration of frusemide in samples from patients and volunteers by
multiplying it by the peak area ratios of these unknown samples.
If the blank samples contained peaks with the same retention time as frusemide the
values were subtracted from the plasma concentrations to give the true frusemide
concentrations. However, when patients were taking frusemide regularly it was
assumed that such peaks represented residual amounts of frusemide and this was taken
into account by using Equation 2.1 as described for paracetamol.
Results of plasma assay
Chromatograms from drug free plasma and from plasma containing frusemide
4.7 mg.l"1 are shown in Fig. 2.4. The retention times of frusemide and the internal
standard were 5.4 and 6.7 min respectively. The detection limit of the plasma assay
was O^mg.r1.
The high and the low range of plasma standards were assayed on 6 different occasions
over a 2 week period and results are shown in Tables 2.1 and 2.2 and Fig. 2.5 and
2.6 respectively. The calibration plots were linear in the range 1 to 10 and 0.2 to 0.5






Fig 2.4. Chromatograms obtained from (a) drug free plasma and (b) plasma obtained
from a patient with end stage renal failure maintained on CAPD 90 min after an oral
dose of 80 mg frusemide. The peaks are frusemide 4.7 mg.l"1 and internal standard.
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Table 2.1. The precision of the plasma frusemide HPLC assay from 1 to 10 mg.l"1












1 0.25 0.26 0.28 0.27 0.25 0.26 0.26
±0.01
4.1
2 0.44 0.45 0.44 0.48 0.44 0.46 0.45
±0.01
3.2
4 0.84 0.86 0.89 0.84 0.81 0.81 0.84
±0.03
3.3
6 1.29 1.24 1.21 1.28 1.24 1.19 1.24
±0.04
2.8
8 1.82 1.74 1.67 1.74 1.73 1.65 1.73
±0.06
3.2
10 2.11 2.26 2.08 2.19 2.13 2.11 2.15
±0.06
2.8
Table 2.2. The precision of the plasma frusemide HPLC assay from 0.2 to 0.5 mg.1"1
during 6 standard runs with calculation of the coefficient of variation (CV %).
Frusemide Peak area ratio mean CV






0.2 0.45 0.36 0.36 0.31 0.37 0.32 0.36
±0.05
12.5
0.3 0.63 0.65 0. 69 0. 65 0.65 0.74 0.67
±0.04
5.5




Mean peak height area ratio
Frusemide concentration (mg/1)
Fig 2.5. Linearity of the HPLC plasma assay for frusemide: Calibration plot of the
mean peak area ratio obtained following repeated analysis (n=6) of plasma containing
frusemide concentrations in the range 1 to id mg.l"1.
Mean peak height area ratio
0 0.1 0.2 0.3 0.4 0.5
Frusemide concentrations (mg/1)
Fig 2.6. Calibration plot of the mean peak height area ratio obtained following
repeated analysis (n=6) of plasma containing frusemide 0.2 to 0.5 mg .l"1.
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Measurement of frusemide in urine
As there was no interference from endogenous peaks, the urine samples were injected
directly into the HPLC system. For estimating the concentration of frusemide in
urine, standard solutions were made up with final concentrations ranging from 1 to
10 mg.l"1. To 200 pi of each standard sample was added 20 p\ of toluic acid
(1 mg.ml"1). The sample was whirlimixed and injected directly onto the HPLC col¬
umn. The factor representing the reciprocal of the slope of the regression line for the
standards was calculated and this was then multiplied by the peak area ratios of the
unknown samples from the patients or volunteers.
Results of urinary assay
Chromatograms from drug free urine and from urine containing frusemide 8.6 mg.l"1
are shown in Fig. 2.7. The retention times of frusemide and the internal standard
were 5.4 and 6.7 min respectively. The detection limit of the urinary assay was
o.Smg.r1.
Urinary standards were assayed on six different occasions over 1 week and results are
shown in Table 2.3 and Fig. 1.8. The calibration plot was linear in the range 1 to 10
mg.l"1 and the coefficient of variation was 6.8 %.
Measurement of frusemide in dialysate














Fig 2.7. Chromatograms obtained from (a) drug free urine and (b) urine collected
from a healthy volunteers 2-4 h after the administration of frusemide 40 mg orally.
The peaks are frusemide 8.6 mg.l"1 and internal standard.
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Table 2.3. The precision of the urine fusemide HPLC assay from 1 to 10 mg.l"1
during 5 standard runs with calculation of the coefficient of variation (CV %).
Frusemide Peak area ratio mean CV




1 0.17 0.15 0.14 0.14 0.15 0.15
±0.01
7.3
2 0.30 0.30 0.28 0.34 0.20 0.30
±0.02
6.7
4 0.70 0.66 0.69 0.59 0.50 0.63
±0.07
11.9
6 1.02 0.94 0.84 0.85 0.88 0.91
±0.07
7.4
8 1.29 1.14 1.14 1.10 1.12 1.16
±0.07
5.8




mean peak height area ratio
Fig 2.8. Linearity of the HPLC urine assay for frusemide: Calibration plot of the
mean peak height ratios obtained following repeated analysis (n = 5) of urine
containing frusemide concentrations in the range 1 to 10 mg.l"1.
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Measurement of plasma renin activity (PRA) by radioimmunoassay
PRA activity was measured by radioimmonoassay (RIA) of angiotensin 1 generated
under standard conditions (Haber et al., 1969). The intra- and inter-assay coefficients
of variation were 4 % and 6 %, respectively.
Measurement of urinary prostaglandin E2 (PGE2) and 6-keto prostaglandin Fln
(6-keto PGF1) by RIA
PGE2 was measured in urine using the RIA (kit number NEK020) supplied by Du
Pont U.K., Ltd., Stevenage, Hertfordshire, England. The intra- and inter-assay coef¬
ficients of variation were 7 % and 14 % respectively. Urinary 6-keto PGFla was
measured by RIA using a modification of a method described by Dray et al., (1975).
The intra- and inter-assay coefficients of variation were 7 % and 19 % respectively.
Urinary Sodium
Urinary sodium was measured by an ion selective electrode (Radiometer Ltd., U.K.).
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SECTION 2.3 PHARMACOKINETIC AND STATISTICAL ANALYSIS
Presentation of data
Results (mean ±standard deviation, s.d.) were presented both in tabular and dia¬
grammatic form. The data were entered onto an Amstrad PC2086/30 micro computer
containing a spread sheet programme ("SuperCalc 5") and the "SIPHAR" pharmaco¬
kinetic and statistics programme (SIMED, 1988).
Pharmacokinetic analysis
Pharmacokinetics deals primarily with the processes of drug absorption, distribution
and elimination and it is the mathematical description of the time course of changes in
the concentration of drugs and their metabolites in the body. Analysis is often based
on the use of mathematical models whereby the body is depicted as a system of inter¬
connected compartments each characterised by its volume and the relationships
between the rates of input and output of the drug. The simplest case is the one com¬
partment model in which it is assumed that a drug is introduced into the circulation,
distributed throughout the body virtually instantaneously and subsequently eliminated
at a rate proportional to its concentration (Gibaldi and Perrier, 1982).
In practice the tissue uptake and distribution of drugs takes time and a 2 compartment
model is often more appropriate. The body is considered as 2 separate but intercon¬
nected compartments, i.e. a central compartment consisting of the circulation and
well perfused organs into which the drug distributes quickly, and a peripheral poorly
perfused compartment representing the rest of the body where uptake is slower
(Gibaldi and Perrier, 1982). In such cases 2 phases are seen in the plot of log concen¬
tration versus time following a rapid intravenous injection (Fig. 2.9). This curve is the




The method of residuals can be used to resolve the drug plasma concentration-time
curve shown in Fig. 2.9 into the 2 exponential components. The terms "curve strip¬
ping" or "peeling" are used to describe this technique. The first steeper part of the
curve represents mainly distribution of the drug. The latter part is referred to as the
beta (B) phase and the decline largely represents elimination. The 2 phases can be
separated out by "curve stripping" where the slope of the elimination phase is extrapo¬
lated back to zero time with intercept "B" on the y axis and the concentrations of this
extrapolated line subtracted from the true plasma concentrations at each time point.
This generates a series of residual values which can be plotted on the graph to de¬
scribe the distribution process with slope "d" and intercept "D" on the y axis (Fig.
2.9).
Similarly, when a drug is administered orally and its plasma concentration-time pro¬
file described according to a 1 compartment model, the slope of the terminal linear
phase can be extrapolated to zero (Fig. 2.10). Subtraction of the true plasma concen¬
tration-time values in the absorptive phase from the corresponding concentration-time
values on the extrapolated line yields a series of residual concentrations which repre¬




Fig 2.9. The log plasma concentration-time curve obtained following a rapid intrave¬
nous injection comprising a rapid distribution (d) and a slower elimination (6) phase.
The 2 phases can be separated out by "peeling" where the slope of the elimination
phase is extrapolated back to zero time with intercept "B" on the y axis. The concen¬
trations of this extrapolated line are subtracted from the true plasma concentrations at
each time point and a series of residual values (■) are generated to describe the distri¬





Fig 2.10. The log plasma concentration-time curve following oral administration of a
drug described according to a 1 compartment model. The slope of the terminal linear
phase can be extrapolated back to zero and the true plasma concentrations in the
absorptive phase subtracted from the values on the extrapolated line yielding a series
of residual concentrations (■) which represents the absorptive phase.
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Using the plot of log plasma concentration against time several important variables
can be estimated.
(1) Cv 7 max
C-max rePresents the maximum concentration of drug in the plasma following an ex-
travascular dose.
(2) Tv 7 max
Tmax represents the time to reach peak plasma concentrations.
(3) **
The drug elimination half-life (t,^) is defined as the time taken for plasma concentra¬
tions to fall by 50% during the linear terminal elimination phase and is calculated as
K Equation 2.2
where K, the elimination rate constant of a drug is the fractional rate of decline per
unit time and ln2 is the natural logarithm of 2 i.e. 0.693 (Gibaldi and Perrier, 1982).
(4) Area under the plasma concentration versus time curve (AUC).
This represents the area under a drug concentration-time plot and it can be calculated
by the trapezoidal rule (Gibaldi and Perrier, 1982). This method involves the descrip¬
tion of a given plasma concentration-time curve by a function that depicts the curve as
a series of straight lines thereby enabling the area under the curve to be divided into a
number of trapezoids (Fig. 2.11). The area of each trapezoid is calculated and
summed. The area from the last experimental point Cn to infinity, oo; (the "tail") is




Fig 2.11. The area under the plasma concentration versus time curve (AUC) repre¬
sents the area under a drug concentration-time plot as a series of trapezoids. The area
of each trapezoid is calculated and summed and the area from the last experimental
point Cn to infinity is estimated as Cn/K.
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Thus, the AUC = the sum of trapezoidal areas + Cn
K Equation 2.3
(5) Volume of distribution (Vd).
The extent to which drugs are distributed or taken up into tissues is reflected by the
apparent volume of distribution which can be considered as the volume into which the
amount of drug in the body at any time would have to be diluted to give the observed
plasma concentration in a 1 compartment model.
Vd = amount of drug in body
plasma concentration Equation 2.4
In a 2 or more compartment model the Vd is determined by the partitioning character¬
istics of the compound as well and it can be estimated as
Vd = CI Equation 2.5
K
where CI is the clearance of the drug (see below). Both methods require that the drug
be given intravenously so that the amount reaching the systemic circulation is known
and equivalent to the administered dose and be known (Gibaldi and Perrier, 1982).
(6) Clearance.
The term "clearance" refers to the removal of drug from the blood as it passes
through an organ of elimination and it is defined as the volume of blood or plasma
from which the drug is totally removed per unit time. The total clearance is the sum
of the individual clearances that comprise drug elimination by parallel pathways (e.g.
liver metabolism and renal excretion) and it can be calculated as:
Total CI = intravenous dose
AUCQ ^ Equation 2.6
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The renal clearance of a drug can by calculated as follows:
Renal CI = amount excreted in a time interval
AUC in the same interval Equation 2.7
Patients with end-stage renal failure who depend on dialysis for elimination of waste
products may also clear drugs by this mechanism. Thus, in patients on peritoneal
dialysis the peritoneal clearance of a drug can be calculated as
Clearance of a drug by haemodialysis may be measured in terms of plasma (Cld)p and
is defined as:
where Qp is the plasma flow through the dialyser
Cap is the "arterial" plasma concentration of the drug
C^ is the "venous" plasma concentration of the drug, i.e. the plasma concentrations
of drug entering and leaving the dialyser (Gibaldi and Perrier, 1982).
(7) Bioavailability
Bioavailability refers to the rate and extent of drug absorption (Gibaldi and Perrier,
1982). The proportion of unchanged drug that reaches the systemic circulation follow¬
ing extravascular administration (F) can be calulated as
F = AUC, , after an oral dose
peritoneal CI = amount excreted into the peritoneum




AUC, , after the same intravenous dose(o-oo) Equation 2.10
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The "SIPHAR" pharmacokinetic programme
The most practical way of analysing pharmacokinetic data is to use a computer with a
programme such as "SIPHAR" (SIMED, 1988) for fitting experimental plasma
concentration-time data to the chosen data. The plasma concentrations were entered in
a data base, the results displayed graphically as a semi-log plot of drug concentration
versus time and the number of exponentials considered suitable to describe the data
were chosen by visual inspection. A theoretical curve was then superimposed on the
experimental points according to the chosen model and the model parameters estimat¬
ed by "peeling" (SIPHAR users manual, 1988).
Drugs were administered orally or by intravenous infusion over 1 h. Different equa¬
tions were used to describe the plasma concentration-time curves depending on the
routes of administration and selection of a 1 or 2 compartment model. Following oral
administration a 1 compartment model with 2 phases was defined by the equation:
C( = -Ae_kat + Be"Kt Equation 2.11
where Ct = the plasma concentration at time "t"
A = intercept on the y axis of the exponential representing absorption
B = intercept on y axis representing elimination
e = the base of the natural logarithm
K = the elimination rate constant of the drug
kg = The absorption rate constant of the drug (Gibaldi and Perrier, 1982).
The corresponding equation for a 2 compartment model was:
C = -Ae~kat + De~kdt + Be"Kt Equation 2.12
where D = intercept on the y axis representing distribution
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kd = the rate constant of distribution
When a drug was administered by intravenous infusion and the plasma concentration
time curve was best described by a single compartment model, the following equation
was used to calculate concentrations during the infusion (Gibaldi and Perrier, 1982).
C( = B(l-eKt)
KT Equation 2.13
where "T" = the duration of the infusion
For calculation of concentrations once the infusion was stopped, the following equa¬
tion was used:-
C, = B(l-e ) eKt\ „-K(t-T)
KT Equation 2.14
The corresponding equations for a 2 compartment model were:-
Ct = D(l-ekdt) + B(l-e'Kt)Kt\
kJ KT Equation 2.15
when t < T and
Ct = D(l-e~kdl) e"Kd(t"T) + B (l-eKt) e-*^
kdT KT Equation 2.16
whent>T (Notari, 1987).
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Using the unrefined model parameters obtained by "peeling" the SIPHAR programme
then minimised the differences between the theoretical curves and the observed data
by iterative non-linear regression analysis with weighting of the data according to the
method of least squares. The sum of the squared differences between the experimental
and computed values were minimised using the error variance as a weighting factor.
The programme improved the initial parameters by iteration so that the function was
minimised and the theoretical curve of best fit was imposed on the experimental
points.
In order to assess the goodness of fit the programme computed the correlation coeffi¬
cient between observed and theoretical values and the coefficients of variation of each
parameter. A coefficient of variation of over 20 to 30% was considered unacceptable
and the computed algorithim was revised using a different weighting. As different
equations could be used to fit the same data, the programme used a number of statisti¬
cal tests to select the best model such as the Akaike, Schwarz and Leonard criteria
(SIMED. 1988).
From the derived "best fit" model the programme calculated the elimination t,A, the
absorption, distribution and elimination rate constants and the AUCQ oe. The Vd and
total clearance were calculated using Equations 2.5 and 2.6 respectively. The latter
variables are model independent parameters and no assumptions are made about the
number of compartments.
Multiple dose simulation and predictions of steady-state concentrations
The SIPHAR programme was also used to describe the kinetic behaviour of a drug
during repeated administration. The theoretical maximum and minimum steady-state
concentrations were computed as well as the time to reach steady-state. The drug
kinetics were assumed to be linear and models with 1 or 2 exponentials were used.
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In order to calculate the plasma concentrations which would be achieved at steady-
state during repeated regular dosing, the superimposition principle was applied
(Gibaldi and Perrier, 1982 and Wagner, 1975). This overlay technique is based on the
assumptions that each dose acts independently of every other dose, that the rate and
extent of absorption and clearance are the same for each dosing interval and that the
kinetics are linear. A characterisation of the concentration-time profile after a single
dose is required and using the derived coefficients and exponentials the programme
displayed a simulated curve which depended on the initial dose, the dosing interval
and the dose given at each interval. From this curve the minimum and maximum
steady-state plasma concentrations could be obtained. The predicted steady-state
concentrations of a drug could be compared with the actual concentrations observed.
Percent absorbed and unabsorbed time plots
A useful way of evaluating the rate of drug absorption following oral administration
is the construction of a percent absorbed versus time plot The amount of drug ab¬
sorbed into the systemic circulation at a given time "t" equals the sum of the drug in
the body plus the cumulative amount of drug eliminated (i.e. by urinary excretion,
metabolism or any other route). The percent of drug absorbed at time "t" is defined as
the ratio between the cumulative amount of drug absorbed from time "0" to time "t"
and the total amount absorbed. It may be used to characterise the rate but not the
extent of absorption (Gibaldi and Perrier, 1982).
For a 1 compartment model a modification of the Wagner-Nelson method may be
used to calculate the percent of drug absorbed (Wagner and Nelson, 1964). Thus,
Ft = AUCp t + C/K
AUCQ ^ Equation 2.17
where F is the fraction of the dose absorbed at time "t". The equation therefore re-
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lates the cumulative amount of drug absorbed after a certain time to the amount of
drug ultimately absorbed. Following an oral dose of a drug, the fraction absorbed at
various time points can be calculated once the elimination rate constant is known.
Statistics
The following statistical tests were used to determine whether observed differences
between groups were significant (Kirkwood, 1990).
Comparison of 2 groups
The Students "t" test was used to test whether the differences between a 2 groups of
observations were significantly different and the level of significance was taken as P
< 0.05 %. The unpaired "t" test was used when the 2 sets of measurements were
completely independent and the paired "t" test was used when they were related to
each other in some way such as repeated observations on the same subjects.
When the t test is used it is assumed that the data are normally distributed and that the
populations from which the samples are drawn share the same variances. These
assumptions characterise the parametric tests. If these conditions were not met or
there was uncertainty, the non-parametric Mann-Whitney U test was used for unpaired
data and the Wilcoxon signed rank test for paired samples (Kirkwood, 1990).
Comparison of several groups
One-way analysis of variance (ANOVA) was used to compare the means of several
groups defined by a single factor. The method is based on how much of the overall
variation in the data is attributable to differences between the group means and
comparing this with differences between individuals in the same group (Kirkwood,
1990). Two-way ANOVA was used for data classified in 2 ways.
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CHAPTER THREE
THE DISPOSITION OF PARACETAMOL FOLLOWING A SINGLE DOSE
IN PATIENTS WITH END-STAGE RENAL FAILURE MAINTAINED
ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
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SECTION 3.1: INTRODUCTION
Continuous ambulatory peritoneal dialysis (CAPD) has become an established form of
renal replacement therapy since its introduction in 1976 (Popovich et al., 1978).
Pharmacokinetic studies in CAPD patients were stimulated early by the need to treat
peritonitis with antibiotics given intraperitoneally but the disposition of drugs taken
regularly by the patients for other diseases has not been studied in detail (Keller et al.,
1990). The need for adjustment of drug dosage in patients with end-stage renal failure
is well recognised (Bennett et al., 1983). However little attention has been paid to the
extent to which peritoneal dialysis alters drug disposition (Paton et al., 1985).
Paracetamol is commonly used by patients with chronic renal failure because it is
considered to be a relatively safe analgesic. In healthy volunteers about 90 % of a
therapeutic dose is excreted in the urine within 24 h, predominantly as the glucuronide
and sulphate conjugate of paracetamol with small amounts of glutathione-derived
conjugates (Forrest et al., 1982). Following the administration of 1 g paracetamol to
conservatively managed patients with chronic renal failure the concentrations of
paracetamol glucuronide and sulphate were greatly increased compared to healthy
volunteers given the same dose. Furthermore, in patients on haemodialysis studied on
an inter-dialysis day, the concentrations were even higher (Prescott et al., 1989).
In CAPD patients taking paracetamol regularly marked accumulation of the conjugates
would therefore be expected unless the peritoneal membrane was acting as an efficient
elimination mechanism. Although peritoneal dialysis has been shown to be an effec¬
tive method for removal of uraemic waste products it is thought to contribute little to
the clearance of most drugs (Paton et al., 1985). In addition little work has been done
on the effect of dialysate clearance on the elimination of drug metabolites but work
with metronidazole and cefotaxime suggests little clearance of their metabolites during
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CAPD (Guay et al., 1984 and Alexander et al., 1984). The glucuronide conjugate of
paracetamol was isolated however in the dialysate of patients on CAPD (Schoots et
al., 1990).
The object of this study was to establish the disposition of a single dose of paraceta¬
mol in patients with end-stage renal failure maintained on CAPD. In particular it was




Six patients (1 female, 5 male) maintained on CAPD for end-stage renal failure
(creatinine clearance < 5 ml.min"1) were studied. Their mean age was 55 yr (range
31-71) and weight 68 kg (range 49-84). Details of the medical histories and medica¬
tion are given in Table 3.1 and results of haematology and biochemistry screening in
Table 3.2. Patients with a history of peritonitis in the previous 3 months were exclud¬
ed as were patients with a haemoglobin concentration of less than 7 g.dl"1. Patients
were asked to avoid taking paracetamol for the 7 days before the study.
Patients performed 3 or 4 peritoneal exchanges each day via indwelling Tenckhoff
catheters at approximately 08.00, 13.00, 18.00 and 23.00 h as described in Chapter 2.
Details of the dialysis regimes and daily fluid allowances are given in Table 3.3.
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Table 3.1. Clinical details of six patients with end stage renal failure maintained on continuous
ambulatory peritoneal dialysis (CAPD) who were given 1 g paracetamol orally.
Patient Age &
No. sex
Medical diagnosis Regular drug therapy
1 62 M Goodpasture's Syndrome
hypertension
"Fefol vit" 2 daily
2 65 M diabetes mellitus type 2
hypertension
chronic renal failure ?cause
gliclazide 80 mg daily
metoprolol 25 mg BD
digoxin 62.5 jig daily
aluminium hydroxide 475 mg TID
"Fefol Vit" 2 daily
3 52 M diabetes mellitus type 2
diabetic nephropathy
gliquidone 30 mg BD
nifedipine retard 10 mg BD
metoprolol 25 mg BD
quinine sulphate 300 mg nocte





isosorbide mononitrate 10 mg daily
metoprolol 25 mg BD
terfenadine 60 mg BD
prednisolone 2 mg daily





nifedipine 5 mg BD
metoprolol 50 mg BD
doxazosin 4 mg BD
"Fefol Vit" 2 daily
aluminium hydroxide 950 mg BD
calcium carbonate 1.26 g daily
71 M proliferative glomerulonephritis
ischaemic heart disease
hypertension
diltiazem 60 mg TID
captopril 25 mg BD
prazosin 2 mg TID
aluminium hydroxide 475 mg TID
* ferrous sulphate 150 mg with vitamins B group and C
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Table 3.2. Clinical biochemical and haematological blood test results in 6 patients
with end stage renal failure maintained on continuous ambulatory peritoneal dialysis
given 1.0 g of paracetamol orally.
Patients
Plasma Normal
concentration 1 2 3 4 5 6 range
protein
g.l"1
68 66 66 57 55 72 60-80
albumin
g.l"1
38 39 38 34 34 42 36-47
calcium
mmol.l 1
2.2 2.3 2.4 2.1 2.3 2.1 2.1-2.6
phosphate
mmol.l 1
2.0 1.7 1.8 1.5 1.8 1.9 0.8-1.4





4 10 7 4 4 6 2-17
alanine amino¬ 16 35 24 16 10 14 10-40
transferase
u.l"1 (ALT)





18 20 23 20 23 20 24-30
creatinine
pmol.l"1
999 1326 1163 1128 1125 1233 55-150
urea
mmol.l"1
20.1 28.9 26.6 21.8 23.2 20.9 2.5-6.6
haemoglobin 8.4 8.7 8.6 10.3 5.8 9.6 13-18
g. dl





253 223 181 268 169 196 150-350
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Table 3:3. Details of the daily fluid allowance and dialysis regimes of six patients
with end stage renal failure maintained on continuous ambulatory peritoneal dialysis
given 1 g paracetamol orally.
Patient Daily fluid Time on Exchanges Glucose content
No. intake CAPD per day of each bag
(ml) (*)
1 750 3 months 3 2.27 X 1
1.36 X 2
2 1500 3 years 4 3.86 X 1
2.27 X 3
3 800 18 months 4 1.36 X 4
4 750 6 months 4 2.27 X 3
1.36 X 1
5 750 6 months 4 2.27 X 3
1.36 X 1




On the morning of the study day the fasting patients came to the CAPD training room
at 08.30 h with their overnight dialysate still in the peritoneal cavity. The weight and
glucose content of a new bag of dialysate was noted and the patients then performed
the first exchange of the day. An intravenous cannula was inserted in a forearm vein
and 1 g of paracetamol was administered orally (2 x 500 mg soluble "Panadol" tab¬
lets) dissolved in approximately 100 ml of water. The patients then remained recum¬
bent for 1 h.
The patients were allowed their normal fluid intake and they regulated this themselves
throughout the day (Table 3.3). Breakfast was served one hour after the dose of
paracetamol when the patients took their normal medications (Table 3.1) and lunch
was taken at 13.00 h according to their usual dietary requirements.
Venous blood (3 ml) was sampled before the paracetamol was administered and then
at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes after the dose.
The 3 or 4 used dialysate bags of that day were kept and the volume measured. All
urine passed during the 24 h period was collected. The patients were free to go home
after their 3rd exchange of the day at approximately 17.30 h.
Samples
All samples were processed as described in Chapter 2.
Drug assay
Plasma, urine and dialysate concentrations of paracetamol and its conjugates were
measured by HPLC as described in Chapter 2.
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Pharmacokinetic analysis of data
The SIPHAR pharmacokinetic programme was used to analyse the plasma concentra¬
tion-time curves of paracetamol as described in Chapter 2. The data were best de¬
scribed by a two compartment model with 3 phases comprising an absorption and
distribution phase followed by an elimination phase from 2 to 8 h. Initial parameters
were estimated by peeling and refined by iterative analysis. The goodness of the fit
was established by comparing the coefficients of variation of each parameter as de¬
scribed in Chapter 2. These are listed in Table 3.4 and were less than 20 to 30 % in
all cases.
Two of the patients (4 and 5) had peaks corresponding to paracetamol glucuronide and
sulphate in the plasma sampled at time 0 before the dose of paracetamol. This was
confirmed by the addition of glucuronidase and sulphatase as described in Chapter 2.
The corrected plasma concentrations of both conjugates were then calculated using
Equation 2.1 as described in Chapter 2.
The fitted model was used to describe the disposition of oral paracetamol and to
estimate the elimination half life. The AUCQ gh and AUC0 m of paracetamol and the
AUC0 gh of its glucuronide and sulphate conjugates was calculated using the trapezoi¬
dal rule. The peritoneal clearances of paracetamol and paracetamol glucuronide and
sulphate were calculated as described in Chapter 2.
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Table 3.4. The coefficients of variation (CV%) for the estimated parameters obtained by
analysis of the plasma concentration-time data following the administration of 1 g
paracetamol to patients with end stage renal failure maintained on continuous ambulatory
peritoneal dialysis. The data were best described by a two compartment model
comprising absorption, distribution and elimination phases. Initial parameters were
estimated by peeling and refined by iterative analysis. Each phase is represented by an
intercept and slope as described in Chapter 2.
Absorption Distribution Elimination
Patient
No. Intercept slope Intercept slope Intercept slope
(CV%) <CV%) (CV%) (CV% ) (CV%) (CV%)
1 0.6 21.0 13.3 21.3 4.0 3.0
2 0.0 28.1 1.4 4.7 2.1 3.1
3 0.8 14.4 16.0 17.2 3.0 2.1
4 0.1 9.8 0.6 9.1 5.8 4.5
5 0.2 23.9 7.4 7.0 4.1 1.9




The individual and mean plasma concentrations of paracetamol following the adminis¬
tration of 1 g orally to the 6 CAPD patients are shown in Figs. 3.1 and 3.2 respective¬
ly and the estimated pharmacokinetic parameters are listed in Table 3.5. Paracetamol
was absorbed rapidly with mean peak plasma concentrations of 15.9 +3.6 mg.l"1
occurring at 27.5 ±5.6 min after the dose (Table 3.5). The AUC0 gh was 2551 +400
min.mg.l"1 and AUC^ was 2998 ±634 min.mg.l"1. The mean elimination half life of
paracetamol derived from the fitted model was 180.3 ±6.2 min (Table 3.5).
Paracetamol glucuronide conjugate
The individual and mean plasma concentrations of the glucuronide conjugate of para¬
cetamol are shown in Figs. 3.3 and 3.2 respectively and the pharmacokinetic parame¬
ters are listed in Table 3.6. Following the administration of paracetamol to the CAPD
patients the mean Cmax of its glucuronide conjugate was 24.2 ±6.5 mg.l"1 and the
mean T was 320.0 +89.4 min. The mean AUC„ was 7623 ±2635 min.mg.l"1.
max — 0-on
The plasma concentrations of the glucuronide conjugate varied little from 2 to 8 h and
it was not possible therefore to accurately estimate the elimination half life (Fig 3.2).
Paracetamol sulphate conjugate
The individual plasma concentrations of the sulphate conjugate of paracetamol are
shown in Fig 3.3 and the pharmacokinetic parameters are listed in Table 3.6. Follow¬
ing the administration of paracetamol to the CAPD patients the mean Cmax of the
sulphate conjugate was 14.1 ±3.5 mg.l"1 and the mean T was 290.0 ±144.6 min.
The AUCQ gh was 4645 ±1482 min.mg.l"1. As in the case of the glucuronide conju¬
gate it was not possible to estimate the elimination half life because the concentration
of the sulphate conjugate varied little from 2 to 8 h (Figure 3.3).
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Table 3.5. Maximum plasma concentration (C ), time to reach maximum concentrationr v max
(T ), area under the plasma concentration time curve from 0 to 8 h and from 0 h tomax' 7
infinity (AUC0 8h and AUC0 oo) and elimination half life (t1/4) of paracetamol in 6 patients
with end stage renal failure maintained on continuous ambulatory peritoneal dialysis













1 12.7 30 2410 2790 160.3
2 16.8 15 3214 4619 318.1
3 12.5 30 2446 2809 166.5
4 21.1 30 2507 2831 162.7
5 19.8 30 2822 3182 132.0
6 12.6 30 1906 2140 142.0
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Table 3.6. Maximum plasma concentration (C ), time to reach maximum*■ y max'
concentration (T ), area under the plasma concentration time curve from 0 to 8 h
(AUC^g) of the glucuronide (G) and sulphate (S) conjugates of paracetamol and the
ratios of the AUC 0 gh of the G and S conjugates in 6 patients with end stage renal












1 G 32.2 300 11117 2.6
S 13.8 180 4191
2 G 14.6 420 4768 0.9
S 13.9 480 5271
3 G 21.4 360 7102 1.3
S 13.9 360 5308
4 G 24. 5 180 6252 3.1
S 8.4 420 1994
5 G 19.8 240 5215 1.2
S 14.4 240 4233
6 G 32.5 420 11281 1.6




Fig 3.1. Plasma concentrations of paracetamol in 6 CAPD patients following 1 g orally.
Plasma concentrations (mg/1)
Time (min)
Fig 3.2. Mean plasma concentrations of paracetamol and its glucuronide and sulphate
conjugates in 6 CAPD patients following 1 g oral paracetamol.
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Time (min)
Fig 3.3. Plasma concentrations of paracetamol glucuronide in 6 CAPD patients following
the administration of 1 g paracetamol orally.
Plasma concentrations (mg/1)
0 60 120 180 240 300 360 420 480
Time (min)
Fig 3.4. Plasma concentrations of paracetamol sulphate in 6 CAPD patients following the
administration of 1 g paracetamol orally.
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Normally paracetamol is metabolised to its glucuronide and sulphate conjugate in a
ratio of 60 to 30 %. This ratio is unchanged in patients with conservatively managed
renal impairment (Prescott et al., 1989). In the present study although the mean ratio
of the AUC,, „. of the glucuronide and sulphate conjugates was 1.8:1, 3 of the 6 pa-U-on
tients had lower ratios than expected (Table 3.6)
Paracetamol cysteine and mercapturate conjugates
The cysteine and mercapturate acid conjugates could not be measured in the plasma of
the CAPD patients.
Urinary recovery of paracetamol and its glucuronide and sulphate conjugates
Three of the 6 patients were anuric (2, 4 and 5). Only one patient (1) had measurable
amounts of paracetamol in the urine in the 24 h following the dose (1.6 mg). The
mean 24 h urinary recoveries of the glucuronide and sulphate conjugates in the 3
patients were 39.2 ±15.5 mg and 11.8 ±4.8 mg respectively.
Recovery of paracetamol and its conjugates in the dialysate
The recovery of paracetamol and its glucuronide and sulphate conjugates during each
exchange is shown in Table 5.7. Only 2 of the 3 used dialysate bags were collected
from patient 1. Significant amounts of paracetamol were recovered in the first two
exchanges only. The total amount recovered was 16.0 ±7.5 mg or 1.6 ±0.7 % of
the administered dose. The corresponding peritoneal clearance from 0 to 8 h was 6.0
±2.1 ml.min"1.
The recovery of the glucuronide conjugate in the dialysate was 69.4 ±33.4 mg in the
8 h following the dose of paracetamol and the corresponding peritoneal clearance was
6.8 ±2.0 ml.min"1. The total recovery in the dialysate in 24 h was 165.2 ±63.0 mg
(n=5).
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Table 3.7. The recovery of paracetamol and its glucuronide and sulphate
conjugates in the dialysate of 6 patients with end stage renal failure maintained
on continuous ambulatory peritoneal dialysis (CAPD). Patients performed 3
(patient 1) or 4 peritoneal exchanges a day starting at approximately 08.30,
13.00, 18.00 and 23.00 h. Paracetamol 1 g was administered orally at the start
of the first exchange at 08.30 h.
Paracetamol recovery (mg)
Patient
1 2 3 4 5 6
Exchange
1 14.1 15.2 10.0 10.5 10.0 8.2
2 2.8 13.8 8.6 3.8 0.0 0.0
3 - 0.0 0.0 0.0 0.0 0.0
4 0.0 0.0 0.0 0.0 0.0
Paracetamol glucuronide recovery (mg)
Patient
1 2 3 4 5 6
Exchange
1 25.9 19.6 8.0 27.2 42.0 30.8
2 44.1 25.3 19.4 40.1 82.6 51.9
3 - 28.3 26.0 59.8 108. 5 52.0
4 33.1 36.1 52.9 32.4 49.8
Paracetamol sulphate recovery (mg)
Patient
1 2 3 4 5 6
Exchange
1 0.0 13.1 6.0 14. 6 0.0 0.0
2 0.0 18.4 10.8 18.9 18.9 0.0
3 - 17.4 12.0 23.4 2.2 0.0
4 18.6 14.0 18.4 0.0 0.0
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Following the dose of paracetamol 27.3 ±7.4 mg (n=3) of the sulphate conjugate had
been recovered in the dialysate by the end of the second exchange at 8 h. No sulphate
conjugate was recovered in the dialysate of patient 1 or 6 during that time or from the
1st and 4th exchange of patient 4 possibly due to technical problems. In the other 3
patients, the mean peritoneal clearance from 0 to 8 h was 4.7 ±1.2 ml.min"1. The
total recovery in the dialysate in the 24 h period was 61.9 ± 13.8 mg (n = 3).
Assuming that paracetamol is metabolised to its glucuronide and sulphate metabolite
in the normal ratio of 2:1 in the CAPD patients and that the absorption of paracetamol
was complete, 27.5 ±10.5 % of the total amount of the glucuronide conjugate formed
and 20.6 ±13.8 % (n = 3) of the sulphate conjugate formed were removed in the
dialysate in the 24 h following the dose of paracetamol. The concentrations of the
cysteine or mercapturate conjugates were too low to be measured in the dialysate.
SECTION 3.4: DISCUSSION
In patients with end-stage renal failure maintained on CAPD, the absorption of para¬
cetamol was rapid and maximum concentrations were achieved within 30 min. Mean
maximum plasma concentrations of paracetamol in fasting healthy subjects have been
noted at 22 min following the ingestion of paracetamol in solution (Nimmo et al.,
1975) and at 20 min (McGilveray and Mattok, 1972), 21 min (Prescott et al., 1989),
60 min (Dordoni et al., 1973) and 1.4 h (Heading et al., 1973) after the ingestion of
paracetamol tablets.
The absorption of paracetamol has previously been shown to be normal in patients
with conservatively managed renal failure and haemodialysis patients (Prescott et al.,
1989) and maximum plasma concentrations and the time taken to achieve them were
similar to the findings in the present study. Similarly, the elimination half life of
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paracetamol from 2 to 8 h in healthy volunteers, conservatively managed patients with
chronic renal failure and haemodialysis patients was in agreement with the elimination
half life of 3 h in the present study.
Following a therapeutic dose, paracetamol is extensively metabolised to its glucuro-
nide and sulphate conjugate in the liver (Forrest et al., 1982). In healthy fasting volun¬
teers given 1 g orally peak plasma concentrations of the glucuronide conjugate of 9.4
±2.6 mg.l"1 occurred 2.0 ±4.4 h after the dose (Prescott et al., 1989). The corre¬
sponding concentrations of the sulphate conjugate were 3.7 ±0.9 mg.l"1 and these
occurred at 1.1 ±0.5 h. In the present study not only were the concentrations of the
glucuronide and sulphate conjugates much higher, but the mean times to reach
maximum concentration were delayed for 5.3 ±1.5 h and 4.8 ±2.4 h respectively.
Similar results were found in conservatively managed patients with chronic renal
failure with residual creatinine clearances of 5 to 23 ml.min'1 (Prescott et al. 1989).
Furthermore, although the relative amounts of glucuronide to sulphate conjugates
formed was similar to normal in the CAPD patients as judged by the mean ratios of
the AUC^gh, the ratio was reduced in some of the patients.
Less than 2 % of the administered dose of paracetamol was recovered in the dialysate
and the mean peritoneal clearance was 6 ml.min"1. The peritoneal clearance of the
glucuronide and sulphate conjugate were similar and less than 30 % of the conjugates
formed were recovered in the dialysate in 24 h, assuming that absorption of paraceta¬
mol was complete and that approximately 60 % and 30 % of the dose was metabolised
to the glucuronide and sulphate conjugate respectively.
The factors which affect the rate of removal of a drug during peritoneal dialysis are
thought to be the physiochemical properties of the drug (including the molecular
weight, water solubility and lipid partition), the physiology of the peritoneal mem-
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brane (surface area, vascularity and ultrafiltration properties of the membrane) and the
peritoneal solution type, flow rate and osmolality (Paton et al., 1985). In addition,
the pharmacokinetic properties of a drug (or drug metabolite) which affect its rate of
removal are the degree to which it is protein bound and its volume of distribution
(Paton et al., 1985). The greatest contribution to clearance by the peritoneum is
thought to be for drugs which are almost exclusively removed by the kidney (Paton et
al., 1985 and Keller et al., 1990). In order for a drug to be cleared by the peritoneal
membrane to a significant degree it has therefore to have low plasma protein binding
(<20 %), a small volume of distribution (< 1 1.kg"1) and little non-renal clearance
under normal circumstances. The low flow rate of the peritoneal effluent (7ml.min"1)
appears to be the most important limiting factor for the extraction capacity of CAPD
(Keller et al., 1989).
The highly polar glucuronide and sulphate conjugates of paracetamol are normally
excreted by the kidneys probably both by filtration at the glomerulus and active secre¬
tion at the tubules resulting in clearances of about 130 and 170 ml.min"1 respectively
(Forrest et al., 1982). The volumes of distribution of the glucuronide and sulphate
conjugate of paracetamol are small (<0.3 l.kg"1) and are similar in healthy volunteers
and patients with chronic renal failure (Prescott et al., 1989). Furthermore, the conju¬
gates do not bind to plasma proteins even at the relatively high concentrations found
in anephric patients (Lowenthal et al., 1976). It was not unexpected therefore that
these patients with end-stage renal failure would eliminate some of the accumulated
conjugates of paracetamol by peritoneal clearance but that the extraction capacity
would be limited to a maximum of about 7ml.min"1.
Although there is some evidence that the biliary excretion of paracetamol conjugates
may be increased in renal failure (Siegers and Klaassen, 1984), CAPD patients are
largely dependent on peritoneal clearance for elimination of paracetamol metabolites.
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Given the low extraction capacity peritoneal dialysis following a single therapeutic
dose of paracetamol, it would seem inevitable that marked accumulation of the glucu-
ronide and sulphate metabolites would occur during regular dosing. Although these
metabolites are thought to be inactive under normal circumstances their biological
effects are unknown at very high concentrations (Prescott et al., 1989). In addition,
some of the retained conjugates might undergo enterohepatic elimination with hydrol¬
ysis in the gut by microflora and subsequent reabsorption of the parent compound
(Veerbeck et al., 1981 (a)). Furthermore the production of the glutathione-derived
metabolites might be increased under such circumstances.
It seems inevitable therefore that patients with end-stage renal impairment who are
maintained on CAPD will accumulate polar drug metabolites given the low extraction
capacity of the peritoneal membrane. It may be necessary to reduce the dose when
renal elimination of either the drugs themselves or their active or inactive metabolites
is limited by renal disease as has been demonstrated for paracetamol.
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CHAPTER FOUR
THE DISPOSITION OF PARACETAMOL AND THE ACCUMULATION
OF ITS GLUCURONIDE AND SULPHATE CONJUGATES
DURING MULTIPLE DOSING
IN PATIENTS WITH CHRONIC RENAL FAILURE
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SECTION 4.1: INTRODUCTION
The excretion of polar drug metabolites is impaired in patients with chronic renal
failure. When single doses of paracetamol were given to patients with renal impair¬
ment, the plasma concentrations of its glucuronide and sulphate conjugates were great¬
ly increased compared with those observed in healthy volunteers (Prescott et al.,
1989). Similarly, as discussed in Chapter 3, patients with end-stage renal failure
maintained on CAPD had very high plasma concentrations of these conjugates follow¬
ing a single dose of paracetamol and their clearance across the peritoneal membrane
was limited by a low effective "flow rate". Furthermore, in anephric patients haemod-
ialysis appeared to be the major route of elimination of paracetamol metabolites (3e et
al., 1975).
Therefore, when patients with moderate to severe renal impairment take paracetamol
regularly over a long period of time, significant accumulation of its polar metabolites
would be expected. Under these conditions it is possible that the retained conjugates
might undergo enterohepatic circulation, with some regeneration of the parent com¬
pound by hydrolysis in the gastrointestinal tract with subsequent reabsorption (Verb-
eeck et al., 1981 (a)). It is also possible that the production of the potentially toxic
glutathione-derived conjugates might be increased.
Few studies have been done to determine the degree of drug and metabolite accumula¬
tion during long term treatment of patients with impaired renal function. The disposi¬
tion of paracetamol and its metabolites was therefore compared in healthy volunteers
and in conservatively managed patients with chronic renal failure taking 1 g of para¬
cetamol three times a day for 10 days. The plasma concentrations of the glucuronide
and sulphate conjugates were compared with those expected on the basis of previous




Studies were carried out in 6 healthy volunteers (3 men and 3 women) of mean age
32 yr (range 18-37) and mean weight 60 kg (range 48-75). They had no medical ill¬
ness, physical examination was normal, they were on no medication, they did not
smoke and they all claimed to drink less than 5 units of alcohol per week. The results
of routine biochemical and haematological screening tests are presented in Table 4.1.
Patients
Six patients (5 men, 1 woman) on conservative management for chronic renal failure
were also studied. Their mean age and weight were 55 yr (range 43-75) and 74 kg
(range 52-97). Details of the medical histories and medication are presented in Table
4.2 and the results of biochemistry and haematology screening in Table 4.3. The
mean plasma creatinine concentration was 451.5 ±178.8 ^mol.l"1 and mean creatinine
clearance 22.8 ±10.6 ml.min"1. Both patients and volunteers were asked to avoid
taking paracetamol for 7 days before and for 4 days after the study.
Experimental Design
The patients and volunteers took paracetamol 1 g (2 x 500 mg soluble "Panadol"
tablets) dissolved in approximately 100 ml of water, at 10.00, 16.00 and 22.00 h for
10 days. Food was avoided for 2 h before and for 2 h after dosing. Venous blood
was sampled at 09.00 h on the first day of the study before starting paracetamol
treatment, at the same time (09.00 h) each morning for the next 10 days, and on the
mornings of the 2nd and 4th days after the last dose of paracetamol.
Samples
All samples were processed as described in Chapter 2.
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Table 4.1. Clinical biochemical and haematological blood test results in 6
healthy volunteers given 1.0 g of paracetamol three times a day for 10 days.
Volunteers
Plasma Normal
concentration 1 2 3 4 5 6 range
protein
g.l-1
70 74 71 68 70 71 60-80
albumin
g.i"1
40 50 45 45 43 48 36-47
calcium
mmol.I-1
2.4 2.5 2.3 2.3 2.4 2.4 2.1-2.6
phosphate
mmol.l 1
1.1 0.9 1.1 0.6 1.3 0.9 0.8-1.4





11 9 5 4 6 2 52-17
alanine amino¬ 49 22 16 23 10 19 10-40
transferase
u.l-1 (ALT)





24 28 28 25 25 24 24-30
creatinine
fjmol. I-1
82 85 75 96 77 64 55-150
urea
mmol.l 1
3.3 5.1 4.6 6.1 4.6 3.8 2.5-6.6




7.7 4.4 4.9 7.2 7.3 5.3 4-11
platelets
x 109.!"1
230 285 216 171 317 218 150-350
87
Table 4.2. Clinical details of six conservatively managed patients with chronic renal failure
taking 1.0 g paracetamol three times a day for 10 days.
Patient Age &
No. sex
Medical diagnosis Regular drug therapy
59 M membranous glomerulnephritis
hypertension
frusemide 40 mg daily
enalapril 2.5 mg daily
aspirin 75 mg daily
sodium bicarbonate 1.5 g TID
40 M Diabetic nephropathy
insulin dependent diabetes mellitus
hypertension
insulin
captopril 25 mg TID
frusemide 40 mg daily
metoprolol 50 mg BD
43 F pyelonephritis sodium bicarbonate 1 g QID
aluminium hydroxide 950 mg QID
la-hydroxycholecalciferol 0.25 ng daily
clonazepam 1 mg nocte
50 M mesangial proliferative
glomerulonephritis
hypertension
nifedepine retard 10 mg BD




for carcinona of bladder
isosorbide mononitrate 10 mg BD
sodium bicarbonate 500 mg QID
65 M diabetic nephropathy
insulin dependent diabetes mellitus
hypertension
insulin
indapamide 2.5 mg daily
enalapril 10 mg BD
sodium bicarbonate 1 g TID
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Table 4.3. Clinical biochemical and haematological blood test results in 6
conservatively managed patients with chronic renal failure taking 1.0 g of paracetamol
three times a day for 10 days.
Patients
Plasma Normal
concentration 1 2 3 4 5 6 range
protein
g.i"1
74 63 64 60 73 65 60-80
albumin
g • i-1
35 40 41 33 42 39 36-47
calcium
mmol.l ^
2.3 2.3 2.6 2.1 2.3 1.9 2.1-2.6
phosphate
mmo1.1
1.0 1.5 2.3 0.8 0.9 1.5 0.8-1.4





4 11 5 6 6 6 2-17
alanine amino¬ 29 27 19 20 10 31 10-40
transferase
u.l"1 (Alt)





15 19 21 23 25 21 24-30
creatinine
pmol.I-1
407 312 774 379 247 590 55-150
urea
mmol.I-1
15.4 20.2 21.2 14.1 14.0 29.4 2.5-6.6
creatinine 22 42 8 18 29 18 >100
clearance
ml .min-1




6.2 8.7 5.6 7.4 8.9 4.8 4-11
platelets
x 109.1-1
153 273 263 306 249 197 150-350
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Drug assay
Plasma concentrations of paracetamol and its conjugates were measured by HPLC as
described in Chapter 2.
Pharmacokinetic analysis of data
Steady-state concentrations of paracetamol glucuronide and sulphate conjugates were
predicted from the relationship between the degree of renal failure and the minimum
steady-state concentrations calculated from data obtained in a previous single-dose
study where a group of conservatively managed patients with chronic renal failure
were given a single dose of 1 g paracetamol (Prescott et al., 1989). The data were
fitted to a single compartment model by the SIPHAR pharmacokinetic programme as
discussed in Chapter 2. The "dose" of conjugate was taken as the amount formed
from the administered paracetamol.
Using the derived coefficients and exponents the minimum steady-state conjugate
concentrations with the present repeated dose schedule were simulated according to
the superimposition principle as described in Chapter 2 (Wagner 1975). The results
are presented on Table 4.4 .
The calculated concentrations of glucuronide and sulphate conjugates were closely
related to the plasma creatinine concentration (r = 0.89 and 0.95 respectively,
p < 0.01), and the corresponding regression equations were used to predict the mini¬
mum concentrations at steady-state in the present study. Thus the concentrations of the
glucuronide conjugate were predicted from the equation
y= 0.36(x) -89.51
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Table 4.4. Simulated minimum steady state plasma concentrations of the glucuronide
and sulphate conjugates of paracetamol calculated from the data from a single-dose
study of paracetamol 1 g in a group of conservatively managed patients with chronic


















where "y" was the expected minimum steady-state concentration of glucuronide
conjugate and "x" is the plasma creatinine.
Similarly, for the sulphate conjugate the steady state concentrations were predicted
from the following equation:
y= 0.18(x) -44.65
where "y" is the expected concentration of the sulphate conjugate at steady state and
"x" is the plasma creatinine concentration as before.
Statistics
The statistical significance of differences was determined by the Mann-Whitney test
and correlations were determined using standard regression analysis. The concentra¬
tions of the conjugates were expressed as paracetamol equivalents.
SECTION 4.3: RESULTS
Paracetamol
The mean daily pretreatment plasma concentrations of paracetamol in the healthy
volunteers and patients with chronic renal failure are presented in Table 4.5 and Fig
4.1. Each day the residual plasma concentrations of paracetamol were higher in the
renal failure patients than in the volunteers. The mean values over the 10 days of
treatment were 3.1 ±0.6 and 1.1 ±0.3 mg.l"1 respectively (p < 0.01).
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Paracetamol glucuronide conjugate
The mean daily pretreatment plasma concentrations of the glucuronide conjugate of
paracetamol in the volunteers and patients are presented in Table 4.5 and Fig. 4.2. As
expected the mean daily concentrations of the glucuronide conjugate were markedly
higher in the patients than in the volunteers.
The mean plasma glucuronide concentrations increased progressively to 87.1 ±67.6
mg.l"1 on day 6, after which there was no further accumulation (Table 4.5 and Fig.
4.1). However, there was considerable interindividual variation in the concentrations
of retained conjugates at steady-state and in the time taken for this to be reached and
the means of the concentrations measured on the 7th to 10th days were therefore
taken to represent steady-state values. The mean steady state concentration of the
glucuronide conjugate was more than twenty five times higher in the patients than in
the volunteers (Table 4.5) and there was a positive correlation with the plasma creati¬
nine concentration (r=0.97, p<0.01, n = 6, Figure 4.3).
Paracetamol sulphate conjugate
The mean plasma concentration of the sulphate conjugate in the renal failure patients
was 21.7 ±11.2 mg"1 after the first 24 h and 24.5 ±18.4 mg.r1 by the 10th day of
treatment with little daily variation (Table 4.5 and Fig. 4.4). The steady-state concen¬
trations were over twenty times higher than in the normal volunteers. However, the
corresponding correlation between the steady state concentrations of the sulphate
conjugate and the plasma creatinine concentration was not statistically significant
(r=0.74, p>0.05, n=6, Figure 4.5).
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Table 4.5. Mean daily pre-dose plasma concentrations of paracetamol and of its glucuro-
nide and sulphate metabolites (mg.r1) in 6 healthy volunteers and 6 patients with chronic







Healthy 1.3 1.4 1.2 1.2 1.7 1.5 0.8 ND
volunteers ±0.5 ±0.5 ±0.5 ±0.7 ±1.6 ±0.7 ±0.5
Renal failure 2.4 2.7 3.1 2.9 2.7 3.4 3.1 ND
patients ±0.4 ±0.7 ±1.1 ±0.9 ±1.5 ±2.0 ±1.3
Glucuronide concentrations (ma.I-1 )
Healthy 2.9 3.8 3.7 3.9 2.6 4.5 3.0 0.3
volunteers ±0.8 ±1.3 ±0.9 ±1.4 ±1.5 ±1.3 ±0.5 ±0.6
Renal failure 39.1 58.0 68.4 69.9 78.0 87.1 87.0 4.4
patients ±19.7 ±36.3 ±47.7 ±51.3 ±61.6 ±67.6 69.0 6.6
Sulphate concentrations (ma -l"1)
Healthy 1.7 1.6 1.4 1.4 1.7 1.9 1.1 0.5
volunteers ±0.6 ±0.4 ±0.6 ±0.6 ±1.0 ±0.9 ±0.4 ±0.3
Renal failure 21.7 25.1 26.3 24.7 25.0 27.6 25.0 1.4
patients ±11.2 ±16.6 ±19.0 ±17.4 ±21.1 ±23.7 ±19.0 ±1.9
ND=not detectable
*mean of concentrations on days 7-10
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Plasma concentrations (mg/1)
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Time (day)
Fig 4.1. Daily pre-dose plasma concentrations (mean +s.d.) of paracetamol in 6
volunteers and 6 conservatively mananaged patients with chronic renal failure taking
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Fig 4.2. Daily pre-dose plasma concentrations (mean ±s.d.) of paracetamol glucuronide
in 6 volunteers and 6 patients with chronic renal failure taking paracetamol 1 g 3 times a
















Fig 4.3. Steady-state plasma concentrations of paracetamol glucuronide plotted against
plasma creatinine in 6 patients with chronic renal failure taking paracetamol 1 g 3 times a




Fig 4.4. Daily pre-dose plasma concentrations (mean ±s.d.) of paracetamol sulphate in 6













Fig 4.5. Steady-state plasma concentrations of paracetamol sulphate plotted against plasma
creatinine in 6 patients with chronic renal failure taking paracetamol 1 g 3 times a day for
10 days.
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Predicted glucuronide and sulphate conjugate concentrations
The minimum steady-state plasma concentrations of the glucuronide conjugate pre¬
dicted from the previous single-dose studies were remarkably similar to the concentra¬
tions observed at steady-state in the patients with renal failure (Table 4.6, Fig. 4.6)
However, predictions of the steady-state concentrations of the sulphate conjugate were
accurate in only 3 of the 6 patients, and were less than 50% of those expected in the
others (Table 4.6, Fig. 4.7). In the patients in whom the predicted and observed
concentrations of sulphate conjugates were similar, the ratios of the plasma concentra¬
tions of the glucuronide to sulphate conjugates were less than about 3.0, as expected
(2.0, 1.9 and 2.5) whereas in the other three the ratios were much greater (5.7, 4.4
and 5.3).
Cysteine and mercapturate conjugates
The cysteine and mercapturic acid conjugates of paracetamol were detected only in the
plasma of the patient with the most severe renal failure and the concentrations were
very low.
Plasma concentrations after stopping paracetamol
Paracetamol and its glucuronide and sulphate conjugates disappeared rapidly from the
plasma in both volunteers and patients once paracetamol was discontinued (Table 4.5).
Only the two patients with the most severe renal failure still had detectable amounts of
retained conjugates in the plasma 4 days after stopping the paracetamol.
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Table 4.6. The observed and predicted minimum steady state plasma concentrations
(mg.l _1) of the glucuronide and sulphate conjugate of paracetamol and the ratio of
steady state plasma concentrations of the glucuronide and sulphate conjugate in patients










1 58.9 57.7 28.1 13.1 4.4
2 24.3 28.1 11.1 14.8 1.9
3 192.8 209.9 93.7 39. 5 5.3
4 48.7 43.2 23.1 7.5 5.7
5 31.4 31.0 12.4 15.5 2.0















Fig 4.6. Observed and predicted minimum steady-state plasma concentrations of
paracetamol glucuronide in 6 patients with chronic renal failure taking paracetamol 1 g 3














Fig 4.7. Observed and predicted minimum steady-state plasma concentrations of
paracetamol sulphate in 6 patients with chronic renal failure taking paracetamol 1 g 3
times a day for 10 days.
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SECTION 4.4: DISCUSSION
Oral paracetamol is metabolised extensively by conjugation with glucuronic acid and
sulphate. A small fraction of the dose is converted to a reactive intermediate metabo¬
lite, which is then conjugated with glutathione and excreted as cysteine and mercaptu-
rate conjugates. Over 90% of a therapeutic dose is normally excreted in the urine as
metabolites within 24 h (Forrest et al., 1982). In patients with renal failure the ability
of the kidney to eliminate polar metabolites is limited, and during repeated dosing
significant accumulation of paracetamol conjugates was expected.
When patients with chronic renal failure were given 1 g of paracetamol 3 times daily
for 10 days, plasma concentrations of paracetamol were higher than in healthy volun¬
teers taking the same dose. This confirms similar findings in a single-dose study of
paracetamol disposition in patients with renal failure (Prescott et al., 1989). The
mechanisms are unknown, but it has been suggested by Siegers and Klaassen (1984)
that biliary excretion of paracetamol conjugates may become more important when
their urinary excretion is reduced in renal failure. They showed that in rats with bilat¬
eral ligation of the ureters the amount of paracetamol conjugates cleared by the biliary
system was markedly increased. In such circumstances the enterohepatic circulation
of glucuronide and sulphate metabolites may be increased and paracetamol may be
regenerated by hydrolysis of the conjugates by gastrointesinal flora, with subsequent
reabsorption of the parent drug (Verbeeck et al., 1981 (a)).
The mean plasma concentrations of the sulphate and glucuronide conjugates were
markedly higher in the patients with renal failure. There was however no evidence
that the concentrations of the potentially toxic glutathione-derived conjugates were
increased under these circumstances. Steady-state concentrations were reached for the
sulphate and glucuronide conjugate by about the 2nd and 6th day respectively. The
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plasma concentrations of the glucuronide conjugate at steady-state depended on the
severity of the renal failure but this relationship did not hold for the sulphate conju¬
gate. Similarly, the steady-state concentrations of the glucuronide conjugate could be
accurately predicted from single-doses studies, but the accumulation of the sulphate
conjugate was much less than predicted in 3 of the 6 patients.
Long term or high dose paracetamol therapy is associated with a reduced rate of
formation of the sulphate conjugate. This is due primarily to sulphate depletion (Levy
& Yamada 1971; Lin & Levy 1981; Clements et al., 1984), although the serum con¬
centrations of inorganic sulphate are not invariably lower than normal (Hendrix-
Treacy et al., 1976). A reduced availability of inorganic sulphate may have limited
the amount of conjugate formed over the 10 day dosing period in some of our pa¬
tients. On the other hand, chronic renal failure is often associated with sulphate reten¬
tion (Freeman & Richards 1979) and so depletion should be less likely to occur even
with large doses of paracetamol (Lin & Levy 1982). The patients were taking other
medications and it is conceivable that this might have influenced paracetamol metabo¬
lism.
Whatever the mechanism, it is clear that the sulphate conjugation of paracetamol was
limited in some of the patients with chronic renal failure. Consequently, the concen¬
trations of the glucuronide conjugate were relatively higher, as shown by the in¬
creased ratio of glucuronide to the sulphate conjugate formed at steady state. Nor¬
mally this ratio is about 2:1 (Forrest et al., 1982). This relationship was maintained
in the three patients in whom the predicted and observed steady-state concentrations of
sulphate conjugate were similar, but not in the other three.
When patients with conservatively managed renal failure took paracetamol regularly
for 10 days there was marked accumulation of the glucuronide conjugates as predict-
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ed. The results suggested possible enterohepatic cycling of the retained conjugates
with regeneration of the parent compound by hydrolysis in the gut, with subsequent
reabsorption. Although the sulphate conjugate accumulated over the 10 days it was
less than predicted and was not dependent on the degree of renal failure. Further
studies of the apparent non-linear sulphate conjugation of paracetamol in patients with
renal failure are indicated, using a range of doses, with simultaneous measurement of
the serum inorganic sulphate concentrations.
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CHAPTER FIVE
THE DISPOSITION OF PARACETAMOL AND ITS CONJUGATES
DURING MULTIPLE DOSING




Patients with end-stage renal failure are frequently maintained on haemodialysis. Such
patients usually require medication to treat both the renal disease and other related or
unrelated conditions (Lee and Marbury, 1984). Due to the marked impairment of
renal function, dosage adjustments may be needed for drugs which produce active
metabolites or are normally largely excreted unchanged (Bennett et al., 1983). On the
other hand a drug may be removed by haemodialysis to the extent that a dosage sup¬
plement is required to maintain therapeutic efficacy. Knowledge of the effect of
haemodialysis on the elimination of specific drugs is therefore essential for rational
dosage regime design in patients undergoing haemodialysis (Lee and Marbury, 1984).
In haemodialysis patients given single doses of paracetamol on an interdialysis day,
there was pronounced accumulation of paracetamol glucuronide and sulphate (Lowen-
thal et al., 1976, Prescott et al., 1989). Furthermore the metabolite concentrations
did not fall significantly over 24 h suggesting that baemodialysis was effectively the
only method for their elimination (Prescott et al., 1989). It was predicted that the
average maximum plasma concentrations of glucuronide and sulphate conjugates
would exceed 500 and 400 mg.l"1 during regular therapy with 1 g paracetamol 4 times
daily in patients with end-stage renal failure on twice weekly maintenance haemodial¬
ysis (Prescott et al., 1989).
The object of this study was to establish the disposition of paracetamol and the
accumulation of its conjugates in haemodialysis patients given paracetamol regularly
over 10 days. In particular, it was hoped to assess the role of haemodialysis in the
elimination of retained paracetamol conjugates and to establish whether the procedure




Six patients (4 male, 2 female) maintained on haemodialysis for end-stage renal fail¬
ure (creatinine clearance <5 ml.min"1) were studied. Their mean ages and weights
were 53 yr (range 23-63) and 69 kg (range 59-79). Details of their medical histories
and medication are presented in Table 5.1 and the results of biochemistry and haema-
tology screening in Table 5.2. Patients were asked to avoid taking paracetamol for 7
days before and for 4 days after the study.
All patients were on maintenance haemodialysis 2 or 3 times weekly as described in
Chapter 2. Details of the dialysis regimes are given in Table 5.3.
Experimental design
The patients took paracetamol 1 g (2 x 500 mg soluble "Panadol" tablets) dissolved in
approximately 100 ml of water 3 times a day for 10 days (Table 5.4). Food was
avoided for 2 h before and for 2 h after dosing. Venous blood was sampled on the
first day of the study before starting paracetamol, each day for the next 10 days and
on dialysis day in the 2 weeks following the last dose of paracetamol. To avoid dis¬
ruption of the patients' normal schedules the times of dosing and blood sampling were
individualised for each patient depending on whether they were dialysed in the morn¬
ing or afternoon. Blood was sampled on dialysis days before starting the procedure
and on interdialysis days at a set time for each patient (Table 5.4).
In addition, clearance studies were performed on two of the patients (5 and 6) on the
day after the last dose (day 10). At the start of dialysis, blood was sampled from the
"arterial" and 1 min later from the "venous" side of the extracorporal dialysis circuit
(i.e. before and after the dialyser, Chapter 2) and repeated hourly during dialysis.
106
Table 5.1. Clinical details of six patients with end stage renal failure maintained on haemo-
dialysis who were given 1 g of paracetamol 3 times a day for 10 days.
Patient Age &
No. sex




















"Fefol vit" 2 daily
glyceryl trinitrate patch
nifedepine 10 mg BD
temazepam 10 mg nocte
calcium resonium 15 g BD
"Fefol Vit" 2 daily
aluminium hydroxide 950 mg TID
digoxin 0.125 mg daily
isosorbide mononitrate 20 mg BD
nifedepine 10 mg BD
labetolol 100 mg BD
temazepam 10 mg nocte
"Fefol Vit" 2 daily
aluminium hydroxide 950 mg TID
metoprolol 75 mg daily
buprenorphine 400 fig PRN
temazepam 10 mg nocte
"Fefol Vit" 2 daily
ferrous sulphate 320 mg mane
aluminium hydroxide 475 mg TID
metoprolol 50 mg BD
la cholecalciferol 0.25/xg mane
calcium resonium 15 g BD
"Fefol Vit" 2 daily
ferrous sulphate 320 mg daily
aluminium hydroxide 950 mg BD
"Fefol Vit" 2 daily
ferrous sulphate 320 mg daily
aluminium hydroxide 950 mg TID
metoprol 50 mg BD
isosorbide mononitrate 10 mg BD
diltiazem 60 mg TID
la cholecalciferol 0.25 fig daily
aspirin 75 mg daily
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Table 5.2. Clinical biochemical and haematological blood test results in 6 patients with
end stage renal failure maintained on haemodialysis taking 1.0 g of paracetamol three
times a day for 10 days. Blood was sampled before dialysis.
Patients
Plasma Normal
concentration 1 2 3 4 5 6 range
protein
g.l"1
70 72 68 70 70 69 60-80
albumin
g.l"1
37 42 37 42 42 43 36-47
calcium
mmol.l 1
2.8 2.1 2.5 2.4 2.5 2.4 2.1-2.6
phosphate
mmo1.1 1
1.9 2.1 2.0 1.7 1.9 1.7 0.8-1.4





3 4 3 4 5 6 2-17
alanine amino¬ 16 15 10 14 13 10 10-40
transferase
u.l"1 (Alt)





22 21 30 17 24 16 24-30
creatinine
pmol.l 1
1166 1407 1094 1263 1604 1094 55-150
urea
mmol.l"1
28.8 31.8 18.1 23. 1 32.9 34.6 2.5-6.6




4.9 8.1 4.2 5.1 5.2 5.4 4-11
platelets
x 109.!"1
292 247 162 201 249 143 150-350
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Table 5:3. Details of the dialysis regimes of 6 patients with end stage renal failure on













1 10 months 2 09.30 3.5
2 1 year 2 16.00 4.5
3 3 years 3 09.30 4.0
4 2 years 2 09.30 4.0
5 7 years 3 16.00 5.0
6 10 years 3 16.00 4.0
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Table 5.4. Dosing regime and time of blood sampling in 6 patients with end stage renal failure
maintained on haemodialysis taking 1 g paracetamol 3 times a day for 10 days.









































16.00 4 16.00 4
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Samples
All samples were processed as described in Chapter 2.
Drug assay
Plasma concentrations of paracetamol and its conjugates were measured by HPLC as
described in Chapter 2.
Pharmacokinetic analysis of data
Two of the patients (5 and 6) had peaks corresponding to paracetamol glucuronide and
sulphate on the chromatograms from plasma sampled before starting the study. The
presence of the metabolites was confirmed by the addition of B-glucuronidase and
sulphatase as described in Chapter 2. Haemodialysis was carried out before the pa¬
tients starting taking paracetamol and the remaining samples could not therefore be
corrected for the residual amounts of conjugates.
The minimum and maximum steady-state concentrations of the glucuronide and sul¬
phate conjugate which would be expected in haemodialysis patients during regular
treatment with paracetamol were calculated using the results of a previous study
where single doses of 1 g were given to haemodialysis patients (Prescott et al., 1989
and Prescott LF : personal communication). Predictions based on the superimposition
principle were made for patients receiving 1 g paracetamol 4 times a day for 10 days
maintained on twice weekly haemodialysis regimes. The clearance of paracetamol
glucuronide and sulphate during haemodialysis was assumed to be the same as in an
earlier study (Zle et al., 1975). Although the dosing regime was different and 3 of the 6
patients in the present study were on thrice weekly sessions of haemodialysis, the
calculations were used as a rough guide to the expected accumulation of the conju¬
gates.
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The plasma clearance of paracetamol and its conjugates during haemodialysis was
calculated for patients 5 and 6 after every hour of the procedure on the 10th day of the
study using Equation 2.9 as described in Chapter 2. This calculates the clearance as
the product of the dialyser plasma flow rate and the extraction ratio of paracetamol or
its conjugates. The latter is the difference between the "arterial" and "venous" plasma
concentrations flowing in and out of the machine divided by the "arterial" concentra¬
tion. The plasma flow rate is the product of the blood flow rate and (1-haematocrit).
During haemodialysis the blood flow rates of patients 5 and 6 were 250 and 200
ml.min"1 respectively and these were taken to represent plasma flow rates in the
haemodialysis patients because the haematocrits were low due to anaemia (0.33 and
0.28, respectively, normal range 0.4-0.54).
The elimination half life of paracetamol and its conjugates during haemodialysis was
estimated from the plasma concentrations of paracetamol taken hourly from the "arte¬
rial" side of the fistula during the procedure. The amount of paracetamol and its
conjugates removed by dialysis were calculated as:
Amount removed = clearance x AUC Equation 4.1
where clearance = clearance by haemodialysis of paracetamol or its conjugates
AUC = corresponding AUC during haemodialysis of paracetamol or its conjugates
or
Amount removed = clearance x plasma concentration x t Equation 4.2
clearance = clearance calculated each hour, plasma concentration = "arterial" plasma
concentration of paracetamol or its conjugates each hour and t = length or dialysis.
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The amount of paracetamol or its conjugates present in the body at the start and end of
dialysis was calculated as
Amount in body = plasma concentration x Vd Equation 4.3
The total clearance during haemodialysis was calulated as
Clearance = 0.693 x Vd Equation 4.4
The Vd of paracetamol in patients with renal failure is 0.9 l.kg"1 (Forrest et al., 1982)
and of its conjugates about 15 1 (Lowenthal et al., 1976).
Statistics
The significance of any observed differences between the haemodialysis patients and
the CAPD or conservatively managed patients dicussed in Chapters 3 and 4 respec¬





The individual and mean daily plasma concentrations of paracetamol in the 6 patients
with the days on which haemodialysis took place are presented in Tables 5.5 and Fig.
5.1.
The mean plasma concentration of paracetamol was 6.8 ±1.9 mg.l'1 after the first
24 h of treatment and 6.4 ±2.2 after the 10th day with little daily variation (Table
5.5). Each day blood was sampled either from 1.5 to 2 h or from 4 to 5 h after the
last dose depending on the individual patients and whether it was a dialysis or interd-
ialysis day (Table 5.4 and 5.5). Thus, in 5 of the 6 patients sampling was usually
carried out 4 or 5 h after the last dose and the concentrations of paracetamol varied
from 4 to 11 mg.l'1 for each patient (Table 5.5). When single doses of paracetamol
1 g were given to patients with end-stage renal failure maintained on CAPD (Chapter
3) the mean plasma concentration measured 4 to 5 h later was 3.5 ±0.7 mg.l"1 . The
corresponding concentrations in the haemodialysis patients measured 4 or 5 h after the
dose were therefore considerably higher (p<0.01).
Paracetamol glucuronide conjugate
The mean daily plasma concentrations of the glucuronide conjugate of paracetamol are
presented in Table 5.6 and Fig 5.1. The mean plasma concentration after the first 24 h
of treatment was 46.8 ±9.9 mg.l"1 and by the 10th day was 60.3 ±7.3 mg.l"1. Appar¬
ent steady-state concentrations of 60.0 ±11.1 mg.l"1 were reached by the 2nd day and
thereafter concentrations varied little on each subsequent day (Table 5.6). Concentra¬
tions measured from the 7th to 10th day were therefore taken to represent steady-state
concentrations.
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The mean steady-state concentrations of paracetamol glucuronide measured in con¬
servatively managed patients with chronic renal failure treated with a similar regime
of paracetamol (Chapter 4) were higher than in the haemodialysis patients at 87.0
+69.0 compared with 67.5 +16.4 mg.l"1 but the differences failed to reach statistical
significance.
Paracetamol sulphate conjugate
The mean daily concentrations of the sulphate conjugate of paracetamol are presented
in Table 5.6 and Fig. 5.1. After the first 24 h of treatment the mean plasma concen¬
tration of the sulphate conjugate was 39.6 ±15.3 mg.l"1 and by the 10th day it was
55.4 +11.8 mg.l"1. As in the case of the glucuronide conjugate, apparent steady-state
concentrations were reached by the 2nd day (54.5 +10.6 mg.l"1) and thereafter there
was little day to day variation (Table 5.5).
The mean steady-state concentration of the sulphate conjugate in the conservatively
managed group was 25.0 +19.0 mg.l"1 and this significantly lower than in the hae¬
modialysis group (55.5 +8.1 mg.l"1, p<0.01).
Plasma cysteine and mercapturate conjugates
The mean daily plasma concentrations of the cysteine and mercapturate conjugates of
paracetamol are presented in Table 5.6 and Fig. 5.1. All of the patients had measura¬
ble amounts of both conjugates but concentrations of the cysteine conjugate were
always higher than those of the mercapturic acid conjugate. Mean steady-state concen¬
trations of 5.7 +2.3 and 3.7 ±1.4 mg.l"1 respectively were reached by the 2nd day
of treatment and there was little variation thereafter during the rest of the study (Table
5.6).
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Fig 5.1. Mean plasma concentrations of paracetamol and its glucuronide, sulphate,
cysteine and mercapturic acid conjugates in 6 patients with end stage renal failure
maintained on haemodialysis taking 1 g paracetamol 3 times a day for 10 days.
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Predicted glucuronide and sulphate conjugates concentrations
Based on the results of a previous single dose study the minimum and maximum
plasma concentrations of the glucuronide conjugates which would be expected in
haemodialysis patients taking 1 g paracetamol 4 times a day for 10 days with twice
weekly haemodialysis sessions were 101 ±37 and 569 ±150 mg.l'1 respectively
(Prescott et al., 1989 and Prescott : personal communication). The corresponding
concentrations expected for the sulphate conjugate were 123 ±24 and 434 ±92 mg.1"1
respectively.
In the present study most of the blood sampling took place either 4 or 5 h after the last
dose of paracetamol (Table 5.4). In patients with end-stage renal failure maintained on
CAPD given single doses of paracetamol it took about 5 h to reach maximum plasma
concentrations of the glucuronide and sulphate conjugate (Chapter 3). Therefore, in
the present study the plasma concentrations of the glucuronide and sulphate conjugates
were measured when maximum or near maximum concentrations would be expected.
The observed mean steady-state concentrations of the glucuronide and sulphate conju¬
gate of 67.5 ±16.4 and 55.5 ±8.1 mg.l"1 respectively were therefore much lower
than the predicted maximum concentrations of 569 ±150 and 434 ±92 mg.l"1 respec¬
tively. Indeed the observed near maximum concentrations were much less than the
predicted minimum steady-state concentrations shown above. Furthermore the ratio of
the steady-state concentrations of the glucuronide and sulphate conjugate was 1:1
apart from patient 3 where a slightly higher ratio of 1.8:1 was found.
Clearance of paracetamol and its conjugates during haemodialysis
The hourly concentrations of paracetamol and its glucuronide, sulphate, cysteine and
mercapturate conjugates in blood entering and leaving the dialyser, extraction ratios
and clearances by haemodialysis in patients 5 and 6 are presented in Table 5.7 and 5.8
and results are presented graphically in Fig. 5.2 and 5.3.
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Table 5.7. Plasma concentrations of paracetamol and its glucuronide and
sulphate conjugates sampled from the "arterial" and "venous" sides of the of
the extracorporal dialysis circuit (i.e. before and after the dialyser) during
haemodialysis on day 10 in 2 patients with end stage renal failure given 1 g
paracetamol 3 times a day for 10 days. Extraction ratios and clearances during













5 1 2.2 1.3 0.40 98.8
6 1 3.5 2.5 0.29 57.1
5 2 2.1 1.2 0.41 102.2
6 2 2.9 2.0 0.32 63.9
5 3 1.7 1.1 0.37 91.9
6 3 2.4 1.3 0.44 88.2
5 4 1.6 1.0 0.36 90.5
6 4 1.7 1.2 0.27 54.1
5 5 1.5 0.6 0.59 149.6
Glucuronide
5 1 47.3 41.5 0.12 30.3
6 1 62.1 55.2 0.11 22.2
5 2 47.7 44.9 r.06 14.8
6 2 56.6 50.1 0.11 22.9
5 3 48.5 42.4 0.12 31.2
6 3 56.8 48.2 0.15 30.3
5 4 44.4 38.7 0.13 31.8
6 4 57.6 44.8 0.22 44.5
5 5 45.5 33.1 0.27 68.2
Sulphate
5 1 44.6 26.7 0.40 122.5
6 1 41.3 25.6 0.38 71.3
5 2 39.7 30.2 0.24 128.6
6 2 34.8 20.1 0.42 85.9
5 3 35.5 17.6 0.50 126.9
6 3 30.2 17.5 0.42 104.9
5 4 27.7 14.9 0.46 140.8
6 4 26.8 12.3 0.54 68.1
5 5 24. 5 8.4 0.66 189.7
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Table 5.8. Plasma concentrations of the cysteine and mercapturate conjugates
of paracetamol sampled from the arteri?! and venous lines of the extracorporal
dialysis circuit (i.e. before and after the dialyser) during haemodialysis on day
10 in 2 patients with end stage renal failure given 1 g paracetamol 3 times a
day for 10 days. Extraction ratios and clearances during haemodialysis were













5 1 2.6 1.3 0.49 122.6
6 1 2.6 1.4 0.44 88.4
5 2 2.3 1.1 0.52 128.8
6 2 2.4 1.1 0.51 102.98
5 3 1.9 0.9 0.55 137.4
6 3 2.0 1.1 0.46 91.8
5 4 1.7 0.8 0.56 141.0
6 4 1.8 1.0 0.43 86.5
5 5 1.3 0.4 0. 73 181.3
Mercapturate
5 1 2.0 1.0 0.49 122.5
6 1 1.6 1.0 0.36 71.3
5 2 1.7 0.8 0.51 128.7
6 2 1.2 0.7 0.43 86.0
5 3 1.3 0.6 0.51 126.9
6 3 1.0 0.5 0.52 104.9
5 4 1.2 0.5 0.56 140.8
6 4 0.9 0.6 0.34 68.1

















Fig 5.2. "Arterial" plasma concentrations of paracetamol and its glucuronide, sulphate,
cysteine and mercapturic acid conjugates measured during haemodialysis in a patient













Fig 5.3. The corresponding concentrations in patient 6.
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The mean extraction ratios of paracetamol in patients 5 and 6 were 42.4% and 26.3%
respectively and the corresponding mean clearances were 106.0 and 65.8 ml.min"1
(Table 5.7). Similar values were noted for the sulphate conjugate (Table 5.7) but the
extraction ratios and plasma clearances for the glucuronide conjugate were much
lower in both patients (14.1 and 12.0% and 35.3 and 24.0 ml.min"1 for patients 5 and
6 respectively, Table 5.7).
The extraction ratios of the cysteine and mercapturate conjugate were similar to those
calculated for paracetamol and its sulphate conjugate as were the plasma clearances
during haemodialysis although the latter were slightly higher in patient 5 at 140
ml.min"1 for both conjugates (Table 5.8).
Elimination half life of paracetamol and its conjugates during haemodialysis
The elimination half life of paracetamol and its conjugates in patients 5 and 6 are
presented in Table 5.9. During haemodialysis the i of paracetamol was 5.6 and 2.9 h
in patients 5 and 6 respectively and values for the sulphate, cysteine and mercapturic
acid conjugates ranged from 3 to 5 hours (Table 5.9). The t1/4 of the glucuronide
conjugate during dialysis was markedly prolonged, however, at 46.4 and 31.9 h in
patients 5 and 6 respectively and this is in keeping with the limited clearance of the
conjugate during the procedure.
Amount of paracetamol and its conjugates removed during haemodialysis
The amount of paracetamol and its conjugates removed during dialysis and the
amounts present in the body at the beginning and end of the procedure are presented
in Table 5.9. At the beginning of the procedure 195 and 597 mg of paracetamol were
present in patients 5 and 6 respectively. The amounts of the glucuronide (731 and
921 mg respectively) and sulphate conjugate were similar in each patient (751 mg and
688 mg respectively). The concentations of the glucuronide conjugate were therefore
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equivalent to only 1 dose of 1 g paracetamol and the sulphate to 2 doses if paraceta¬
mol was metabolised to its glucuronide and sulphate conjugate in the normal ratio of
2:1.
There was good agreement using Equations 4.1 and 4.2 to calculate the amounts of
paracetamol and its conjugates removed during haemodialysis. Similar amounts of
paracetamol and its cysteine and mercapturate conjugates were removed (Table 5.9).
Despite the fact that there were similar amounts of paracetamol glucuronide and
sulphate present in the body at the start of the procedure, much less glucuronide was
removed than sulphate during haemodialysis (494 and 423 versus 1573 and 700 mg,
Table 5.9).
When the difference between the amount of paracetamol and its conjugates present in
the body at the start and end of dialysis was calculated considerably more paracetamol
had been removed during dialysis than estimated from the dialysis clearances (Table
5.9). This presumably reflects clearance by metabolism as well as dialysis. On the
other hand, the amounts of the glucuronide and sulphate metabolites removed during
haemodialysis appeared to be much less when calculated by this method but this may
also reflect their ongoing production from paracetamol metabolism. In agreement with
this the total clearance of paracetamol in both patients calculated from Equation 4.4
was much greater (144 and 297 ml.min'1) than the corresponding clearances by
haemodialysis calculated from the extraction ratios (106.0 and 52.7 ml.min"1) and the
clearances of the glucuronide and sulphate conjugates was much less (Table 5.9).
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Table 5.9. Elimination half life (t,^) of paracetamol and its conjugates, plasma clearance
(0.693 x Vd/tI/S), amount removed from the body during haemodialysis (HD) (clearance x
AUC during dialysis) or (mean hourly clearance x hourly "arterial" plasma concentrations
(c) x time (t) of dialysis), where clearance is calculted from the extraction ratio of the
dialyser, the amount present in the body at the start and end of the procedure (plasma
concentration x Vd) and the calculated differences in amounts in 2 haemodialysis patients
taking 1 g paracetamol 3 times a day for 10 days. Calculations were performed during
haemodialysis on the tenth day of the study.
Clear Amount removed Amount in body
-ance during HD during HD
CI x AUC Cl x c x t start end Start-end
(h) (ml.min (mg) (mg) (mg) (mg) (mg)
Paracetamol 5.6 144.4 62 57 195 42 153
2.9 278.8 54 41 597 84 513
Glucuronide 46.4 3.7 494 480 731 496 235
conjugate 31.9 5.4 423 408 921 672 279
Sulphate 4.7 36.9 1572 1410 751 126 625
conjugate 5.0 34.7 700 648 688 185 503
Cysteine 4.0 92 81
conjugate 4.6 53 50
Mercapturate 3.5 67 57
conjugate 3.3 26 21
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Plasma concentrations after stopping paracetamol
Plasma concentrations of paracetamol and its conjugates were measured in 5 of the 6
patients within 4 days of stopping paracetamol (Tables 5.5 and 5.6). All of the pa¬
tients had been dialysed on day 10 and these samples were taken from days 11 to 14
before any further haemodialysis had taken place. Patient 6 had large concentrations
of paracetamol in his plasma suggesting recent ingestion so the data were omitted. All
of the other 4 patients had measurable quantities of paracetamol in the plasma and the
mean concentration was 1.5 ±0.5 mg.l"1. The corresponding mean concentration of
the glucuronide conjugate was 54.3 ±10.3 mg.l"1 which was similar to that observed
during treatment (Table 5.6). The concentration of the sulphate conjugate was lower
than during the treatment days at 19.3 ±6.6 mg.l"1 as were concentrations of the
cysteine and mercapturate conjugates at 1.8 ±0.8 and 1.7 ±0.4 respectively (Table
5.6).
Further samples were taken in 4 of the 6 patients between 7 and 10 days of stopping
treatment. Small amounts of paracetamol were present in 3 of the 4 patients with
mean concentrations of 0.6 ±0.4 mg.l"1 (Table 5.5). The glucuronide conjugate was
present in the plasma at mean concentrations of 13.7 ±8.1 mg.l"1 and the sulphate
conjugate at 6.4 ±2.1 mg.l"1. The cysteine but not the mercapturate conjugate was
still measurable in 2 patients (Table 5.6).
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SECTION 5.4: DISCUSSION
In haemodialysis patients taking regular doses of paracetamol the concentrations of
paracetamol measured 4 or 5 h after the last dose were higher than expected based on
the results of the single dose study in a similar group of patients with end-stage renal
failure maintained on CAPD (Chapter 3). This confirms the findings in conservatively
managed patients with chronic renal failure on a similar regime of paracetamol where
higher than normal concentrations of paracetamol were measured in the plasma sever¬
al hours after the previous dose (Chapter 4).
Although the results may be explained by enterohepatic recycling of retained paracet¬
amol conjugates with regeneration and subsequent reabsorption of the parent com¬
pound (Verbeeck et al., 1981 (a)) an alternative explanation is limited conjugation to
paracetamol glucuronide and sulphate under conditions of prolonged dosing (Slattery
and Levy, 1979). In keeping with this, the accumulation of the glucuronide and sul¬
phate metabolite was much less than had been predicted from a previous single dose
study in haemodialysis patients and the elimination half life of paracetamol was pro¬
longed in one of the 2 patients in whom it was measured.
The limited capacity of the body to metabolise paracetamol to its sulphate conjugate
has been well documented (Galinsky and Levy, 1981, Clements et al., 1984, Lin and
Levy, 1981, Hendrix-Treacy et al., 1986) and is thought to be due to the limited
availability and consequent depletion of inorganic sulphate. Infusion of paracetamol
in rats was associated with pronounced accumulation of paracetamol in the plasma due
to decreased formation of the sulphate metabolite which could be prevented by
concomitant infusion of sodium sulphate (Galinsky and Levy, 1981).
Paradoxically, sulphate retention occurs in renal failure and is thought to be a conse-
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quence of decreased renal excretion of sulphate together with continued ingestion of
sulphur containing foodstuffs (Freeman and Richards, 1979). Although haemodialysis
has been shown to significantly reduce the plasma sulphate in patients with end-stage
renal failure (Holmes et al., 1960) the amount removed may depend on the type of
system used for haemodialysis (Freeman and Richards, 1979). Even when a distinct
decrement in serum sulphate occured during haemodialysis the post dialysis values
were still elevated compared to normal and the subsequent predialysis sulphate values
were 4 to 5 times greater than in normal subjects.
The conjugation of paracetamol with sulphate is facilitated in animals with renal fail¬
ure due to the retention of inorganic sulphate and sulphate depletion does not occur
even during prolonged intravenous infusion of paracetamol (Lin and Levy, 1982). It is
thought, however, that depletion would occur eventually if the administration rate of
paracetamol was sufficiently high and prolonged (Levy, 1986).
This may explain why the sulphate conjugate did not accumulate as predicted in the
haemodialysis patients during the 10 days of paracetamol treatment despite the fact
that sulphate retention was likely. On the other hand it may explain the altered ratio of
paracetamol glucuronide to sulphate in the plasma which indicated that concentrations
of the conjugates were present in roughly equal proportions rather than the 2:1 ratio
normally expected. The accumulation of the sulphate conjugate was significantly less
in the conservatively managed patients possibly because sulphate retention would be
less marked with that degree of renal impairment. Furthermore, conservatively
managed patients are restricted in their intake of protein including the sulphur contain¬
ing amino acids whereas haemodialysis are allowed to eat more protein presumably
leading to higher concentrations of inorganic sulphate available for conjugation.
Following a single dose of paracetamol in patients with chronic renal failure the frac-
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tional urinary recovery of paracetamol plucuronide was normal (Prescott et al., 1989).
There is some evidence, however, that glucuronide conjugation may also be limited in
man (Slattery and Levy, 1979). Although this has been demonstrated for salicylamide
(Levy and Matsuzawa, 1967) and salicylic acid (Levy et al., 1972) it has not been
feasible to administer sufficiently large doses of paracetamol to human subjects to test
the hypothesis but analysis of urine samples following self administration in suicide
attempts indicate that the fractional conversion of the drug to both its sulphate and
glucuronide conjugate decreased with increasing dose (Slattery and Levy, 1979).
Furthermore, inhibition of paracetamol sulphate formation by concomitant administra¬
tion of ascorbic acid causes an increase in the fraction of paracetamol excreted un¬
changed and as the glucuronide conjugate but the latter was not increased as much as
expected (Houston and Levy, 1976). Increasing doses of paracetamol in rats were
associated with a less than proportional increase in the rate of formation of paraceta¬
mol glucuronide (Galinsky and Levy, 1979).
The evidence for saturation of glucuronide metabolism in overdose patients has been
challenged however and results from other studies in patients without liver damage
following paracetamol overdose show an increased ratio of paracetamol glucuronide to
the parent compound and the sulphate conjugate (Prescott, 1983). Although glucuro¬
nide conjugation becomes impaired in the presence of hepatic necrosis following
overdose there was no evidence of saturation kinetics of the pathway in patients
without liver damage based on a number of studies (Prescott, 1983).
Another explanation for the lower than predicted plasma concentrations of the glucu¬
ronide conjugate might be increased biliary excretion of the retained metabolites in the
haemodialysis patients. Enterohepatic recycling may become more important in renal
failure and increased biliary excretion of the glucuronide conjugate with hydrolysis in
the gut and subsequent reabsorption of the parent compound paracetamol may have
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compensated for the reduced renal clearance in these patients (Verbeeck et al.,1981
and Siegers and Klaassen, 1984). In addition, various tissues in the body may possess
glucuronidase activity which may lead to deconjugation and liberation of the paracet¬
amol (Wakabayashi, 1970). The patients were all taking a variety of other medications
which could have conceivably altered the metabolism of paracetamol.
If glucuronide (or sulphate) metabolism were limited in these patients then increased
formation of the glutathione-derived conjugatesmight be expected. In healthy subjects
given 1 g paracetamol the ratios of paracetamol and its glucuronide, sulphate, cysteine
and mercapturate conjugates in the urine were 4.1 : 60.7 : 28.1 : 3.0 and 4.1 % and
similar ratios were seen in patients with impaired renal function given the same dose
(Prescott et al., 1989). In patients who had taken paracetamol overdoses but had not
suffered liver damage the corresponding ratios were 8.6 : 75.3 : 9.3 : 6.9 % where
the last value refers to combined cysteine and mercapturate conjugates. The latter
value was increased to 15.2 % in patients who had suffered liver damage (Prescott,
1983). In the present study the ratios of steady-state plasma concentrations (from day
7 to 10) of paracetamol and its conjugates were 7.7: 67.5 : 55.5 : 6.7 : 4.1 mg.l"1.
The combined cysteine and mercapturate conjugates were therefore in an appropriate
ratio to the paracetamol and paracetamol glucuronide suggesting that production of the
glutathione-derived conjugates was not increased in the haemodialysis patients.
In patients with end-stage renal failure, extraction ratios of 0.46 to 0.78 for paraceta¬
mol and 0.13 to 0.60 for paracetamol sulphate during haemodialysis were reported
and these are in agreement with the present findings (Zie et al., 1976). Similarly, in
another study, the extraction efficiency of dialysis averaged 47.5 and 43 % for the
parent compound and total metabolites (glucuronide and sulphate) respectively (Lee et
al., 1981). The corresponding dialysis clearances were 112 ml.min"1 and
105.8 ml.min"1 respectively.
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The extraction ratio of the glucuronide metabolite in the present study was surprising¬
ly low in the 2 subjects and the corresponding clearance during dialysis was less than
40 ml.min"1 in both cases. In addition, much less of the glucuronide than sulphate
conjugate was removed during dialysis despite similar amounts of both being present
in the body at the start of the procedure and the elimination half life of the former
conjugate was greatly prolonged.
It is unclear why less paracetamol glucuronide was cleared during haemodialysis and
the results should be interpreted cautiously because data was available from only 2
patients. The low clearance may possibly be due to the greater size of the glucuronide
compared to the sulphate conjugate and presumably explains why the plasma concen¬
trations of the glucuronide conjugate fell less rapidly once paracetamol was stopped.
Despite limited clearance by haemodialysis, a concentration of the glucuronide conju¬
gate equivalent to only 1 g paracetamol was present in the body at the start of the
procedure on the 10th day of the study. Possible explanations for this finding include
reduced absorption of paracetamol or reduced metabolism to the glucuronide conju¬
gate, both of which seem unlikely, as has been discussed or increased biliary excre¬
tion of the retained conjugates under these conditions.
In these patients with end-stage renal failure maintained on haemodialysis the accumu¬
lation of the glucuronide and sulphate conjugates of paracetamol during 10 days
therapy was much less than had been predicted from a single dose study. Relatively
more of the sulphate conjugate was formed in relation to the glucuronide conjugate,
however, possibly due to sulphate retention in these patients. There was some evi¬
dence of enterohepatic recycling of the retained conjugates and higher than expected
concentrations of the parent compound was measured each day in the plasma. Satura-
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tion of the glucuronide and sulphate pathways also may have occurred during chronic
therapy but stauration of the former metabolic pathway is exceedingly unlikely. Clear¬
ance of the glucuronide conjugate by haemodialysis appeared to be restricted. There
was no evidence of increased production of the potentially toxic glutathione-derived
conjugates under the conditions of the study.
Further studies are indicated to establish the capacity of these patients to conjugate
paracetamol during chronic dosing and to establish associated changes in serum sul¬
phate concentrations. In addition more studies are needed to establish whether the
clearance of paracetamol glucuronide is limited during haemodialysis which might
have implications for the clearance of other drug metabolites during the procedure.
132
CHAPTER 6
STUDIES WITH SINGLE DOSES OF FRUSEMIDE
IN HEALTHY MALE VOLUNTEERS
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SECTION 6.1: INTRODUCTION
The potent loop diuretic frusemide is used in the treatment of oedematous states asso¬
ciated with cardiac, hepatic and renal failure. Therapy is frequently complicated by
apparently erratic systemic availability from the oral route and from unpredictable
responses to a given dose (Boles-Ponto and Schoenwald, 1990). Frusemide is believed
to act at the surface of the ascending limb of the loop of Henle by inhibiting the active
reabsorption of chloride (Burg, 1973). It is delivered to its site of action by active
secretion via the non-specific organic acid pump in the proximal tubule and the re¬
sponse is related to the concentration of the drug in the urine rather than in the plasma
(Chennavasin et al., 1979).
The pharmacokinetic behaviour of frusemide is characterised by a large degree of
variability (Benet, 1979). Although this may be in part due to differences between
subjects, study protocols or the assays used to estimate frusemide, a large proportion
appears to be due to inter- and intra-subject variation. In addition, various disease
states such as renal impairment will alter its disposition. This is particularly important
in view of the fact that the fraction of the dose excreted in the urine represents the
amount available for pharmacological action.
The object of this study was to investigate the disposition of frusemide in a group of
healthy drug-free male volunteers with normal renal function. They received single
doses of frusemide both orally and intravenously with concurrent rehydration and
serial measurements of frusemide concentrations in the plasma and urine were per¬
formed. It was thus hoped to characterise the handling of frusemide by healthy sub¬





Eight healthy male volunteers of mean age 38 yr (range 29 - 54) and weight 89 kg
(range 79 - 98) were studied. They had no medical illness, physical examination was
normal, they were on no medication, they did not smoke and they all claimed to drink
less than 5 units of alcohol per week. The results of routine biochemical and haemato-
logical screening tests are presented in Table 6.1.
Experimental design
Each subject was studied on 2 occasions. On the first, the fasting volunteers attended
at the Clinical Pharmacology Unit at 08.30 h and a cannula was inserted into a fore¬
arm vein. Frusemide tablets 40 mg (Hoechst U.K. Ltd.) were administered orally
with 100 ml of water and the volunteers remained recumbent for one hour. 100 ml of
water was given at 15 min intervals during this first hour and thereafter fluid was
replaced according to the volume of urine passed at the 2 hourly collection times.
Breakfast (toast and water or still orange juice) was served one hour after the adminis¬
tration of frusemide (09.30 h) and lunch was taken at 13.00 h.
Blood was sampled before and at 7.5, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360,
420 and 480 min after the frusemide was given and urine was collected at 0, 30, 60,
120, 240, 360 and 480 min. Subjects were free to go at 16.30 h and were asked to
collect all urine passed until the end of the 24 hour period after the administration of
frusemide.
On the second study day the procedure was the same but frusemide 40 mg was infused
intravenously over one hour at a constant rate in 400 ml of 0.9% saline via an "IMED
960" volumetric infusion pump (Warner-Lambert Health Tech. Ltd., England). Extra
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Table 6.1: Results of routine biochemistry and haematology screening in 8 healthy
volunteers give 40 mg frusemide orally and by intravenous infusion over 1 h.
Volunteer




78 81 72 72 73 71 70 72 60-80
albumin
g.l-1
49 46 46 44 45 46 45 46 36-47





15 8 10 8 16 9 10 11 2-17
alanine amino¬ 31 28 38 68 16 18 20 31 10-40
transferase
u.l-1 (Alt)





31 24 26 21 30 22 23 25 24-30
creatinine
pmol.l ^
91 99 93 92 99 91 99 98 55-150
urea
mmol.l-^
4.7 3.9 4.8 4.6 7.0 6.8 3.1 3.6 2.5-6.6
calcium
mmol.l
2.6 2.5 2.5 2.4 2.5 2.4 2.3 2.4 2.1-2.6
phosphate
mmol.1 ^
0.9 0.7 0.8 1.2 0.8 1.2 1.0 0.9 0.8-1.4




5.8 10.1 4.4 6.4 6.2 5.6 5.3 5.0 4-11
platelets
x 109.!-1
226 281 285 245 176 217 230 238 150-350
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blood samples were taken at 75, 105 and 150 min and fluid was replaced according to
the urinary volumes as described above once the infusion was complete.
Samples
All samples were processed as described in Chapter 2.
Drug assay
Plasma and urinary concentrations of frusemide were measured by HPLC as described
in Chapter 2.
Pharmacokinetic analysis
The plasma concentration-time data were analysed using the SIPHAR pharmacokinet¬
ic programme as described in Chapter 2.
Due to the low plasma concentrations following oral frusemide, accurate curve fitting
was not possible and the analysis was therefore restricted. The elimination half life,
t,A, was estimated by visual inspection of the plasma concentration time curve with
peeling of the terminal phase. The AUC^ was calculated by the trapezoidal rule and
the bioavailability as the ratio of the AUCQ ^ after the oral and intravenous adminis¬
tration of frusemide.
The plasma concentration-time curves following the intravenous dose were best de¬
scribed by a two compartment model comprising a distribution and elimination phase.
Initial parameters were estimated by peeling and refined by iterative analysis. The
goodness of the fit was assessed using the coefficient of variation of each parameter
and the values are presented in Table 6.2. In addition, model independent analysis
was used to estimate t1/4, AUCQ w, total clearance and Vd following the intravenous
infusion.
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Table 6.2. The coefficients of variation (CV%) for the parameters obtained by
analysis of the plasma concentration-time data following the infusion of 40 mg
frusemide intravenously over one hour to 8 healthy male volunteers. The data were
best described by a two compartment model. Initial parameters were estimated by
peeling and refined by iterative analysis. The distribution process is represented by
intercept "D" and slope "d" and the elimination phase by intercept "B" and slope
"8" as described in Chapter 2.
Distribution phase Elimination phase
No. Intercept "D" Slope "d" Intercept "B" Slope "13"
(CV%) (CV%) (CV%) (CV%)
1 21.0 49.1 10.3 5.8
2 25.7 46.4 45.0 23.4
3 10.5 23.5 13.0 8.6
4 6.2 14.2 20.9 13.2
5 15.9 24.6 7.6 5.1
6 8.8 15.2 47. 5 26.6
7 3.7 5.5 28.2 18.3
8 8.6 14.8 47.8 24.9
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A modified version of the Wagner Nelson method was used to estimate the fraction of
the oral dose absorbed at each time point as described in Chapter 2. Thus
Ft = AUCp,, + C/K
AUC^
where AUCQ , Ct were from the data obtained following the oral dose of frusemide
and K and AUCQ ^ from the intravenous data. The latter represents the maximum
AUC that would have been achieved if all of the oral dose had been absorbed.
Total clearance was calculated as intravenous dose divided by AUCn and the renal■> 0-co
clearance as the amount of frusemide (oral or intravenous) excreted 24 h divided by
the corresponding AUC0 ^ as described in Chapter 2. The non-renal clearance was
estimated as the difference between the total and the renal clearance following the
intravenous dose. Bioavailability was also calculated from the ratio of the urinary
recoveries following the oral and intravenous dose respectively.
Statistics
Correlation and linear regression were used to establish the relationship between
parameters estimated following the oral and intravenous administration of frusemide
and the significance of any observed differences was determined by the Wilcoxon test.
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SECTION 6.3: RESULTS
Plasma concentrations of frusemide
The individual plasma concentration-time curves following the oral administration and
intravenous infusion of 40 mg frusemide in the 8 volunteers are shown in Fig. 6.1 and
Fig. 6.2 respectively and the mean concentrations are shown in Fig. 6.3. Subject
number 6 had a higher AUC after oral than intravenous frusemide and this may reflect
inaccuracies due to an interfering peak which was visible on the blank sample. The
data were therefore not included in the analysis.
The absorption and distribution of frusemide
The oral absorption of frusemide was characterised by marked inter-subject variability
(Fig. 6.1) and there were striking differences in individual values for C , T andv ° 7 ° max' max
AUC (Table 6.3). The mean C was 1.49 +0.82 mg.l"1 and the T ranged fromv ' max — ° max °
60 to 120 min with a mean value of 90 min. The AUC„ was also variable with a0- 00
mean value of 171 +86 min.mg.l"1 and the bioavailability of oral frusemide calculated
from the AUC ranged from 27.6 to 84.3% with a mean of 53.6% (Table 6.3).
The mean fraction of the dose absorbed at each time point is shown on Figure 6.4.
Following the oral administration of frusemide just under 30% of the dose had been
absorbed at 60 min (26.7 ±28.8). By 90 min the absorption process was complete
with 53.3 +24.2% of the dose absorbed corresponding to the mean bioavailability.
As expected, the individual plasma concentration-time curves were more uniform
following the intravenous infusion of frusemide (Fig. 6.2). In this case, the mean Cmax
was 3.34 +0.54 mg.l'1 and the mean AUC^ was 301 +58 min.mg.r1 (Table 6.4).
Frusemide had a small volume of distribution (Vd) of 14.1 +3.8 1.
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Table 6.3. Maximum plasma concentration (Cmax), time to reach maximum concen¬
tration (T ), area under the plasma concentration time curve (AUC^), bioavail¬
ability and half life of elimination (t,A) of frusemide in 7 healthy male volunteers
following the oral administration of 40 mg. Bioavailability was calculated as the ratio
of AUCL after oral and intravenous administration of the same dose on different
0-oo
occasions.
Subject Cmax Tmax AUCn mO—oo Bioavailability ft or
(mg/1) (min) (min.mg/1) (%) (min)
1 2.79 90 328 84.3 63.5
2 2.37 90 192 62.9 45.7
3 1.97 60 242 77.9 69.5
4 1.01 90 155 57.0 82.4
5 0.98 120 136 35.4 77.9
7 0.79 90 78 27.6 53.0
8 0.49 90 63 30.4 63.8
mean 1.49 90 171 53.6 65.1
±sd 0.82 16 86 21.3 12.0
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Table 6.4. Maximum plasma concentration (Cmax), area under the plasma concentra¬
tion time curve (AUC0 oo), Volume of distribution (Vd), plasma half life of elimination
(t1/5) and total clearance of frusemide in 8 healthy male volunteers given 40 mg by
intravenous infusion over one hour.
No. C
max
AUC Vd VI Total Clearance
(mg/1) (min.mg/1) (1) (min) (ml/min)
1 4.12 389 9.0 60.5 102.9
2 3.75 306 9.5 50.4 130.9
3 3.06 311 12.4 66.7 128.6
4 2.88 271 14.2 66.8 147.5
5 4.13 385 8.7 58.1 103.7
6 2.88 254 20.9 92.0 157.1
7 3.23 283 16.9 82.8 141.4
8 2.70 210 14.5 52.9 190.6
mean 3.34 301 14.1 66.3 137.8
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Fig 6.1. Plasma concentrations of frusemide in 7 healthy volunteers following the
administration of 40 mg orally.
Plasma concentrations (mg/1)
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Fig 6.2. Plasma concentrations of frusemide in 8 healthy volunteers following the
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Fig 6.3. The mean plasma concentrations of frusemide in 8 healthy volunteers follow¬
ing the oral administration (n=7) and intravenous infusion over 1 h of 40 mg.
Percent of dose absorbed
Time (h)




The mean t1/4 calculated by peeling was 65.1 ±12.0 min after oral frusemide and 60.3
±13.4 min after the intravenous infusion. The values were positively correlated (r =
0.77, p<0.05, n=7) and 3 of the 7 volunteers had lower t,, values following intrave¬
nous frusemide. Using the fitted model, the t,A of frusemide was 66.3 ±13.5 min after
the intravenous infusion (Table 6.4). The total clearance of frusemide was 137.8
±26.9 ml.min"1.
The renal excretion of frusemide
When frusemide was administered orally the mean recovery in the urine was 13.9
±3.6 mg or 34.7 ±8.9% of the dose (Table 6.5). Following the intravenous dose the
recovery was higher at 22.1 ±1.9 mg or 55.2 ±4.8% of the total dose infused (Fig.
6.5).
As expected, the time course of delivery of frusemide into the urine differed with both
routes as shown in Fig. 6.6. Little frusemide was excreted in the first hour after oral
dosing (<3%). Most of the amount excreted was recovered between 1 to 2 h (14.9
±7.3%) and from 2 to 4 h (11.33 ±2.4%) after which the excretion rate declined
sharply (Fig. 6.6). By contrast, over 25% of the total dose was excreted during the
hour-long intravenous infusion of frusemide (26.1 ±3.3%) and in the subsequent two
hours a further 20% was eliminated (21.1 ±9.1%). The amount excreted then fell
sharply and was less at each collection point than following the oral dose (Fig. 6.6).
These differences presumably reflect the relatively slow and incomplete absorption of
oral frusemide.
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Table 6.5. Twenty four hour urinary recovery, renal clearance and bioavailability
of frusemide in 8 healthy male volunteers given 40 mg frusemide orally and in¬
travenously and the calculated non renal clearance of the intravenous dose. The
bioavailability is calculated as the ratio of the twenty four hour urinary recovery













1 21.1 64.4 95.6
★
1 22.1 56.8 46.2
2 15.4 80.0 69.2
★
2 22.2 72.7 58.2
3 14.2 58.6 58.8
★
3 24.2 77.7 50.9
4 11.0 71.4 56.6
it
4 19.5 71.9 75.6
5 12.6 92.1 65. 7
it
5 19.1 49.6 54.1
6 16.6 66.1
it
6 25.2 98.9 58.3
7 10.2 131.3 47.0
it
7 21.8 76.9 64.4
8 9.9 154.5 43.8
★






















Percent of dose excreted
Time (h)
Fig 6.5. The cumulative urinary excretion of frusemide following 40 mg orally and by
intravenous infusion over 1 h in 8 healthy volunteers.
Percent of dose excreted
Fig 6.6. The rate of excretion of frusemide in 8 healthy volunteers following oral and
intravenous administration of 40 mg.
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The total urinary recovery following the oral dose was positively correlated with the
bioavailability calculated from AUC^ values (r = 0.82, p<0.05, n=7). The mean
bioavailability of frusemide calculated from the ratio of its urinary recoveries follow¬
ing oral and intravenous administration was 62.9 ±15.0% and this was slighty higher
than the corresponding value estimated from the AUC^ (53.6 ±21.3%, p=0.2).
The renal clearance of frusemide was 93.2 ±33.6 ml.min"1 following the oral dose
and 76.5 ±18.0 ml.min"1 following the intravenous infusion but the differences were
not significant.
The non-renal clearance of frusemide
The non-renal clearance after intravenous frusemide was 61.4 ±11.8 ml.min"1, or just
less than half of the total clearance (Table 6.5). In two of the 8 subjects the non-renal
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Fig 6.7. The individual renal and non-renal clearances of frusemide following the
intravenous infusion of 40 mg in 8 healthy volunteers.
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SECTION 6.4: DISCUSSION
When frusemide was administered orally to healthy fasting male volunteers the pattern
of absorption differed between individuals and the C , T and bioavailabilityr max' max J
were very variable. The absorption of frusemide is known to be erratic (Boles Ponto
and Schoenwald, 1990) and reported values of the Tmax and bioavailability of oral
frusemide in healthy volunteers are summarised in Table 6.6. In general the Tmax is
reported to be between 60 and 90 min (Beermann et al., 1975, Branch et al., 1977,
Kelly et al., 1974 and Waller et al., 1982, Table 6.6) although values may be much
higher or lower (Hammarlund et al., 1984). The bioavailability of frusemide calculat¬
ed from urinary recoveries or AUC values has been reported in a number of studies
and is also characterised by a high degree of variability both within and between
studies, ranging from 20 to 100 % in young volunteers (Table 6.6). In the present
study the Tmax varied from 60 to 120 min and the bioavailability from 28 to 84%
when calculated from the AUC.
The reasons proposed to explain the erratic and variable absorption of frusemide
include inter- and intra-subject variability, the use of different dosage forms and dif¬
ferent study protocols including whether the subjects were in a fasting or a non-fasting
state (Boles Ponto and Schoenwald, 1990). The methods used to measure frusemide
are also potential sources of variability (Benet, 1979).
The rate and extent of absorption of oral frusemide may vary when different formula¬
tions are compared such as solutions, tablets or immediate and sustained release
preparations. In healthy subjects the rate of absorption of frusemide in solution was
faster than the equivalent dose given as a tablet but there was no difference in overall
bioavailability (Hammurlund et al., 1984). Similarly, Kelly et al., 1974, found no
differences in the absorption of a solution or a tablet in fasting volunteers. The absorp-
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tion of tablets made by different manufacturers has also been compared. In one study,
seven marketed brands of frusemide 40 mg were compared and only one brand was
considered to be inequivalent to the other six on the basis of greater inter-subject
variability in the plasma concentration-time curves and AUC values (Straughn et al.,
1986). Similarly, there were no differences in the AUC or urinary recoveries of
"Lasix" and "Impugan", two marketed brands of frusemide (Beermann et al., 1978).
However comparison of a branded and generic formulation of frusemide suggested
that the latter was significantly less bioavailable (Martin et al., 1984) and sustained
release preparations may have reduced bioavailability when compared to conventional
tablets (Beermann, 1982). It is therefore unclear to what extent the reported erratic
and variable absorption of frusemide can be explained by the use of different formula¬
tions. In the present study all volunteers were given a standard 40 mg tablet of fru¬
semide manufactured by Hoechst ("Lasix").
The fasting or non-fasting state is another factor which may lead to variability . Post¬
prandial administration delayed the appearance of frusemide in the plasma with a
lower Cmax and more prolonged concentrations but no differences in overall bioavail¬
ability (Kelly et al., 1974). In contrast, Beermann and Midskow (1986) found a
reduced but parallel plasma concentration time profile in the fasting and non-fasting
states with a 30 % reduction in bioavailability. Hammarlund et al., (1984), found that
while the presence of food in the stomach dramatically changed the shapes of the
plasma concentration-time curves for most individuals with a reduction in C and a
max
delay in Tmax, it did appear to diminish the interindividual variability. Food intake
slighty reduced the bioavailability but not to a significant extent. In the present study
all subjects fasted for the first hour after frusemide administration.
Secondary or multiple peaks may occur in the plasma following the administration of
frusemide and this has been explained on the basis of enterohepatic cycling (Waller et
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al., 1982 and Smith et al., 1980 (a)). However, the impact of this small amount of
drug has been discounted since on average 50% of the dose remains available for
absorption in the gastrointestinal tract as judged by the bioavailability (Hammurlund et
al., 1984). Furthermore, in the rat 20 to 30% of an oral dose of frusemide is metabo¬
lised in the gut wall and stomach during absorption and hepatic elimination accounts
for less than 10% (Lee and Chiou, 1983). The findings suggested that metabolism of
frusemide in the gastrointestinal tract may account for at least some of the erratic
absorption that occurs with oral dosing.
Frusemide may also exhibit site-specific absorption. As a weak acid it could be
absorbed from the stomach as well as from the intestine where most weak acids are
absorbed because of the larger absorptive area (Hammurlund et al., 1984). In the rat
the stomach has a greater absorptive capacity for frusemide than the intestine despite
its smaller surface area (Chungi et al., 1979).
The role of the stomach as an absorptive site for frusemide is complicated however by
the fact that it is also a potential site for frusemide metabolism (Lee and Chiou, 1983).
Furthermore, although food will delay gastric emptying allowing the drug to remain
in the stomach longer, it will also buffer the pH and slow absorption (Boles Ponto and
Schoenwald, 1990). At the moment there is no conclusive evidence to suggest that
frusemide is primarily absorbed in the stomach in humans but inter and intra individu¬
al variation in gastric emptying could explain some of the variability in frusemide
absorption from the small intestine.
Finally, the variable absorption patterns found in different studies may be partly due
to problems with the different assays used to measure frusemide (Benet, 1979). The
most consistent results are obtained with HPLC (Benet, 1979 and Boles Ponto and
Schoenwald, 1990).
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Following intravenous frusemide the plasma concentrations were best described by a
two compartment model. This model is probably the most appropriate from a pharma¬
cokinetic perspective (Cutler and Blair, 1979). The high plasma protein binding and
low lipid solubility of frusemide restricts its distribution and the reported values of Vd
are 2 to 5 times the plasma volume which is 2.8 to 3.5 1 in a 70 kg man (Diem and
Lentner, 1970). The Vd of just over 14 1 in the present study is therefore consistent
with the previous reports listed in Table 6.7.
The reported values for the plasma half life of frusemide in healthy subjects are also
variable but usually fall in the range of 30 to 120 min (Table 6.7). The progressively
longer values reported in more recent studies may be due to longer sampling times
made possible by more sensitive assays (Boles Ponto and Schoenwald, 1990). A three
compartment model has been used for analysis with estimation of the t1/4 from the
terminal phase. However, this segment represents only 10 % of the AUC and plasma
concentrations at this time are well below those which would produce pharmacologi¬
cally active urinary concentrations of frusemide (Hammarlund et al., 1984). The
problem may be compounded by the use of different methods of curve fitting (Chen-
navasin et al., 1981). Using equal weighting factors gives shorter values for t1/4 than
using weighting factors giving more weight to lower concentrations of the drug be¬
cause with the former the terminal portion of the curve is ignored.
The reported total plasma clearance of frusemide in healthy volunteers has ranged
from 80 to 288 ml.min"1 with an average value of about 170 ml.min 1 (Table 6.6)
Renal and non-renal processes contribute in highly variable but often equivalent
magnitude to the total clearance (Table 6.7). This is in agreement with the results of
the present study where the renal clearance contributed just over half the total clear¬
ance of almost 140 ml.min"1.
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The reasons for the widely different values for total clearance quoted in the literature
are unlikely to be related to assay sensitivity or methods of curve fitting (Chennevasin
et al., 1981). The clearance of frusemide is calculated from the AUCQ ^ and the
terminal portion of the tail (which is the only estimated part), normally contributes
little to the overall AUC. The plasma clearance of frusemide was similar in smokers
and non smokers although the latter tended to have a higher non renal clearance
(Lambert et al., 1983). The renal clearance is thought not to be affected by dose
(Waller et al., 1985) or route of administration (Smith et al., 1980 (a)) but is reduced
in the elderly presumably because of the decline in renal function in such individuals
(Andreason et al., 1983, Kerremans et al., 1983).
Since the diuretic site of action of frusemide is primarily at the luminal surface of the
ascending limb of the loop of Henle, the fraction of the dose excreted unchanged in
the urine represents the amount available for pharmacological action (Brater, 1986).
This appears to be variable and after an intravenous dose of frusemide approximately
50 to 80 % of the dose will be excreted in the urine but after oral administration the
corresponding fraction is only 20 to 55 % (Tables 6.6 & 6.7). In the present study the
mean amounts were 55 and 34 % respectively. The amount of frusemide recovered in
the urine can also be used to measure bioavailability (Waller et al., 1982) and in the
present study this gave a value of 63%.
The present study confirms the previously reported variable absorption of oral fru¬
semide in healthy fasting volunteers. Frusemide had a small volume of distribution
presumably due to its polarity and high plasma protein binding and its disposition after
intravenous infusion was best described by a two compartment model. About half of
the intravenous dose and one third of the oral dose was available for pharmacological
action as judged by the fraction excreted in the urine. The non-renal clearance ac¬
counted for about half of the overall plasma clearance.
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CHAPTER 7
STUDIES WITH SINGLE DOSES OF FRUSEMIDE
IN PATIENTS WITH END-STAGE RENAL FAILURE




Frusemide is a powerful diuretic and one of its major advantages is its ability to
induce diuresis even in patients with advanced renal impairment (Allison and Kenne¬
dy, 1971). It is therefore extensively used in the treatment of patients with chronic
renal failure but large doses are often required to cause a diuresis (Brater et al.,
1986). Studies have shown that frusemide must gain access to the tubular lumen of the
kidney to cause an effect (Chennavasin et al., 1979). Frusemide is highly bound to
plasma proteins so this access occurs by active secretion into the lumen by the organic
acid secretory pump of the proximal tubule (Odlind, 1983). In patients with chronic
renal failure endogenous organic acids accumulate and block frusemide secretion
(Rose et al., 1976). Larger doses are therefore required to force sufficient amounts of
drug into the lumen to cause an effect.
The disposition of frusemide has been extensively studied in patients with chronic
renal failure following both oral and intravenous administration (Tables 7.10 and
7.11) but the results are often conflicting (Benet, 1979). This may partly reflect dif¬
ferences in study protocols including the assays used, the nature and degree of renal
impairment, the dose of frusemide or inter-individual differences in the handling of
frusemide as discussed for the normal volunteers.
The object of this study was to determine the disposition of frusemide in a group of
patients with end-stage renal failure maintained on CAPD who were not taking fru¬
semide as part of their regular medication. Little specific information is available on
drug absorption and bioavailability in peritoneal dialysis but it is generally accepted
that the gastrointestinal disturbances associated with end-stage renal disease may in
some way affect drug absorption in these patients (Paton et al., 1985). The renal
clearance of all drugs including frusemide should be minimal and clearance by non-
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renal mechanisms may include elimination across the peritoneal membrane. It was
thus hoped to characterise the disposition of frusemide in patients with end-stage renal
failure and to determine the extent of non-renal clearance including peritoneal clear¬
ance in these patients.
SECTION 7.2: METHODS
Patients
Eleven patients (3 female, 8 male) with end-stage renal failure (creatinine clearance
< 5 ml.min"1) maintained on continuous ambulatory peritoneal dialysis (CAPD) were
studied on 2 separate occasions. Their mean age was 66 yr (range 57 - 73) and
weight 64 kg (range 48 - 74). Details of the medical histories and medication are
presented in Table 7.1 and results of haematology and biochemistry in Tables 7.2 and
7.3. None of the patients were being treated with frusemide at the time of the study
and patients with a history of peritonitis in the previous 3 months were excluded as
were patients with haemoglobin concentration of less than 7 g.dl"1.
All patients performed four peritoneal exchanges each day with 2000 ml of standard
dialysate solutions via indwelling Tenckhoff catheters as described in Chapter 2.
Details of the patients' dialysis regimes and daily fluid allowances are given in Table
7.4.
Experimental Design
The patients were studied on 2 separate occasions at least a week apart. On the
morning of the first study day the patients came to the CAPD training room at 08.30 h
with their overnight dialysate still in the peritoneal cavity. The weight and glucose
content of a new bag of dialysate was noted and the patients then performed the first
exchange of the day. An intravenous cannula was inserted in a forearm vein and 80
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mg frusemide (2 x 40 mg tablets, Hoechst, U.K. Limited) was given orally with 100
ml of water. The patients then remained recumbent for an hour.
Following this, the patients were allowed their normal fluid intake (Table 7.4)
throughout the day. Breakfast was served one hour after the dose of frusemide when
the patients took their normal medications (Table 7.1) and lunch was taken at 13.00 h
according to their usual dietary requirements.
Venous blood (3ml) was sampled before the administration of the frusemide and at 15,
30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480 min after. The used dialysate
bags of that day were kept and the volumes measured. All urine passed during the 24
h period was collected. The patients were free to go home after their 3rd exchange of
the day at approximately 17.30 h.
A week later the study was completed. On this occasion frusemide 80 mg was infused
intravenously over one hour at a continuous rate in 50 or 100 ml of 0.9% saline
(depending on the daily fluid allowance) via an "IMED 960" volumetric infusion
pump. Blood sampling was the same as described above with extra samples taken at
75, 105 and 150 min after the start of the infusion.
Samples
All samples were processed as described in Chapter 2.
Drug assay
Plasma, urine and dialysate concentrations of frusemide were measured by HPLC as
described in Chapter 2.
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Table 7.1: Clinical details of 11 patients with end stage renal failure maintained on CAPD.
Patient Age Medical Regular drug therapy
No. sex diagnosis
1 58 F pyelonephritis
asthma
angina pectoris
prednisolone 5 mg daily
ranitidine 75 mg BD
"gaviscon"
aluminium hydroxide 475 mg TID
2 70 F glomerulonephritis ferrous sulphate 320 mg daily
folic acid 5 mg twice per week
3 67 M pyelonephritis
nephrocalcinosis
hypertension
metoprolol 25 mg BD
aluminium hydroxide 475 mg TID
"Fefol vit" 1 TID
4 73 M glomerulonephritis
coeliac disease
hypothroidism
alfacalcidol 0.25 fig daily
"Fefol vit" 2 daily
aluminium hydroxide 950 mg TID
thyroxine 100 fig daily
5 68 M Goodpasture's Syndrome
ischaemic heart disease
"Fefol vit" 2 daily
isosorbide mononitrate 20 mg BD
aluminium hydroxide 475 mg TID




alfacalcidol 0.25 fig daily
"Fefol vit" 2 daily
metoprolol 50 mg BD
ranitidine 150 mg nocte
7 57 M polyctstic kidneys
hypertension
"Fefol vit" 2 daily
nifedipine slow release 20 mg BD
metoprolol 50 mg BD
8 67 M hypertensive neph
ropathy
aluminium hydroxide 950 mg BD
"Fefol vit" 2 daily
aspirin 375 mg daily
9 67 M glomerulonephritis
hypertension
transient ischaemic attacks
aluminium hydroxide 950 mg TID
nifedipine slow release 20 mg BD
"Fefol vit" 2 daily
metoprolol 25 mg BD
aspirin 375 mg daily
ranitidine 75 mg nocte




aluminium hydroxide 475 mg daily
"Fefol vit" 2 daily
metoprolol 25 mg BD
digoxin 0.0625 mg daily
gliclazide 40 mg BD
11 70 M glomerulonephritis
ischaemic heart disease
hypertension
diltiazem 60 mg TID
"Fefol vit" 2 daily
captopril 25 mg BD
prasozin 2 mg TID
alfacalcidol 0.5 fig daily
aluminium hydroxide 475 mg TID
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Table 7.3. Results of haematological tests in 11 patients with end











1 12.0 8.3 218
2 7.2 5.4 302
3 8.8 5.1 190
4 9.7 8.6 314
5 8.1 10.5 296
6 10.6 4.2 260
7 17.9 6.3 180
8 7.5 6.0 328
9 10.9 6.9 201
10 10.7 5.4 209
11 9.2 4.1 199
Normal 13-18 4-11 150-350
range
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Table 7:4. Details of the daily fluid allowance and dialysis regimes of 11 patients















1 500 4 years 4 2.27 X 4
2 1500 10 years 4 2.3 X 4
3 750 7 years 4 1.5 X 4
4 1000 7 months 4 2.27 X 2
3.86 X 2
5 750 6 months 4 2.27 X 1
1.36 X 3
6 500 2 years 4 2.27 X 3
1.36 X 1
7 750 7 months 4 2.27 X 2
1.36 X 2
8 750 2 years 4 2.27 X 4
9 1000 4 years 4 2.27 X 4
2.27 X 3
10 1500 3 years 4 3.86 X 1
2.27 X 3




The "Siphar" pharmacokinetic programme was used to analyse the plasma concentra¬
tion-time data as described in Chapter 2.
The plasma concentration-time curves obtained with oral dosing were fitted to a one
compartment model. Initial parameters were estimated by peeling and refined by itera¬
tive analysis. The goodness of the fit was established by the coefficients of variation
of each parameter as described in Chapter 2 and these are listed in Table 7.5. These
were less than 20-30% in all cases except for patient 4.
The plasma concentration-time data obtained following the intravenous dose was best
described by either a one (patients 1, 8 and 9) or two (patients 2, 3, 5, 6, 10 and 11)
compartment model. Coefficients of varaition of the estimated parameters were usual¬
ly less than 20-30% (Table 7.6).
The fitted model was used to describe the disposition of oral and intravenous frusemi-
de and to estimate the lag time and tJ/2. The Wagner-Nelson method was used to
estimate the percent of the dose absorbed with time as described in Chapter 2. Model
independent analysis was used to estimate the AUC^, the total, renal and peritoneal
clearances and the V..
d
Statistics
The significance of any observed differences was determined using the Students "t"
test or the Wilcoxon or Mann-Whitney test for paired and un-paired data respectively,
where approriate.
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Table 7.5. The coefficients of variation (CV%) for the estimated parameters ob¬
tained by analysis of the plasma concentration time data following the administra¬
tion of 80 mg frusemide orally to patients with end stage renal failure maintained on
continuous ambulatory peritoneal dialysis. The data were best described by a one
compartment model comprising an absorption and elimination phase. Initial parame¬
ters were estimated by peeling and refined by iterative analysis. The absorption
phase is represented by intercept "A" and slope "a" and the elimination phase by
intercept "B" and slope "8" and described in Chapter 2.
Absorption phase Elimination phase
No. Intercept "A" Slope "a" Intercept "B" Slope "13"
(CV%) (CV%) (CV%) (CV%)
1 0.9 30.6 13.7 20.1
2 3.4 31.5 14.3 13.8
3 10.2 12.6 7.5 5.6
4 3.7 41.2 19.5 21.3
5 4.9 24.1 10.8 17.3
6 0.9 14.7 2.7 10.4
7 3.1 24.6 9.4 15.4
8 3.7 26.7 10.3 19.8
9 0.6 11.6 0.8 6.1
10 0.8 29.1 11.3 21.0
11 0.2 13.1 0.2 8.6
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Table 7.6. The coefficients of variation (CV%) for the estimated parameters ob¬
tained by analysis of the plasma concentration time data obtained following the
administration of 80 mg frusemide intravenously to patients with end stage renal
failure maintained on continuous ambulatory peritoneal dialysis. The data were best
described by either a one or two (*) compartment model. The latter included a dis¬
tribution and elimination phase. Initial parameters were estimated by peeling and
refined by iterative analysis. The distribution phase is represented by intercept "D"
and slope "d" and the elimination phase by intercept "B" and slope "8" as described
in Chapter 2. The data from patient 4 were not included in the analysis due to
technical problems and patient 7 did not receive intravenous frusemide.
Distribution phase Elimination phase
No. Intercept "D" Slope "a" Intercept "B" Slope "fi"
(CV%) (CV%) (CV%) (CV%)
1 12.6 5.6
"ft
2 29.1 37.9 3.8 6.2
★
3 12.0 38.0 10.7 9.4
5 7.4 14.1 21.2 28.8
6* 15.1 38.1 19.5 19.6
8 3.4 2.3
9 3.6 1.9
10* 17.8 30.3 6.0 10.0
11* 21.4 36.7 7.5 7.0
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SECTION 7.3: RESULTS
Plasma concentrations of frusemide
The individual plasma concentration-time curves following the oral and intravenous
administration of 80 mg frusemide are shown in Figures 7.1 and 7.2 respectively and
the mean concentrations are shown in Figure 7.3. The intravenous data from patient 4
were thought to be inaccurate because of problems with venous access and patient 7
had a renal transplant before completing the second study day. The intravenous data
are therefore presented for the other 9 patients.
The absorption and distribution of frusemide
The oral absorption of frusemide in patients on CAPD was characterised by marked
intersubject variability (Figure 7.1). In most cases oral frusemide was absorbed slowly
with a mean lag time derived from the raw data of almost 26 min (25.4 ±26.4).
However, two of the patients (patients 7 and 8) had much longer lag times and fru¬
semide was not detected in the plasma until 90 and 120 min respectively (Table 7.7).
In the other nine patients the lag time was zero in three, 15 min in three and 30 min in
three. Using the fitted model the mean lag time was considerably shorter at 14.8
±9.1 min.
The mean Cmax following the oral administration of frusemide to patients on CAPD
was 2.91 ±1.37 mg.l"1 and the mean T was 126 min (range 60 to 240 min, Table
7.7). The AUC was variable with a mean value of 1113 ±440 min.mg.l"1. The
mean bioavailability was 70.1 ±13.1% (n=9).
When the plasma concentration-time curves following oral frusemide were compared
in healthy volunteers and patients with end-stage renal failure, it appeared that the
absorption of frusemide in the latter was slower but more complete. Due to the low
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plasma concentrations of frusemide measured in healthy volunteers following adminis¬
tration of 40 mg frusemide it was not possible to define the lag time with certainty.
However, the Tmax occurred earlier in the volunteers than the patients (90 ±16
compared with 126 ±58 min, respectively, NS). Despite this, the mean bioavailabili¬
ty of frusemide was higher in the patients with renal failure than in the volunteers
although not significantly so (70.1 ±13.1 and 53.6 ±21.3 %, respectively).
A similar pattern was observed when the fraction of the dose absorbed with time was
compared in the CAPD patients and the volunteers (Fig. 7.4). The patients had ab¬
sorbed 35.5 ±28.8 % of the dose by the end of the first hour and 52.6 ±21.7 % by
the end of the second. In most patients the absorption process was not complete until 4
h after dosing with a mean 65.5 ±18.4 % absorbed. This is in striking contrast to the
absorption profile in the normal volunteers where absorption was virtually complete
by 90 min (Fig 7.4). However despite this, the total fraction of the dose eventually
absorbed was greater in the CAPD patients and the mean AUC to 240 min estimated
from the plot of cumulative percent of dose absorbed versus time was 9385 ±4344
and 11025 ±4594 min.mg.l"1 in the volunteers and patients respectively. The differ¬
ences were not statistically significant.
As in the case of the healthy volunteers, there was less variation in the plasma concen¬
trations in the patients on CAPD following the 60 minute intravenous infusion of
frusemide than after oral administration (Fig 7.2). The mean C was 5.95 ±1.58v ° ' max —
mg.l"1 and the mean AUC0 ^ was 1429 ±425 min.mg.l"1' The mean Vd was 16.5
±8.3 1 and was similar to the corresponding value of 14.1 ±3.8 1 in the healthy
volunteers (Table 7.8).
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Table 7.7. Lag time, maximum plasma concentration (C ), time to reach maximum
concentration (T ), area under the plasma concentration-time curve (AUC^) bioa¬
vailability and half life of elimination (t,A) of frusemide in 11 patients on continuous
ambulatory peritoneal dialysis following the ingestion of 80 mg of frusemide. The
bioavailability was calculated as the ratio of the AUC^ after the oral and intravenous
administration of the same dose of frusemide on two separate occasions. It could not
be calculated accurately in patient 4 due to technical problems on the second day of




















1 15 15 2.19 120 990 74. 7 251.8
2 30 15 3.16 90 1080 64.2 171.4
3 0 13 5.43 60 1937 98.0 226.3
4 30 15 4.68 90 1663 206.9
5 30 15 1.37 180 948 70.8 414.9
6 15 15 4.62 180 1514 78.3 178.8
7 60 30 2.89 240 1112 210.9
8 90 30 1.49 180 469 55.4 134.1
9 0 0 1.18 60 451 50.5 225.7
10 15 15 2.52 120 1254 65.6 290.3

















calculated from raw data
**
calculated from fitted model
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Table 7.8. Maximum plasma concentration (C ), area under the plasma concentra¬
tion time curve (AUC^), volume of distribution (Vd), plasma half life of elimina¬
tion (t,^) and total clearance of frusemide in 9 of 11 patients on continuous ambulato¬
ry peritoneal dialysis following the intravenous infusion of 80 mg of frusemide over
one hour. The data obtained from patient 4 were ommitted due to technical problems
and patient 7 did not receive intravenous frusemide.
No. C
max
AUC Vd Total Clearance
(mg.l-1) (min.mg.I-1) (1) (min) (ml.min-1)
1 7.43 1326 7.3 84.2 60.3
2 7.91 1683 10.2 149.3 47.6
3 5.48 1976 14.6 249.4 40.5
5 4.67 1340 34.6 401.8 59. 7
6 7.79 1935 12.4 207.3 41.3
8 4.17 849 19.6 144.3 94.2
9 4.21 892 16.6 128.2 89.7
10 6.03 1913 14.5 240.3 41.8
11 5.13 1142 16.9 166.9 70.1
mean 5.95 1429 16.5 194.9 61.9
±sd 1.58 425 8.3 98.0 20.4
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Fig 7.1. Plasma concentrations of frusemide in 11 patients with end stage renal failure


















Fig 7.2. Plasma concentrations of frusemide in 9 patients with end stage renal failure




0 60 120 180 240 300 360 420 480
Time (min)
Fig 7.3. The mean plasma concentrations of frusemide in 11 CAPD patients following
the oral administration and intravenous infusion (n=9) over 1 h of 80 mg.
Percent of dose absorbed
Time (h)
Fig 7.4. The fractional absorption of oral frusemide in CAPD patients compared with
healthy volunteers. Results are expressed as mean +s.e.m.
173
Elimination of frusemide
The mean elimination half life was 227.6 ±71.3 min following oral frusemide and
194.9 ±98.0 min following the intravenous infusion (Table 7.7 and 7.8). The differ¬
ences were not statistically significant. The txh was significantly longer in the patients
than in the volunteers where it was 65.1 ±12.0 min (p<0.001) and 66.3 ±13.5 min
(p< 0.001) after the oral and intravenous dose respectively. The total clearance of
frusemide in the CAPD patients was 61.9 ±20.4 ml.min"1 (Table 7.8) and was virtu¬
ally the same as the non-renal clearance of frusemide in the healthy volunteers (61.4
±11.8 ml.min"1).
Renal excretion of frusemide
Of the 11 patients, 3 were anuric (patients 1,5 and 10). Following the oral dose of 80
mg frusemide, the mean 24 hour urinary volume of the other 8 patients was only 235
±244 ml (Table 7.9). Very little frusemide was excreted in the urine in 24 hours
(0.24 ±0.27 mg or 0.3 ±0.3% of the dose). The mean renal clearance was 0.28
±0.33 ml.min"1 (Table 7.9).
Following intravenous frusemide the mean 24 hour urinary volume was 194 ±242 ml
with a mean output of 0.32 ±0.44 mg or 0.4 ±0.6% of the dose over the same peri¬
od. Three of the patients had no detectable frusemide in the urine (patients 2,4 and 9)
and the mean renal clearance was 0.28 ±0.4 ml.min"1.
Peritoneal clearance of frusemide
Frusemide was undetectable in all samples of peritoneal fluid. Given that the detection
limit of the assay was 0.1 mg.l"1 an average sample of 2000 ml dialysate would have
to contain about 0.2 mg frusemide in order to give a measurable quantity. In the 24 h
period the maximum that could have been excreted in this way would be 0.8 mg or 1
% of the dose of 80 mg. Thus, the peritoneal clearance of frusemide was negligible.
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Table 7.9. Twenty four hour urinary volume, urinary recovery and
renal clearance of frusemide in 8 of 11 patients on continuous
ambulatory peritoneal dialysis given 80 mg frusemide orally and
intravenously*. Patients 1, 5 and 10 were anuric.
No. Urinary Frusemide Renal
volume recovery clearance
(ml) (mg) (ml.min-1)
2 76 <0.01 <0.01
k
2 58 0.00 0.00
3 160 0.08 0.04
k
3 169 0.16 0.08
4 8 0.00 0.00
4* 12 0.00 0.00
6 160 0.30 0.20
^k
6 197 0.33 0.17
7 505 0.53 0.48
8 185 0.25 0.54
k
8 130 0.46 0. 54
9 30 0.00 0.00
k
9 26 0.00 0.00
11 755 0.78 0.93
*
11 763 1.32 1.16
mean 235 0.24 0.28
±sd 244 0.27 0.32
*
mean 194 0.32 0.28
±sd* 242 0.44 0.40
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SECTION 7.4. DISCUSSION
When frusemide was administered orally to patients with end-stage renal failure its
absorption was characterised by marked inter-subject variability. A lag time of 15 to
120 min was observed in 8 of the 11 patients. The mean Tmax was delayed for more
than 2 h compared to 90 min in the volunteers and the absorption process was not
complete until 4 h after dosing. However despite this, a greater fraction of the dose
was absorbed in the CAPD patients and both the mean bioavailability and the percent
absorbed at 4 h were greater than in the volunteers, but not significantly so. Thus, in
CAPD patients the absorption of frusemide was slower but tended to be more com¬
plete than in the healthy volunteers.
The disposition of frusemide following oral administration in patients with varying
degrees of chronic renal failure has been described by several investigators and the
findings are summarised on Table 7.10. The results were variable and at times con¬
flicting.
Huang et al., (1975), administered 1 g of frusemide orally to 12 patients with ad¬
vanced chronic renal failure and found that the T varied from 2 to 9 h with a mean
max
of 4.4 h. The 4 patients with the most rapid absorption rate had lag times of between
30 and 45 min. Beermann et al., (1977), studied two patients with end-stage renal
failure who were not yet on dialysis following the ingestion of 2 and 3 g of frusemide
respectively and found that the Cmax was reached by 3.5 and 3.75 h (Table 7.10).
Riva et al., (1982), studied 7 children with end-stage renal failure undergoing
haemodialysis given 75 to 225 mg of frusemide per day. There was no significant
difference between the plasma concentrations of frusemide at the time of dosing and
3 h later indicating grossly delayed absorption. In 2 patients given 25 and 75 mg
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frusemide, blood was sampled more frequently. In one the Tmax was 6 h and in the
other no peak was observed at all. In contrast, Kiihnel et al., (1987), gave repeated
doses of 40, 80 and 250 mg of frusemide to patients with moderate chronic renal
failure and found the Tmax was 49.8 +4.8 min with 40 mg, 86.4 +54.6 with 80 mg
and 58.8 +27.6 with 250 mg. In some patients however pharmacokinetic analysis was
apparently impossible because absorption was markedly delayed and the lag time
varied from 8.4 +6.0 (40 mg) to 15.6 ±0.6 (80 mg) and 21.0 ±15.6 min (250 mg,
Table 7.10). There was also a significant decrease in the values ofAUC^ and C
normalised for dose following the highest dose suggesting dose-dependent bioavail¬
ability.
Finally, Boutron et al., (1981) studied the disposition of frusemide following the
administration of 500 and 1000 mg to eleven patients in end-stage renal failure main¬
tained on CAPD. The mean T was 4 +1 h with 500 mg and 5 +2.4 h after 1000max — & —
mg (4 patients).
The results of the present study suggest that the absorption of frusemide might be
abnormally slow in patients with chronic renal failure and the findings are consistent
with previous reports. In 4 previous studies the oral bioavailability of frusemide in
patients with chronic renal failure was reported as 75.7 ±19.8% (Huang et al., 1975),
48 ±16 (Kelly et al., 1977), 46.3 ±8.5% (Rane et al., 1978) and 43.4 ±7.4% (Til-
stone and Fine, 1978, Table 7.10). The latter three values are somewhat lower than in
normal subjects but the present study is in agreement with the report of Huang et al.,
(1975) in which the bioavailability was higher than in normal volunteers despite the
delayed absorption.
The reason why the absorption of frusemide was delayed in these patients with end-
stage renal failure is unclear. Little specific information is available on drug absorp-
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tion and bioavailability in patients on peritoneal dialysis (Paton et al., 1985). During
CAPD the absorption of digoxin (De Paoli Vitali et al., 1981), metronidazole (Bush et
al., 1983) and diltiazem (Grech-B6Ianger et al., 1988) does not appear to be abnor¬
mal. By contrast, the absorption of ketoconazole in CAPD patients was impaired with
peak plasma concentrations of only 25% of those achieved with the same dose in
normal subjects (Chapman and Warnock, 1983).
It is possible that the gastrointestinal disturbances associated with end-stage renal
disease may in some way affect drug absorption in patients on CAPD (Paton et al.,
1985). Possible factors include delayed gastric emptying or the effects of other
medication. If frusemide is absorbed from the stomach as well as from the intestine as
discussed in the previous chapter then delayed gastric emptying and slow gatrointesti-
nal transit might well result in enhanced bioavailability.
All of the patients were taking other medication. Three were receiving ranitidine
which may have enhanced the dissociation of frusemide by producing a higher gastric
pH and so delayed its absorption. Of the 3 patients, one had no lag time and Cmax was
achieved in 60 min although the bioavailability was only 51%. The other two had lag
times of 15 min each, T values of 2 and 3 h and bioavailabilities of 75 and 78%' max
respectively.
Eight patients were were receiving aluminium hydroxide although they did not take
this until one hour after the frusemide. This antacid may alter the absorption of drugs
by increasing gastric pH and by delaying gastric emptying but it seems to mostly
affect drugs which are highly soluble and rapidly absorbed (Hurwitz et al., 1977).
Indeed poorly absorbed drugs may even be absorbed better if intestinal motility is
slowed (Manninen et al., 1973).
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Five patients were taking metoprolol and 8-adrenergic blockers have been shown to
slightly increase the rate of paracetamol absorption by stimulating gastric emptying
(Clark et al., 1980). Ten of the 11 patients were on iron therapy and this has been
shown to interfer with the absorption of some drugs by forming insoluble chelates
(Neuvonen et al., 1970) but this is unlikely to apply to frusemide. Nonetheless, given
the wide variety of medication taken by these patients with end-stage renal failure, it
is possible that at least some influenced the absorption of frusemide.
Another contributory factor may have been oedema of the gut wall. In a case report of
a woman suffering from idiopathic oedema the oral bioavailability of frusemide was
less than 20% during an oedematous period compared to 74% in the oedema-free state
(Odlind and Beermann, 1980 (b)). Furthermore, in compensated congestive cardiac
failure the lag time and T decreased and the C of orally administered frusemide° max max J
increased when compared with the decompensated state (Vasko et al., 1985). In both
these situations slow absorption and reduced bioavailability may have been due to
gastrointestinal oedema. In the present study, 6 patients had abnormally low plasma
albumin concentrations from 28 to 34 g.l"1 and this may have contributed to oedema
of the gut wall. Finally, it is also possible that alterations in blood flow and permeabil¬
ity during peritoneal dialysis may have delayed drug absorption.
Following the infusion of 80 mg of frusemide over one hour the plasma concentration
time data was best described by either a one (three patients) or two (six patients)
compartment model. The mean Vd was 16 1 and this was similar to that observed in
the normal volunteers. The elimination t,A was significantly prolonged following both
oral and intravenous frusemide compared to the healthy volunteers.
The elimination of frusemide has been studied in patients with various degrees of
chronic renal failure and the plasma t,A has been reported to vary from normal to as
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long as 24 h (Table 7.11). For example, using radiolabeled frusemide, Tilstone and
Fine (1978) reported the plasma t,A as 14.2 ±2.3 h in patients in end-stage renal fail¬
ure. The use of radiolabeled material for pharmacokinetic studies of this kind has
been criticised however because frusemide metabolites are also measured (Benet,
1979).
Using a fluorometric assay Huang et al., (1975) reported a mean plasma t^ of 9.7 h
(range 3.6 to 20 h) in a group of conservatively managed patients with advanced renal
impairment given 1 g frusemide intravenously. In contrast, Cutler et al., (1974),
observed a mean tl/t of only 80.7 min with a range of 40 to 120 min in patients on
haemodialysis. This discrepancy may be explained by the use of a shorter sampling
time (Beermann et al., 1977) giving a spuriously low t,A (Chennavasin et al., 1981).
Finally, in CAPD patients the plasma half life of frusemide after an oral dose of 500
mg was reported 10.5 ±1.2 h (Boutron et al., 1981, Table 7.11).
Riva et al., (1982) and Keller et al., (1981) studied frusemide disposition in 2 children
on haemodialysis and a group of adults on intermittent peritoneal dialysis respectively
using gas liquid chromatography. Similar t,A values of 3.7 and 4.5 h were found in
the children and the corresponding value in the adults was 3.3 ±0.9 h (Table 7.11).
HPLC has often been used to measure frusemide (Table 7.11). Voelker et al., (1987)
studied the disposition of frusemide in conservatively managed patients with chronic
renal failure (creatinine clearance 3-27 ml.min"1) and reported the mean t,^ as 2.6
±0.3 h. The same value of 2.6 ±0.4 ml.min'1 was found in a similar group of pa¬
tients and it was not altered by haemodialysis (Rane et al., 1978). In a separate group
(creatinine clearance 0.6-53 ml.min"1) the t,A varied from almost normal up to 24 h
and it was unrelated to the degree of renal impairment (Beermann et al., (1977).
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In most reports the elimination half life of frusemide in patients with various degrees
of renal impairment is in the range of 2 to 4 h and this is in good agreement with the
present study. However, both shorter and much longer values have been reported not
consistently related to the assay, route of administration or the dose of frusemide. The
problem may be compounded by the different methods of curve fitting as discussed
for the normal volunteer studies (Chennavasin et al., 1981).
In patients with end-stage renal failure, frusemide was cleared essentially by non-renal
mechanisms and renal contribution was negligible. The former route accounts for
about half the plasma clearance of frusemide in normal volunteers so the value of 62
ml.min"1 obtained in the present study is consistent with this. However, the values
reported by others for the non-renal clearance of frusemide vary greatly and a reduc¬
tion has been noted in patients with chronic renal failure (Rane et al., 1978, Beermann
et al., 1977).
Less than 1 % of the dose was eliminated by peritoneal dialysis and the removal of
frusemide by this route was negligible. Similar findings were reported by Boutron et
al., (1981) who found that less than 1 % of an oral dose of 500 or 1000 mg was ex¬
creted in the dialysate in CAPD patients. Although peritoneal dialysis is an effective
method for removing uraemic waste products it contributes little to the clearance of
most drugs (Paton et al., 1985). The low flow rate of the peritoneal effluent equiva¬
lent to approximately 10 litres per day or 7 ml.min"1 limits the clearance of the perito¬
neal membrane (Keller et al., 1990). Removal of drugs during dialysis needs to be
considered clinically only if the total clearance increases by 30% or more (Lee and
Marbury, 1984). When drugs are eliminated to a significant extent by non-renal
mechanisms the contribution of CAPD to their clearance is minimal (Keller et al.,
1990). This certainly applies to frusemide.
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The pharmacokinetic properties of a drug which influence its removal from the body
during peritoneal dialysis are its volume of distribution, the degree to which it is
bound to plasma proteins and its non-renal clearance (Paton et al., 1985). In order for
drugs to be significantly eliminated by CAPD they need to have a low volume of
distribution to provide high plasma concentrations and hence an effective concentra¬
tion gradient to diffuse in the peritoneal cavity to an appreciable extent. The other
important factor is the extent of protein binding (Peterson and Gerding, 1980). Al¬
though the plasma protein binding of frusemide is reduced in uraemia it is still 94 to
97% (Rane et al., 1978, Andreason et al., 1978). In the present study the plasma
albumin concentrations were below normal in 6 of the patients and thus the free frac¬
tion of frusemide may have been increased slightly. Nonetheless, the fraction of
bound frusemide was undoutedly still very high which would have limited the amount
of frusemide removed from the body by CAPD despite the low volume of distribution
of the drug. Thus, because of the high plasma protein of frusemide and the significant
clearance of the drug by non-renal mechanisms, the low peritoneal clearance was not
unexpected.
The present findings indicate as in other reports that the absorption of frusemide was
markedly delayed in patients with end-stage renal failure compared to healthy volun¬
teers. Despite this the total amount of frusemide absorbed tended to be higher in these
patients than in the volunteers possibly due in part to uraemia and interactions with
other medication. Frusemide was eliminated almost completely by non-renal mecha¬
nisms but little was cleared across the peritoneal membrane possibly due to high
plasma protein binding.
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CHAPTER 8
THE DISPOSITION OF FRUSEMIDE DURING LONG TERM THERAPY
IN CONSERVATIVELY MANAGED PATIENTS
WITH CHRONIC RENAL FAILURE
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SECTION 8.1: INTRODUCTION
Frusemide is extensively used in patients with chronic renal failure and it remains an
effective diuretic even when renal function is severely impaired (Allison and Kenne¬
dy, 1971). Frusemide must gain access to the tubular lumen to exert an effect (Chen-
navasin et al., 1979), and its active secretion may be blocked by endogenous organic
acids in chronic renal failure (Rose et al., 1976). This may necessitate the use of very
large doses (Brater et al., 1986). With the use of such doses chronically, it is possible
that accumulation of frusemide might occur in the plasma due to reduced renal elimi¬
nation. Although most of the side effects of frusemide including hyponatraemia and
hypokalaemia relate to its effects on the kidney, plasma concentrations of over 50
mg.l"1 have been associated with ototoxicity (Lloyd Mostyn and Lord, 1971, Morelli
et al., 1971, Gallagher and Jones, 1979).
In healthy volunteers the non-renal clearance of frusemide accounts for about 50 % of
the total clearance and in CAPD patients it was eliminated almost entirely by non¬
renal mechanisms. It seems likely that conservatively managed patients will also
depend to a significant degree on non-renal clearance to eliminate the large daily
doses of frusemide which they often require. The site of non-renal clearance is unclear
however (Branch, 1983) and a reduction has been noted in patients with uraemia
(Rane et al., 1978).
Although the disposition of frusemide has been studied extensively in patients with
chronic renal failure following a single dose, the results are often conflicting and little
attention has been given to patients taking the diuretic chronically in large doses. The
purpose of this study was to investigate the handling of frusemide in such patients in
order to assess the degree of accumulation during chronic dosing. It was hoped to
elucidate the absorption of frusemide under these circumstances and to determine the
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amount which is delivered to its active site in the kidney and to see how closely this
relates to the degree of renal impairment. Finally, it was of interest to investigate the
elimination of frusemide during chronic administration of large doses in order to




Ten patients (5 male, 5 female) on conservative management for stable chronic renal
failure took part in the study. Their mean age was 52 yr (range 32 - 68) and mean
weight 76 kg (range 66 - 88). Details of the medical histories and medication are
presented in Table 8.1 and results of haematology and biochemistry screening in
Tables 8.2, 8.3 and 8.4. The mean plasma creatinine was 516 ±268 /xmol.T1 and
mean creatinine clearance 21 ±17 ml.min'1 (Table 8.3). Although 4 of the patients
had proteinuria in the nephrotic range (>4.5 g.l"1) only patient 3 was hypoalbumi-
naemic. The other 3 had plasma albumin concentrations at the lower limit of normal
(Table 8.2). All the patients were on once daily maintenance doses of frusemide
(Hoechst, U.K. Ltd.,) ranging from 80 to 500 mg ( Table 8.1) and renal function had
remained stable in the 3 months before the study. Patients were encouraged to main¬
tain a high fluid intake of 2 to 3 1 daily except for patient 4 who was restricted to a
daily fluid intake of 500 ml.
Experimental design
The patients were studied on 2 separate occasions which were usually on consecutive
days. For one week before the study the patients were instructed to take the usual
maintenance dose of frusemide at exactly the same time each morning 1 h before
breakfast. In the 48 h before the study the patients made two 24 h collections of urine.
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On the morning of the first study day the fasting patients attended at the Clinical
Pharmacology Unit at 08.30 h and a cannula was inserted into a forearm vein. The
patients were then asked to take their normal dose of frusemide and other medications
(Table 8.1) with 200 ml of water, after which they remained recumbent for 1 h.
Breakfast was served at 09.30 h and lunch at 13.00 h according to the patient's
normal low protein, low salt dietary requirements. The patients were allowed their
normal daily fluid allowance taken as water or still orange juice and they regulated
this themselves throughout the day.
Blood (3 ml) was sampled before and then at 15, 30, 45, 60, 90, 120, 180, 240, 300,
360, 420 and 480 min after the frusemide was given and urine was collected at 0, 30,
60, 120, 240, 360 and 480 min. Patients were free to go at 16.30 h and were asked to
collect all urine passed until the end of the 24 h period after the administration of
frusemide.
On the second study day the procedure was the same but half of the usual maintenance
dose of frusemide was infused intravenously over 1 h at a constant rate in 100 ml of
0.9% saline via an "IMED 960" volumetric infusion pump. The patients took their
regular medications at 08.30 h. Sampling was the same as described above with extra
blood samples at 7.5, 105 and 150 min after the start of the infusion.
Samples
All samples were processed as described in Chapter 2.
Drug Assay
Plasma and urinary concentrations of frusemide were measured by HPLC as described
in Chapter 2.
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nifedipine 20 mg TID 80
metoprolol 100 mg TID
alfacalcidol 0.5 fig daily
aluminium hydroxide 475 mg TID
metoprolol 50 mg TID 250
enalapril 10 mg daily
sodium bicarbonate 300 mg TID
ranitidine 75 mg nocte
allopurinol lOOmg daily 160
captopril 50 mg TID
captopril 50 mg TID 240
isosorbide mononitrate 25 mg TID
captopril 12.5 mg TID 250
digoxin 0.0625 mg mane
warfarin 5 mg nocte
prazosin 1 mg TID
prednisolone 15 mg daily
azothioprine 75 mg daily
chloroquine 125 mg nocte
captopril 50 mg BD 160
nifedipine slow release 20 mg TID
aluminium hydroxide 475 mg nocte
cyclophosphamide 50 mg daily 120
prednisolone 12.5 mg
ranitidine 75 mg BD
captopril 50 TID 250
nifedipine 20 mg BD
allopurinol 100 mg daily
thyroxine 500 fig daily
metoprolol 50 mg BD
enalapril 10 mg daily 500
nifedipine 20 mg BD
metolozone 5 mg daily
metoprolol 25 mg BD
atenolol 100 mg daily 80
"slow K" TID
cephalexin 150 mg nocte
S.L.E. =systemic lupus erythematosus
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1 607 26.8 13 0.3
2 647 25.5 13 5.7
3 581 23.6 16 4.6
4 337 33.2 8 0.4
5 457 26.0 23 1.0
6 777 25.6 6 0.8
7 354 14.3 18 2.7
8 222 11.4 48 7.7
9 1071 42.8 7 5.1
10 112 9.3 56 0.3
Normal
range
55-150 2.5-6.6 >100 <0.1
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Table 8.4. Results of haematological tests in 10 conservatively managed








1 11.7 5.2 234
2 8.3 6.3 250
3 9.5 9.1 282
4 10.7 8.3 172
5 10.3 8.9 254
6 9.8 4.5 291
7 10.4 5.9 216
8 15.0 8.0 264
9 9.0 8.5 221
10 15.2 8.3 231




When blood samples contained residual amounts of frusemide from the previous dose,
corrected plasma concentrations were calculated using Equation 2.1 as described in
Chapter 2. The SIPHAR pharmacokinetic programme was then used to analyse the
corrected data as described in Chapter 2.
The plasma concentration-time curves obtained with oral dosing were fitted to a one
compartment model. Initial parameters were estimated by peeling and refined by itera¬
tive analysis. The goodness of the fit was established by comparing the coefficients of
variation of each parameter as described in Chapter 2 and these are listed in Table
8.5. They were usually less than 20-30 % except for patients 3, 5 and 6 where they
were slightly greater.
Following the intravenous dose the plasma concentration-time curves were best de¬
scribed by a two compartment model. Coefficients of variation of the estimated
parameters were less than 20-30% in all cases except for patient 2 (Table 8.6).
The fitted model was used to describe the disposition of oral and intravenous frusemi¬
de and to estimate the lag time and the elimination half life (tVi). The Wagner-Nelson
method was used to estimate the percent of the dose absorbed with time as described
in Chapter 2. Model independent analysis was used to estimate the AUCq m, the total,
renal and non-renal clearances and the V..
d
Statistics
The significance of observed differences was determined using the Students "t" test or
the Wilcoxon or Mann-Whitney test for paired and un-paired data respectively, where
appropriate.
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Table 8.5. The coefficients of variation (CV%) for the estimated parameters ob¬
tained by analysis of the plasma concentration time data following the administra¬
tion of frusemide 80 to 500 mg orally to conservatively managed patients with
chronic renal failure. The data were best described by a one compartment model
comprising an absorption and elimination phase. Initial parameters were estimated
by peeling and refined by iterative analysis. The absorption phase is represented by
intercept "A" and slope "a" and the elimination phase by intercept "B" and slope
"B" and described in Chapter 2.
Absorption phase Elimination phase
No. Intercept "A" Slope "a" Intercept "B" Slope "3"
(CV%) (CV%) (CV%) (CV%)
1 0.0 9.4 0.0 21.2
2 1.2 14.9 2.7 14.0
3 44.0 33.1 48.8 31.8
4 14. 5 24.3 23.2 26.0
5 34.8 35.0 55.0 52.1
6 36.1 31.9 42.0 33.1
7 14.5 18.1 20.2 15.4
8 11.2 15.2 13.1 9.5
9 12.6 21.3 20.6 16.3
10 15.1 18.0 26.1 10.8
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Table 8.6. The coefficients of variation (CV%) for the estimated parameters ob¬
tained by analysis of the plasma concentration time data obtained following the
administration of frusemide 40 to 250 mg intravenously to conservatively managed
patients with chronic renal failure.The data were best described by a two compart¬
ment model comprising a distribution and elimination phase. Initial parameters were
estimated by peeling and refined by iterative analysis. The distribution phase is
represented by intercept "D" and slope "d" and the elimination phase by intercept
"B" and slope "6" as described in Chapter 2.
Distribution phase Elimination phase
No. Intercept "D" Slope "d" Intercept "B" Slope "fi"
(CV%) (CV%) (CV%) (CV%)
1 11.9 26.6 11.0 18.3
2 28.2 42.8 6.0 6.3
3 9.2 18.8 17.9 28.9
4 15.1 26.1 2.6 2.1
5 6.4 14.6 5.0 4.2
6 7.6 17.4 6.5 5.5
7 7.1 13.0 7.3 4.0
8 4.8 9.4 4.8 2.7
9 9.0 21.3 6.9 4.4
10 13.0 6.6 28.1 15.5
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SECTION 8.3: RESULTS
Plasma concentrations of frusemide
The individual plasma concentration-time curves following the oral and intravenous
administration of frusemide are shown in Figures 8.1 and 8.2 respectively. Plasma
concentrations were corrected for residual traces of frusemide which was present in
all baseline samples (Cq) except patient 8, study day 2. The values varied from 0.12
mg.r1 to 1.07 mg.l"1 (Tables 8.7 and 8.8).
The absorption and distribution of frusemide
The oral absorption of frusemide in conservatively managed patients with chronic
renal failure was characterised by marked inter-subject variability (Fig. 8.1). The
patients were all taking different doses of frusemide however which may have ac¬
counted for some of this variability. In most cases frusemide was absorbed rapidly
with a mean lag time derived from the raw data of 5 + 7 min and in 7 of the 10 pa¬
tients no lag time was observed. Using the fitted model, the mean lag time was longer
at 13 ±9 min (Table 8.7).
The mean Cmax following the oral administration of frusemide to these patients was
7.29 +4.34 mg.l"1 and the mean Tmax was 102 +46 min (Table 8.7). As expected the
AUC0 ^ was variable with a mean value of 2570 +1461 min.mg.l"1. The mean bioa¬
vailability of oral frusemide was 61.3 +18.8 % (Table 8.7). The corresponding
values for Tmax and bioavailability did not differ significantly in the healthy volunteers
(90 +16 min and 53.6 +21.3 % respectively, Table 8.9).
Following the oral administration of frusemide in the CAPD patients the lag time
derived from the raw data of 26 +26 min was significantly longer (p<0.05) than the
corresponding value of 5 ±7 min observed in the conservatively managed group.
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However, when the fitted model was used the lag times were similar in both groups of
patients at 15 ±9 and 13 ±9 min, respectively. Similarly, although the Tmax was
longer in the CAPD patients at 126 ±58 min and the bioavailability higher at 70.1
±13.1 %, the differences failed to reach statistical significance (Table 8.9).
The fraction of the dose absorbed with time was also compared (Figs 8.3 and 8.4). In
the conservatively managed patients 42.0 ±22.8 % of the dose was absorbed in 1 h.
The corresponding percentages in the healthy volunteers and CAPD patients were less
but not significantly so at 26.7 ±28.8 and 35.5 ±28.8 % respectively. By the end of
the second h 54.1 ±18.6 % of the dose had been absorbed by the conservatively
managed patients and similar amounts had been absorbed by the volunteers and CAPD
patients (52.4 ±19.6 and 52.6 ±21.7 %, respectively). The absorption process was
similar in the healthy volunteers and conservatively managed patients with little fur¬
ther absorption after 2 h (Fig 8.3). In contrast, the absorption process was not
complete in the CAPD patients for 4 h (Fig 8.4). Despite this, the cumulative AUC to
4 h calculated from the plot of the percent of the dose absorbed with time was not
significantly different in the healthy volunteers (9385 ±4344 min.mg.l1), CAPD
patients (11025 ±4594 min.mg.l"1) and the conservatively managed patients with
chronic renal failure (10956 ±3957 min.mg.l"1).
Following the intravenous infusion of frusemide the mean Cmax in the conservatively
managed patients was 9.24 ±4.70 mg.l"1 (Table 8.8). The Vd of 12.8 ±2.1 1 was
similar to that observed in the healthy volunteers (14.1 ±3.8 1). The Vd in the CAPD
patients was slightly higher at 16.5 ±8.3 1 but the differences were not significantly
different (Table 8.9).
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Table 8.7. Lag time, residual plasma concentration at time zero (CQ), maximum plasma
concentration (Cmax), time to reach maximum concentration (Tmax), bioavailability and half
life of elimination (t1/4) of frusemide in 10 conservatively managed patients with chronic
renal failure following the ingestion of 80 to 500 mg of frusemide. The bioavailability was
calculated as the ratio of the AUCn after the oral and intravenous administration of0- oo



















1 0 0 0.74 5.71 45 2627 87.0 371.6
2 15 15 1.06 4.29 180 2645 43.3 324.2
3 0 8 0.44 4.24 120 1520 40.5 177.7
4 0 14 0.45 6.44 120 2790 60.4 250.4
5 0 O 0.99 8.75 180 3985 74. 5 262.1
6 0 10 0.57 6.25 90 1666 41.0 202.3
7 15 24 0.12 7.61 90 1991 93.1 154.8
8 0 13 0.37 9.20 45 2250 62.0 140.9
9 0 14 0.20 18.67 90 5971 70.8 174.6
10
•



















calculated from raw data
**
calculated from fitted model
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Table 8.8. Residual plasma concentration at time zero (C^, maximum plasma concentration
(Cmax), area under the plasma concentration time curve (AUC^), volume of distribution
(V ), plasma half life of elimination (tl/4) and total clearance of frusemide in 10 conserva¬
tively managed patients with chronic renal failure following the intravenous infusion of 40
to 250 mg of frusemide over one hour.
No. C0 Cmax AUC Vd Total
Clearance
(mg. I"1) (min.mg.1~*) (1) (min) (ml.min-"'")
1 1.04 3.81 1509 13.3 347.7 26.5
2 1.07 8. 70 3054 11.7 198.7 40.9
3 0. 57 5.61 1878 16.5 358.9 31.9
4 0.88 11.04 2308 11.4 152.5 52.0
5 0.84 10.86 2673 13.0 192.8 46.8
6 0.53 9.49 2029 10.3 181.3 39.4
7 0.40 6.35 1069 11.0 136.0 56.1
8 0.00 12.36 1815 11.6 117.0 68.9
9 0.16 20.40 4219 12.1 141.7 59.3
10 0.72 3.80 312 16.7 90.3 128.0
mean 0.62 9.24 2087 12.7 191.7 55.0
±sd 0.34 4.70 1025 2.1 86.9 27.2
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Table 8.10. Comparison of pharmocokinetic variables in healthy volunteers, conserva¬
tively managed patients with chronic renal failure and CAPD patients following the
administration of frusemide orally and intravenously (iv).





90 ±16 102 ±46 126 ±58
Bioavail¬ 53.6 ±21.3 61.3 ±18.8 70.1 ±13.1
ability
(%)




65.1 ±12.0 213.5 ±84.5 227.6 ±71.3
tjj (iv)
(min)
66.3 ±13.5 191.7 ±86.9 194.9 ±98.0
Total clearance
(ml.min-^)
137.8 ±26.9 55.0 ±27.2 61.9 ±20.4
Renal clearance 93.2 ±33.6 11.8 ±21.6 0.3 ± 0.3
(oral)




34.7 ± 8.9 7.4 ± 5.4 0.3 ± 0.3
fex <iv>
(%)
55.2 ± 4.8 7.9 ± 6.3 0.4 ± 0.6




Fig 8.1. Plasma concentrations of frusemide in 10 conservatively managed patients
with chronic renal failure following the administration of 80 to 500 mg orally.
Fig 8.2. Plasma concentrations of frusemide in 10 conservatively managed patients
with chronic renal failure following the administration of 40 to 250 mg by intravenous
infusion over 1 h.
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Percent of dose absorbed
Time (h)
Fig 8.3. The fractional absorption of oral frusemide (mean + s.e.m.) in conservatively
managed patients with chronic renal failure compared with healthy volunteers.
Percent of dose absorbed
Fig 8.4. The fractional absorption of oral^rusemide (mean ±s.e.m.) in conservatively
managed patients compared with CAPD patients.
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Elimination of frusemide
In patients with chronic renal failure the mean elimination half life of frusemide was
213.5 ±84.5 and 191.7 ±86.9 min respectively following oral and intravenous dosing
(Tables 8.7 and 8.8). The differences between routes were not statistically significant.
The t'A was significantly longer (p< 0.001) following both routes of administration
than the corresponding values of 65.1 ±12.0 and 66.3 ±13.5 min respectively ob¬
served in the healthy volunteers. However, the \>h values in the patients with chronic
renal failure are remarkably similar to those observed in the CAPD patients (227.6
±71.3 and 194.9 ±98.0 min) following the oral and intravenous routes of administra¬
tion (Table 8.9). The total body clearance of intravenous frusemide was 55.0 ±27.2
ml.min"1 and this was significantly less than the corresponding value of 137.8 ±26.9
ml.min"1 observed in the volunteers (p<0.001, Tables 8.8 and 8.9).
Renal excretion of frusemide
When oral frusemide was administered daily to patients with chronic renal failure in
doses of 80 to 500 mg, the mean urinary recovery in the two 24 h collections preced¬
ing the study was 12.8 ±11.6 and 16.0 ±11.7 mg respectively or 7.4 ±5.4 and 11.0
± 12.9 % of the total dose. A similar amount (12.4 ±7.4 mg or 7.9 ±6.3% of the
dose) was recovered in the 24 h period following oral dosing on the first study day
(Table 8.9). Following the intravenous infusion of 40 to 250 mg frusemide a mean of
11.0 ±7.1 mg was recovered in the urine or 14.1 ±14.0% of the total dose infused
(Table 8.10). As expected, the urinary recovery of frusemide was dependent on the
residual renal function, and was positively correlated with the creatinine clearance
following both oral and intravenous administration (r = 0.89, p< 0.001 and r=0.87,
p<0.01, p<0.01 respectively).
The urinary recovery of frusemide was significantly less in the patients with renal
failure than in the healthy volunteers in whom 34.7 ±8.9% and 55.2 ±4.8%
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(p< 0.001) of the oral and intravenous doses respectively were recovered in the urine
in 24 h. Furthermore, the renal clearance of frusemide in the patients was only 11.8
+21.6 ml.min"1 and 11.2 ±19.4 ml.min"1 respectively following oral and intravenous
dosing and this was dramatically less than the corresponding values in the healthy
volunteers (93.2 +33.6 ml.min"1 and 76.5 ±18.0 ml.min"1, p< 0.001). In keeping
with this the renal clearance of frusemide in subject 10 was normal reflecting the
patients relatively good creatinine clearance of 56 ml.min"1.
The non-renal clearance of frusemide
The non-renal clearance of frusemide was 43.8 ±12.2 ml.min"1 in the patients with
chronic renal failure. This was significantly less than the corresponding values of 61.4
±11.8 and 61.9 ±20.4 ml.min"1 observed in the volunteers and CAPD patients re¬
spectively (p<0.05).
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Table 8.10. The twenty four hour urinary recovery and renal clearance of frusemide in
10 conservatively managed patients with chronic renal failure given 80 to 500 mg fru¬
semide orally and 40 to 250 mg by intravenous infusion and the calculated non renal
clearance of the intravenous dose. "1" and "2" refer to the two twenty four hour collec¬
tions of urine in the two days before the start of the study.












1 5.5 6.9 4.9 6.1 7.8 9.8 3.0
★
1 4.0 10.1 2.7 23.8
2 8.8 3.5 11.0 4.4 8.2 3.3 3.1
★
2 9.8 7.9 3.2 37.7
3 11.9 7.4 12.5 7.8 10.5 6.6 6.9
3* 11.1 13.9 5.9 26.0
4 10.0 4.2 9.6 4.0 10.6 4.4 3.8
ic
4 6.3 5.3 2.7 49.3
5 16.3 6.5 22.7 9.1 17.7 7.1 4.4
★
5 20.0 16.0 7.5 39.3
6 1.7 1.0 1.7 1.0 2.1 1.3 1.3
★
6 2.7 3.3 1.3 38.1
7 14.6 12.2 18.6 15.5 10.7 9.0 5.4
★
7 7.0 11.6 6.5 49.6
8 45.0 18.0 35.0 14.0 29.4 11.8 13.1
★
8 22.1 17.7 12.2 56.8
9 3.9 0.9 6.7 1.3 7.3 1.5 1.2
k
9 5.1 2.0 1.2 58.1
10 10.9 13.6 37.7 47.2 19.2 23.9 75.9
10* 21.4 53.5 68.5 59.6
mean 12.8 7.4 16.0 11.0 12.4 7.9 11.8
std 11.6 5.5 11.7 12.9 7.4 6.3 21.6
*
mean 11.0 14.1 11.2 43.8




In patients with chronic renal failure taking once daily doses of frusemide 80 to 500
mg, all blood samples taken before the morning dose contained residual amounts of
the drug from the doses of the previous day. In most studies in which the disposition
of oral frusemide in patients with chronic renal failure has been investigated, single
doses have been used in patients not already taking frusemide (Boutron et al., 1981,
Huang et al., 1974 and Tilstone et al., 1978). Even when the patients were taking
long term frusemide, the diuretic was usually stopped for up to a week before the start
of the study (Kelly et al., 1977, Kiihnel et al., 1987 and Rane et al., 1978). There is
little information on the accumulation of frusemide during chronic oral dosing in
patients with chronic renal failure, but the present findings are in agreement with
those of Riva et al., (1982). In 7 children with end-stage renal failure on haemodialy-
sis receiving 25 to 75 mg frusemide 2 or 3 times a day, the trough blood concentra¬
tions ranged from 0.71 to 1.94 mg.l"1. Furthermore drug concentrations were similar
at 0 and 8 h after dosing indicating that there was little or no accumulation of the
drug. This presumably reflects compensatory non-renal clearance of frusemide as the
contribution of haemodialysis to drug elimination was minimal.
Following the oral administration of frusemide in the present patients study, absorp¬
tion took place rapidly with a measurable lag in only 3 of the 10 patients. Therefore,
in most patients absorption had begun within 15 min and the mean T was 102 ±46
min. The absorption process was virtually complete by 2 h and the bioavailability of
oral frusemide was just over 60 % (61.3 ±18.9 %).
The rapid absorption of frusemide in these patients was similar to that observed in the
healthy volunteers. However, in the CAPD patients the lag time was significantly
longer and absorption was not complete for 4 h. Despite this, the mean Tmax was not
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significantly longer and the mean bioavailability was similar in the CAPD patients.
The absorption of frusemide has frequently been noted to be delayed in patients with
chronic renal failure as discussed in the previous chapter (Huang et al., 1975, Beer-
man et al., 1977, Boutron et al., 1981 and Riva et al., 1982). However in one of the
few studies involving multiple doses of frusemide, the Tmax was short at 49.8 ±4.8,
86.4 ±54.6 and 58.8 ±27.6 min with 40, 80 and 250 mg frusemide respectively
taken 4 times a day for 72 h. It is difficult to see how chronic administration of
frusemide would lead to more rapid absorption, however, and both Riva et al., (1982)
and Beerman et al., (1977) reported delayed absorption in patients on regular mainte¬
nance therapy. The differences in absorption observed in the conservatively managed
and CAPD patients may simply reflect inter-subject variation and this has been in¬
voked to explain individual differences in frusemide disposition in healthy volunteers
(Boles Ponto and Schoenwald, 1990). In keeping with this is the long Tmax observed in
some of the conservatively managed patients. Alternatively it may reflect genuine
differences in absorption in patients on CAPD.
Following the intravenous infusion of frusemide the plasma concentration-time data
were best described by a two compartment model. The Vd was similar to that ob¬
served in the healthy volunteers and CAPD patients. With both oral and intravenous
administration of frusemide, the elimination half life was significantly longer than in
the healthy volunteers but were remarkably similar to those observed in the CAPD
patients. As discussed in the previous chapter the present findings are in good agree¬
ment with the reported values in the literature of 2 to 4 h (Table 7.11). As expected,
the total clearance of frusemide was significantly lower than in the healthy volunteers.
In most cases, there was very little frusemide in the urine following both oral and in¬
travenous administration and the recovery was dependent on the severity of the renal
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failure. The renal clearance was much lower than normal. This partly explains why
much larger than normal doses may be needed in patients with renal failure in order to
achieve sufficient concentrations in the lumen of the kidney to elicit a therapeutic
response (Chennevasin et al., 1979).
The urinary recovery of frusemide in patients with chronic renal failure is usually
very low. Beerman et al., (1977) administered 2 and 3 g frusemide respectively to 2
patients with end-stage renal failure and recovered only 1.4 and 0.7 % of the dose in
the urine. Similarly, in a group of CAPD patients the urinary recovery of frusemide
was 4.7 ±1.1 and 5.8 ±0.9 % of a 500 and 1000 mg dose respectively (Boutron et
al., 1981).
Following the intravenous administration of frusemide 120 to 160 mg to patients with
severe renal impairment (creatinine clearances 5 to 18 ml.min"1), the mean urinary
recovery was 11 ±2 % of the dose (Brater et al., 1986, (b)). A similar percentage
was recovered in patients given 40 or 80 mg intravenously whose plasma creatinine
concentrations ranged from 250 to 1150 ^mol.l"1 (Traeger et al., 1984) and in patients
given 80 to 600 mg with creatinine clearances of 3 to 27 ml.min"1 (Voelker et al.,
1987).
The renal clearance of frusemide in patients with impaired renal function has been
described and is summarised in Chapter 7, Table 7.11. The present findings are in
agreement with reported low values in patients with severe or end-stage renal failure
which range from less than 1 to 9 ml.min"1 (Beerman et al., 1977, Huang et al., 1974,
Keller et al., 1981, Rane et al., 1978, Riva et al., 1982, Tilstone et al., 1978, Traeger
et al., 1984 and Voelker et al., 1987).
The non-renal clearance of frusemide was significantly lower in the patients with
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chronic renal failure than in the normal volunteers or CAPD patients. Similarly, Rane
et al., (1978) reported a 41 % reduction in the non-renal clearance of frusemide in
patients with uraemia compared to normal volunteers. However, in 3 other studies no
differences were noted (Beerman et al., 1977, Keller et al., 1981 and Kelly et al.,
1977). In contrast, Cutler et al., (1974) noted a marked increase in the non-renal
clearance of frusemide in patients with chronic renal failure compared to normal
volunteers and the non-renal clearance of frusemide has been shown to be increased in
the nephrotic syndrome (Keller et al., 1982 and Smith et al., 1985).
The non-renal clearance of frusemide accounts for about 50 % of the total clearance
of frusemide in normal circumstances (Chapter 6). Although non-renal clearance
partly comprises glucuronide conjugation, other unknown mechanisms account for the
rest (Branch, 1983). In healthy subjects about 14 % of an oral and intravenous dose of
frusemide was excreted in the urine as the glucuronide conjugate and corresponding
amount in kidney transplant patients was 8 % (Smith et al., 1980 (a) and Smith and
Benet, 1983).
Although the non-renal clearance of frusemide was previously thought to occur
predominantly by metabolism its disposition is not altered in cirrhosis (Fuller et al.,
1981, Sawhney et al., 1981 and Verbeek et al., 1982). In the dog the non-renal clear¬
ance of frusemide was unaltered when the entire liver was removed and that the uri¬
nary recovery of frusemide glucuronide was unchanged (Verbeek et al., 1981 (b)). On
the basis of these findings it has been suggested that glucuronidation may take place in
extrahepatic sites including the kidney and that the liver does not contribute signifi¬
cantly to the non-renal component of its elimination (Branch 1983).
Probenecid pre-treatment in healthy subjects reduces both the renal and non-renal
clearances of frusemide (Chennavasin et al., 1979) although in a later study a signifi-
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cant effect was only shown on the renal clearance (Smith et al., 1980 (b)). Probenecid
might decrease active transport of frusemide into the gut and that accumulated organic
acids might have the same effect in chronic renal failure (Branch 1983). However,
intestinal perfusion studies performed in healthy volunteers during intravenous fru¬
semide administration showed that its clearance from the gastrointestinal tract was
only 2 ml.min"1 compared to a renal clearance of over 90 ml.min"1 (Valentine et al.,
1986). Finally it is possible that the other drugs that the patients were taking had an
effect on the non-renal clearance or metabolism of frusemide.
In patients with conservatively managed chronic renal failure taking regular mainte¬
nance doses of frusemide, significant accumulation of the drug was not observed. The
absorption and distribution of frusemide was similar to that observed in the healthy
volunteers. Despite the large doses of frusemide administered to the patients, little
appeared in the urine and recovery was dependent on residual renal function. The half
life was prolonged and the plasma clearance was much lower than normal due not
only to the expected reduction in the renal clearance but also to a smaller but signifi¬
cant reduction in the non-renal clearance.
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CHAPTER 9.
THE INTERACTION OF PARACETAMOL WITH FRUSEMIDE
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SECTION 9.1: INTRODUCTION
Frusemide produces a marked increase in the excretion of renal prostaglandins which
may mediate at least some of its pharmacological actions such as the rise in plasma
renin activity and natriuresis (Abe et al., 1977 and Scherer and Weber, 1979). In
support of this the nonsteroidal anti-inflammatory drugs which inhibit prostaglandin
synthesis have been shown to decrease the transient rise in plasma renin activity
induced by frusemide (Patak et al., 1975, Rumpf et al., 1975, Frohlich et al., 1976
and Passmore et al., 1989).
There is more controversy regarding the effects of the nonsteroidal anti-inflammatory
drugs on the natriuretic response to frusemide (Atallah, 1979). Some investigators
have reported a reduction when these drugs were coadministered (Patak et al., 1975,
Frohlich et al., 1976, Favre et al., 1983, Mackay et al., 1984 and Passmore et al.,
1989) but others have found no such interaction (Williamson et al., 1975 (a), Bailie et
al., 1976, Weber et al., 1977 and Riley et al., 1985).
Paracetamol has been considered in the past to be only a weak inhibitor of prostaglan¬
din synthesis (Brune, 1983). However, the administration of paracetamol to healthy
female volunteers under conditions of controlled sodium intake caused a reduction in
PGE2 excretion (Prescott et al., 1990) . This was associated with a reduction in
sodium excretion and a delay in the onset of diuresis following an acute water load
suggesting that paracetamol may share at least some of the properties of the other
nonsteroidal anti-inflammatory drugs . This is particularly important in patients with
impaired renal function who are often recommended to take paracetamol because it is
considered to be a "safe" analgesic in such patients.
The purpose of this study was to investigate the effects of paracetamol pretreatment on
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the renal excretion of prostaglandins following an intravenous dose of frusemide. The
effect of paracetamol on frusemide-induced diuresis, natriuresis and rise in plasma
renin activity was also studied to determine whether it had the potential to interfere
with these actions in patients taking both drugs.
SECTION 9.2: METHODS
Volunteers
Ten healthy female volunteers of mean age 32 yr (range 22 - 47) and weight 72 kg
(range 46 - 101) were studied. They had no medical illness and physical examination
was normal. They were taking no regular medications other than the oral contracep¬
tive pill, they did not smoke and they all claimed to drink less than 5 units of alcohol
per week. The results of routine biochemical and haematological screening tests are
presented in Tables 9.1 and 9.2 respectively.
Experimental design
Following the administration of either placebo or paracetamol for two days the effects
of an intravenous dose of frusemide were studied on a third day after a final dose of
either placebo or paracetamol. All subjects received both treatments which were given
under single blind conditions in random order. Placebo (two lactose tablets) or 1 g
paracetamol (two 0.5 g "Panadol" tablets) were taken at 08.30, 12.30, 16.30 and
20.30 h for two days. Food was avoided for 2 h before and for 2 h after dosing. To
avoid problems with premenstrual fluid retention, the studies were carried out during
the eighteen days following the end of a normal menstrual period. At least a week
separated both studies.
The volunteers were instructed by the hospital dietician how to restrict their intake of
sodium to 75 mmol per day for the two days before and during the period of drug
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administration. Volunteers were asked to avoid sexual activity before the third study
day on each occasion and to take no other drugs apart from the oral contraceptive pill
for seven days before or during the study.
On the third day of the study on both occasions the fasting volunteers attended at the
Clinical Pharmacology Unit at 08.00 h. An intravenous cannula was placed in a fore¬
arm vein and 200 ml of water was taken. The volunteers then remained recumbent for
30 min and 10 ml of venous blood was sampled for basal plasma renin activity (PRA
activity). At 08.30 h the bladder was emptied and a final dose of either placebo or
paracetamol 1 g was taken with 200 ml water. The patients remained recumbent and
1 h later (09.30 h) blood was again sampled for PRA activity and a urine sample col¬
lected.
Frusemide 20 mg (Hoechst U.K. Ltd.,) was then administered intravenously over 3
min via a butterfly needle in the opposite arm to the indwelling cannula. The volun¬
teers drank 400 ml of water at this point and further amounts of 100 ml were then
taken at 15 minute intervals for the next hour. Thereafter fluid was replaced accord¬
ing to the volume of urine passed at the 2 hourly collection points. Breakfast (toast
and water or still orange juice) was served after the administration of frusemide and
lunch was taken approximately 3 h later. No caffeine containing drinks were allowed
during the day.
After the administration of frusemide blood was sampled at 15, 30 and 60 min for
measurement of PRA activity. Urine was collected at 30, 60, 120, 240 and 360 min.
Subjects were free to go at approximately 15.30 h and were asked to collect all urine
passed until the end of the 24 h period after the administration of frusemide.
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Table 9.2. Results of haematological tests in 10 healthy female volunteers
given 20 mg frusemide intravenously following treatment with either place¬












1 12.2 7.8 215
2 14.4 7.2 258
3 14.0 10.5 342
4 13.2 3.6 220
5 11.3 8.0 192
6 12.9 5.3 242
7 13.4 3.9 253
8 12.9 5.8 328
9 13.8 3.3 338
10 13.2 6.2 194




All samples were processed as described in Chapter 2.
Assay of samples
Plasma renin activity was measured as described in Chapter 2. Urinary sodium was
measured by an ion selective electrode, urinary frusemide by HPLC and urinary
prostaglandins PGE2 and 6-keto PGFJa by radioimmunoassay (Chapter 2).
Statistics
Two way analysis of variance (ANOVA) was used to assess the significance of the
effects of frusemide on each day. The significance of differences between the effects
of frusemide with either placebo of paracetamol pre-treatment was assessed by split
plot design ANOVA and 1-way ANOVA where appropriate.
SECTION 9.3: RESULTS
Frusemide induced diuresis
The mean urinary volumes following the administration of 20 mg frusemide intrave¬
nously are shown in Table 9.3 and Fig 9.1. In the hour following the administration
of placebo or paracetamol the mean urinary volumes were 2.9 ±2.1 ml.min"1 (n=9)
and 3.8 ±3.1 ml.min"1 (n=9) respectively. Subject number 1 failed to pass urine in
this h. Frusemide administration caused a highly significant diuresis at 30 min of 23.9
±2.5 ml.min"1, p< 0.001, which was not altered by pre-treatment with paracetamol
(23.0 ±5.8 ml.min"1). A significant diuresis of 18.6 ±4.9 and 7.6 ±3.3 ml.min"1 was
maintained at 60 and 120 min respectively which was similar with paracetamol pre-
treatment (16.6 ±5.1 and 7.6 ±2.6 ml.min"1). By 4 h after the dose of frusemide the
urinary outputs had returned to basal values in both cases.
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Frusemide induced natriuresis
The mean urinary sodium excretion rates following the administration of frusemide is
shown in Table 9.3 and Fig 9.2. The mean basal excretion rates in the h after placebo
or paracetamol were 232 ±420 ^mol.min"1 (n=8) and 241 ±377 ^mol.min"1 (n=9).
Subject number one failed to pass urine at this point on either day and subject number
4 passed only 8 ml which was insufficient for analysis. The administration of frusemi¬
de induced a highly significant natriuresis at 30 and 60 min compared to the control
sodium excretion rate (1998 ±415 and 1336 ±375 /zmol.min'1, p< 0.001 respective¬
ly). With paracetamol pre-treatment the natriuresis was greater at 30 min (2192 ±682
jimol.min"1) and less at 60 min (1133 ±356 ^mol.min"1) but the differences were not
significant. The mean sodium excretion rate at 120 min was similar to the basal rate
with either placebo or paracetamol pre-treatment (329 ±127 and 339
±134 /xmol. min"1, respectively). However the next two urine collections showed an
apparent rebound with reduced excretion rates of sodium at 6 h with placebo (61 ±47
jimol.min"1) or paracetamol pre-treatment (70 ±24 ^mol.min"1).
Urinary excretion of prostaglandin E2 (PG E2) and 6-keto prostaglandin F
(PGFJ
The urinary excretion rate of PGE2 is shown in Table 9.3 and Fig 9.3. The concentra¬
tions of PGE2 in subject number 2 were extremely high on the first study day and it
was assumed that sexual intercourse had taken place. The data from this subject were
therefore omitted for both days. The mean basal urinary excretion rate of PGE2 was
higher with placebo than with paracetamol pre-treatment (18.5 ±14.3, n=7 compared
with 7.6 ±4.3 ng.h"1, n = 8, respectively) but the differences failed to reach statistical
significance. Following the administration of frusemide the rate of excretion of PGE2
increased in the first h to 34.5 ±32.0 ng.h"1 with placebo and this effect was signifi¬
cantly blunted by paracetamol pre-treatment (16.4 ±7.2 ng.h"1, p<0.05).
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Thereafter the excretion rates varied little between both study days. With placebo pre-
treatment there was a rebound decrease in the output of PGE2 at 2 h and although this
had increased by 6 h it was still lower than the basal rate (13.1 ±6.9 ng.h"1). With
paracetamol pre-treatment there was no rebound decrease in output of PGE2 at 2 h and
at this time the output was similar to basal levels at 9.3 ±3.7 ng.h"1.
The corresponding excretion rates of 6-keto PGFla are shown in Table 9.3 and Fig
9.4. The mean basal excretion rate of 6-keto PGFla was also higher with placebo than
paracetamol (61.7 ±38.5, n = 8 compared with 38.7 ±24.4 ng.h"1 n=9, respectively)
but the differences were not significant. In the 30 min following the administration of
frusemide there was a transient increase in the urinary excretion rate of 6-keto PGFla
which was less with paracetamol pretreatment (101.2 ±63.7 v 64.2 ±30.3 ng.h"1).
Again these differences were not statistically significant. At each subsequent collec¬
tion point the mean excretion rate was always higher with placebo pre-treatment but
not significantly. Nonetheless, the cumulative output over the first 2 h after frusemide
was significantly lower with paracetamol than with placebo pre-treatment (137.1
±99.9 v 72.0 ±33.8 ng.h"1, p<0.05).
Urinary recovery of frusemide
The urinary recovery of frusemide following intravenous administration is given in
Table 9.3 and Fig 9.5. In the first 30 min 5.9 ±1.4 mg was recovered in the urine
and with paracetamol the corresponding recovery was significantly higher at 7.2 ±1.5
mg (p<0.05). Subsequently, the recovery of frusemide was much less and was not
altered by paracetamol pre-treatment. The mean 24 h recovery was 11.6 ±1.6 mg
with placebo and 12.7 ±1.4 mg with paracetamol (p<0.05).
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Plasma renin activity
The mean PRA activity following the administration of frusemide is shown in Table
9.4 and Fig 9.6. When the volunteers had rested for 30 min the basal PRA activity
was 2.0 ±1.4 ng.mr'.h"1 with placebo and 1.5 ±0.6 ng.mr'.h"1 with paracetamol
pretreatment. One h later the values were very similar following the final dose of
either placebo or paracetamol (1.7 ±0.9 v 1.4 ±0.5 ng.mr'.h"1). With placebo,
frusemide induced a significant increase in PRA activity at 15 (3.4 ±2.7 ng.mr'.h"1,
p<0.01), 30 (3.5 ±2.1 ng.mr'.h*1, p<0.001) and 60 min (4.3 ±2.9 ng.ml"'\h"1,
p< 0.001). The response was significantly reduced with paracetamol pre-treatment
and the corresponding values at 30 and 60 min were 2.3 ±1.4 and 2.7 ±1.9
ng.mr'.h"1 respectively, (p<0.01 compared with placebo).
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Table 9.3. The diuresis, natriuresis, urinary excretion rate of prostaglandins PGE2
and 6-keto PGF[a and frusemide observed following the administration of 20 mg
frusemide intravenously to ten healthy female volunteers pre-treated with either




0 30 60 120 240 360 1440
Volume 2.9 23.9 18.6 7.6 2.7 2.6 1.0
ml ±2.1 ±2.5 ±4.9 ±3.3 ±1.6 ±1.4 ±0.5
* 3.8 23.0 16.6 7.6 3.0 3.7 0.9
±3.1 ±5.8 ±5.1 ±2.6 ±1.2 ±1.2 ±0.5
Sodium 232 1998 1336 329 60 61 26
/jmol .min-"'' ±420 ±415 ±375 ±127 ±47 ±47 ±9
it 241 2192 1133 339 73 70 31
±377 ±682 ±356 ±134 ±43 ±24 ±21
pGE2_ 18.5 46.6 20.1 8.1 7.3 13.1 8.8
ng. h ±14.3 ±48.0 ±17.9 ±6.0 ±3.3 ±6.9 4.3
★ 7.6 22.3 10.4 5.9 10.7 9.3 8.3
±4.3 ±13.1 ±4.3 ±1.6 ±10.8 ±3.7 ±2.2
6-keto PGF,
_i la
61.7 101.2 74.6 49.3 37.1 47.3 51.5
ng. h ±38.5 ±63.7 ±51.4 ±63.1 ±27.3 ±28.0 ±33.7
* 38.7 64.2 38.3 20.8 18.2 38.5 38.4
±24.4 ±30.3 ±19.3 ±11.6 ±11.2 ±38.0 ±26.2
Frusemide 0.0 5.9 2.5 1.7 1.2 0.3 0.0
mg ±0.0 ±1.4 ±0.5 ±0.5 ±0.5 ±0.2 ±0.0
* 0.0 7.2 2.3 1.9 1.1 0.4 0.0
±0.0 ±1.5 ±0.5 ±0.4 ±0.3 ±0.4 ±0.0
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Table 9.4. The plasma renin activity (ng.ml.h1) observed in 10 healthy female
volunteers given frusemide 20 mg intravenouly at time 0 following pretreat-
ment with placebo and paracetamol (1 g 4 times per day) for 2 days with a final
dose at time -60. Results are expressed as mean ±s.d.
Time
mins
-60 0 15 30 60
Placebo 2.0 1.7 3.4 3.5 4.3
pretreatment ±1.4 ±0.9 ±2.7 ±2.1 ±2.9
Paracetamol 1.5 1.4 2.4 2.3 2.7
pretreatment ±0.6 ±0.5 ±1.5 ±1.4 ±1.9
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Urinary excretion rate (ml/min)
30-1
i 1 Placebo Paracetamol
Time (h)
Fig 9.1. The diuresis (mean ±s.d.) induced by intravenous frusemide 20 mg in 10
volunteers pretreated with placebo or paracetamol (1 g 4 times a day) for 2 days.
Sodium excretion rate (umol/min)
Fig 9.2. The natriuresis (mean ±s.d.) induced by intravenous frusemide 20 mg in 10
volunteers pretreated with placebo or paracetamol (1 g 4 times a day) for 2 days.
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0 12 3 4
Time (h)
Fig 9.3. The urinary output of prostaglandin E, (mean ±s.e.m.) following 20 mg















Fig 9.4. The urinary output of prostaglandin F (mean +s.e.m) following 20 mg
intravenous frusemide to 9 volunteers pretreated with placebo or paracetamol.
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Urinary frusemide (mg)
Fig 9.5. The urinary recovery of frusemide (mean ±s.d.) following an intravenous
dose of 20 mg in 10 volunteers pretreated with placebo or paracetamol.
PRA (ng/ml/h)
o H 1 1 1 1 1 1
-0.5 -0.25 0 0.25 0.5 0.75 1
Time (h)
Fig 9.6. Plasma renin activity induced by 20 mg intravenous frusemide (mean ±s.d.)
in 10 volunteers pretreated with placebo or paracetamol.
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SECTION 9.4: DISCUSSION
The administration of 20 mg of frusemide intravenously to 10 healthy female volun¬
teers caused a brisk natriuresis and diuresis which was not reduced by paracetamol
pre-treatment. Frusemide also caused a transient rise in the urinary excretion of PGE2
and 6-keto PGFJa and a rise in plasma renin activity. These effects were significantly
reduced by paracetamol.
At least some of the pharmacological actions of frusemide are mediated by the pros¬
taglandins. Thus infusions of PGE2 and prostacyclin (PGI2) into the renal artery in¬
crease renal blood flow, sodium and potassium excretion and renin release (Fitzgerald
etal., 1980, Gerber et al., 1978, Jackson et al., 1982, Jones et al., 1981, Martinez-
Maldonado et al., 1972 and Schwertschlag et al., 1982). Williamson et al., (1975 (b))
first reported that the administration of frusemide to dogs was associated with in¬
creased levels of PGE2 in renal venous blood and an increase in prostaglandin excre¬
tion following frusemide has also been shown in man (Abe et al., 1977, Scherer and
Weber, 1979).
The loop diuretics might inhibit the metabolism of prostaglandins and this effect could
be responsible for the prostaglandin-mediated effects of frusemide. Frusemide inhibits
the enzyme PGE2-9-ketoreductase which converts PGE2 to the inactive PGF2a and
15-hydroxy prostaglandin dehydrogenase which converts active prostaglandins to their
inactive 15-keto metabolites (Stone and Hart, 1976, Paulsrud and Millar, 1974).
However, as pointed out by Gerber (1983) these experiments were performed in cell-
free systems derived from placenta and kidney and the concentration of frusemide
necessary to produce 50% inhibition of the enzymes was 10 to 100 times higher than
those achieved in humans. Furthermore, in man, frusemide increases the urinary
excretion of all the prostaglandins and the increase in PGE, output is not at the ex-
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pense of PGF2a as would be expected with 9-ketoreductase inhibition (Ciabattoni et
al., 1979). It seems more likely that frusemide causes an increase in de-novo synthesis
of prostaglandins possibly due to the increased availability of the prostaglandin sub¬
strate arachadonic acid (Weber et al., 1977).
The rise in PRA activity activity induced by frusemide is prostaglandin-mediated
(Gerber et al., 1981) and this effect is consistently blocked by the nonsteroidal anti¬
inflammatory drugs which inhibit the formation of prostaglandins (Patak et al., 1975,
Rumpf et al., 1975, Frohlich et al., 1976, Tan and Mulrow, 1977, Mackay et al.,
1984, Riley et al. ,1985 and Passmore et al., 1989). The relationship between the
prostaglandin system and the natriuretic effect of frusemide is less clear-cut and there
is considerable controversy regarding the effects of the nonsteroidal anti-inflammatory
drugs on this response (Attallah, 1979). Some investigators have reported a reduced
natriuretic response to frusemide when nonsteroidal anti-inflammatory drugs were
given at the same time (Patak et al., 1975, Frohlich et al., 1976, Favre et al., 1983,
Passmore et al., 1989 and Mackay et al., 1984). However other reports showed no
such interaction (Williamson et al., 1975 (a), Bailie et al., 1976, Weber et al., 1977
and Riley et al., 1985).
The natriuretic effect of the prostaglandins may be mediated by an increase in renal
blood flow with redistribution towards medullary nephrons (Kirschenbaum et al.,
1974). Alternatively, it has been proposed that PGE2 exerts a direct effect on the
collecting tubule or medullary thick ascending Loop of Henle (Stokes and Kokko,
1977 and Stokes, 1979). These effects however were only present when PGE2 was
added to the peritubular as opposed to the luminal surface of the nephron where
frusemide exerts its action (Burg et al., 1973). Fine and Kirschenbaum (1981) were
unable to reproduce these findings.
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It is perhaps not surprising that several investigators failed to show a blunting of the
natriuretic effect of frusemide with the nonsteroidal anti-inflammatory drugs. Differ¬
ences between studies may be due to variations in protocol particularly with respect to
fluid and sodium balance, and residual renal function (Riley et al., 1985). Sodium
balance seems to be particularly important. In dehydrated dogs frusemide caused an
increase in renal blood flow which was abolished by indomethacin. However in dogs
treated with a high salt diet and deoxycorticosterone acetate (DOCA), a regime which
inhibits the renal vascular effects of frusemide (Gerber, 1980), the administration of
frusemide failed to cause vasodilitation and indomethacin did not affect renal blood
flow (Nies et al., 1982). On the basis of these findings it has been suggested that the
frusemide-induced diuresis and natriuresis that occurs in volunteers taking a normal
sodium diet may not be mediated by prostaglandins (Riley et al., 1985). However, in
most of the studies where there was a demonstrable inhibition of frusemide-induced
natriuresis by the nonsteroidal anti-inflammatory drugs, the volunteers were taking
either a diet containing 120 to 150 mmol sodium per day (Patak et al., 1975, Frohlich
et al., 1976, Favre et al., 1983 and Passmore et al., 1989) or an unrestricted sodium
diet (Mackay et al., 1984). The role of the prostaglandins in the tubular response to
frusemide is therefore tenuous and is most likely to be attributable to prostaglandin-
mediated renal vasodilatation .
Paracetamol has been considered to be only a weak inhibitor of prostaglandin biosyn¬
thesis although it has been suggested that it may be more effective against enzymes in
the central nervous system than those in the periphery (Flower and Vane, 1972). For
this reason it is generally thought not to share the properties of the other nonsteroidal
anti-inflammatory drugs such as fluid retention and interference with loop diuretics.
However, the administration of paracetamol to healthy female volunteers under condi¬
tions of controlled sodium intake caused a reduction in PGE., excretion (Prescott et
al., 1990). This was associated with a reduction in sodium output and a delay in the
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onset of a diuresis following an acute water load. An earlier study by Haylor (1980)
found that paracetamol caused a reduction in sodium and water output and it also has
an antinatriuretic effect in patients with diabetes insipidus (Nusynowitz and Forsham,
1966). In contrast, Berg et al., (1990) found a reduction in sodium and PGE2 output
with paracetamol therapy in healthy elderly volunteers and not in young subjects.
These reports suggest that paracetamol may share at least some of the properties of
the other nonsteroidal anti-inflammatory drugs. In the present study it was found that
although paracetamol reduced the frusemide-induced increase in PGE2 and 6-keto
PGF, , it had no effect on the natriuresis or diuresis. Paracetamol also reduced thela7
PRA activity activity which is presumably related to its inhibition of renal prostaglan¬
din synthesis. In the present study, significantly more frusemide was recovered in the
urine when volunteers had taken paracetamol. However, this was not associated with
a significant increase in the natriuresis or diuresis despite the fact that the action of
frusemide is dependent on the amount present at the luminal side of the ascending
loop (Burg et al., 1973). It is possible that paracetamol competitively inhibited glucu-
ronide metabolism of frusemide so that relatively more unchanged frusemide was
excreted in the urine.
The results of this study are of relevance to patients with impaired renal function.
Paracetamol is widely used in patients with renal failure because it is considered to be
a "safe" analgesic. However we have clearly shown that it has an effect on renal
prostaglandins and in particular that it blunts the rise in the excretion of prostaglan¬
dins and in PRA activity induced by frusemide. Most, if not all, of the nonsteroidal
anti-inflammatory drugs can cause sodium retention, development or aggravation of
oedema, hyperkalaemia, interference with the actions of diuretics and 6-blockers and
the development of renal failure, particularly under conditions of reduced renal perfu¬
sion (Garella and Matarese, 1984). There is evidence that paracetamol may be impli-
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cated in the development of acute renal failure following overdose without severe liver
damage (Kleinman et al., 1980, Coben et al., 1982 and Bjorck et al., 1988) and long
term daily use is associated with an increase risk of chronic renal disease (Sandler et
al., 1989). Paracetamol may therefore not be as safe an analgesic as was first thought





In the present study a number of changes in the disposition of the commonly used
analgesic, paracetamol, and the loop diuretic, frusemide, were demonstrated in pa¬
tients with chronic renal failure. Although some of the findings were predictable,
others were not and could not be explained simply by the presence of renal impair¬
ment. It does appear, however, that patients with renal failure who are maintained on
long term medication in high doses may absorb, metabolise and eliminate these drugs
in unexpected ways. This may account for some of the variability in drug action and
increased incidence of side effects often noted in such patients.
In patients with end-stage renal failure maintained on CAPD, the absorption of fru¬
semide, but not paracetamol, was delayed. Despite this, the bioavailability of frusemi¬
de was not reduced and indeed it tended to be higher than in normal volunteers. On
the other hand, conservatively managed patients with chronic renal impairment ab¬
sorbed frusemide normally, and there was no evidence of dose-dependent absorption.
It may be that absorption of frusemide is impaired only in the presence of severe renal
failure because of more marked alterations in gastrointestinal motility or the presence
of gut oedema. On the other hand absorption may be influenced by the presence of
large volumes of dialysate in the peritoneal cavity. If this is the case it is difficult to
account for the apparently normal absorption of paracetamol under similar circum¬
stances and it may simply be a further manifestation of the previously noted marked
inter-individual variation in the oral absorption and disposition of frusemide.
The peritoneal membrane is an effective method of removing uraemic waste products
but contributes little to the clearance of most drugs as demonstrated for paracetamol
and frusemide. The clearance by peritoneal dialysis even of those drugs or drug
metabolites which have a low volume of distribution and little binding to plasma
proteins will be very small and limited by the "low flow" rate of the peritoneal efflu¬
ent. This was certainly the case for the polar glucuronide and sulphate metabolites of
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paracetamol which are normally readily excreted by the kidney. The peritoneal
membrane could therefore not effectively eliminate these conjugates during chronic
dosing in patients with end-stage renal failure and marked accumulation would seem
inevitable under such circumstances. The clearance of frusemide by the peritoneal
membrane was minimal, possibly because of high plasma protein binding. Marked
accumulation of frusemide would not occur during chronic dosing in CAPD patients,
however, because of substantial non-renal clearance.
The metabolism of both paracetamol and frusemide may have been affected in patients
with chronic renal failure. Thus, in conservatively managed patients taking regular
doses of paracetamol over 10 days, the glucuronide but not the sulphate conjugate
accumulated as predicted. This may simply have been a result of sulphate depletion
caused by frequent administration of therapeutic doses of paracetamol, although this is
less likely in patients with renal failure who tend to retain sulphate. There was also
evidence of enterohepatic circulation of retained conjugates with some regeneration of
paracetamol by hydrolysis in the gut. Although this is probably not of great impor¬
tance with paracetamol, similar regeneration of the parent compound with other drugs
could be of vital clinical significance.
In patients with end-stage renal failure maintained on haemodialysis taking a similar
regime of paracetamol neither the glucuronide nor the sulphate conjugate accumulated
as predicted. It is difficult to explain these findings but the possibilities include poor
compliance, reduced absorption of paracetamol, altered metabolism, increased biliary
excretion of metabolites or greater than expected clearance of paracetamol during
haemodialysis. It is unlikely that all of the patients would show poor compliance and
the absorption of single doses of paracetamol in end-stage renal failure was normal.
Altered metabolism is possible, particularly of the sulphate conjugate. Increased bil¬
iary excretion of the retained conjugates may also have occurred under such circum-
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stances possibly with some regeneration of the parent compound by hydrolysis of the
conjugates in the gut. The clearance of paracetamol glucuronide during haemodialysis
was restricted to less than 40 ml.min'1 and this certainly does not help to explain the
findings. The most likely explanation is a compensatory increase in enterohepatic
circulation of the polar conjugates of paracetamol during chronic dosing in these
patients, but altered metabolism of paracetamol, perhaps to compounds which were
not detected by the assay, is also possible.
There was also evidence that the metabolism of frusemide was altered in conservative¬
ly managed patients with chronic renal failure in that the non-renal clearance was
reduced during chronic dosing. It was, however, unaltered in the CAPD patients
following single doses. Although frusemide is partly metabolised to a glucuronide
conjugate, most of the non-renal clearance occurs by unknown mechanisms which are
not thought to involve the liver. Elimination of frusemide by this mechanism undoubt¬
edly explains the lack of accumulation of frusemide observed in the conservatively
managed patients despite the large daily doses of diuretic they required. It is possible
that saturation of this pathway would occur during chronic dosing leading to the
observed reduction in the non-renal clearance in the conservatively managed but not
the CAPD patients who were not taking frusemide regularly. Indeed one of the strik¬
ing findings was how little of the frusemide taken by the conservatively managed
patients actually reached the active site at the tubular lumen.
The patients were all taking a variety of other medication and the observed changes
in the disposition of paracetamol and frusemide could have been due to interactions
with some of these. One of the expected findings was that paracetamol and frusemide
themselves could interact with one another. Pretreatment with paractamol reduced the
rise in plasma renin activity and increased excretion of urinary prostaglandins induced
by intravenous frusemide but not the natriuresis or diuresis.
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The present findings have important implications for drug prescribing in patients with
chronic renal failure. Absorption of many drugs, including diuretics may be impaired.
Furthermore, under conditions of chronic dosing metabolism may be abnormal with
increased compensatory elimination of drug metabolites in the bile. The possibility
then exists for regeneration of the parent compound by hydrolysis of conjugates in the
gut with subsequent reabsorption resulting in higher than normal therapeutic, or toxic,
plasma concentrations. Accumulated drug metabolites may also lead to unexplained
toxicity in the presence of renal failure. The peritoneal membrane may not be relied
upon to effectively eliminate drugs in CAPD patients as the clearance of drugs by this
route is very limited. Haemodialysis may not eliminate polar drug metabolites as
effectively as was thought and the reasons for this are unclear. Drug interactions may
not always be obvious and the use of paracetamol in patients with chronic renal fail¬
ure, particularly those requiring diuretics, should be reviewed.
Several important questions have arisen from these studies and much work still needs
to be done. In particular, detailed absorption studies should be done in patients with
chronic renal failure following both single and multiple doses of paracetamol and
frusemide. A crucial area of research is to explain why paracetamol metabolites did
not accumulate as predicted during chronic dosing and, in particular, to determine
whether increased biliary excretion of retained metabolites was responsible. Such
studies might involve the use of radiolabeled drug. In addition, measurement of
plasma inorganic sulphate levels during multiple dosing might help to determine
whether saturation of sulphate conjugation occurs in patients with renal failure under
such circumstances. Elucidation of the mechanisms of the non-renal clearance of
frusemide are required both in normal volunteers and renal failure patients and much




Paracetamol and frusemide provide very useful models of altered drug disposition in
patients with renal impairment and the present studies underline our ignorance about
how patients deal with the large doses and chronic administration of drugs required
for therapeutic purposes. Many of the observed changes in disposition could be ex¬
plained simply by the reduced renal function. However, some of the alterations in
absorption, metabolism, metabolite accumulation and non-renal clearance including
clearance by dialysis were completely unexpected and not readily explained. In addi¬
tion, the studies illustrate how frequently commonly used drugs may interact with one
another in unsuspected ways. Clearly great care is needed to ensure safe and appro¬
priate drug prescribing in patients with chronic renal failure.
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ABBREVIATIONS
The following abbreviations have been used:
AUC area under the plasma concentration-time curve
C centigrade
Ct drug plasma concentration at time "t"
Cmax the maximum concentration of drug in the body
g gram
h hour
K the elimination rate constant of a drug
ka the absorption rate constant









s.e.m. standard error of the mean
T the time to reach peak plasma concentrationsmax r r
t,A the drug elimination half life
/x 1 microlitre
jxmol micromole
VJ volume of distributiond
yr year
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Summary. We have compared the disposition of oral
paracetamol (1.0 g t.d.s. for 10 days) in 6 healthy volun¬
teers and 6 conservatively-managed patients with chronic
renal failure (mean plasma creatinine 451 pmol■ 1"').
Blood was sampled daily for 10 days before the morning
dose of paracetamol.
Each day the pretrealment plasma concentrations of
paracetamol were higher in the renal failure patients
than in the volunteers, with mean values over the 10 days
of 3.1 and 1.1 mg l"1 respectively. The mean daily plasma
concentrations of the sulphate and glucuronide con¬
jugates of paracetamol were markedly higher in the renal
failure group and apparent steady-state concentrations of
about 25 and 85 mg T1 were reached on the 2nd and 6th
days respectively. The mean steady-state plasma concen¬
trations of the glucuronide conjugate on the 7th to 10th
da\^ of treatment were positively correlated with the
plasma creatinine concentration (r =0.97), but this rela¬
tionship did not hold for the sulphate conjugate. Cysteine
and mercapturate conjugates could only be detected in
one patient.
Predictions of steady-state concentrations based on
previous studies with single doses of paracetamol in renal
failure patients were remarkably accurate for the glucu¬
ronide but not for the sulphate conjugate.
These results are consistent with some extra-renal
elimination of retained paracetamol conjugates in pa¬
tients with chronic renal failure, with limited regeneration
of the parent compound. The sulphate metabolite did not
accumulate as predicted, possibly because of depletion of
inorganic sulphate.
Key words: Paracetamol, Renal failure, glucuronide con¬
jugation, sulphate conjugation, multiple dosing, accumu¬
lation
The excretion of polar drug metabolites is impaired in
patients with chronic renal failure, and when single doses
of paracetamol were given to such patients the plasma
concentrations of its glucuronide and sulphate con¬
jugates were greatly increased compared with those
observed in healthy volunteers [Prescott et al. 1989],
Furthermore, in anephric patients haemodialysis ap¬
peared to be the major route of elimination of paraceta¬
mol metabolites [0ie et al. 1975], Therefore, when pa¬
tients with moderate to severe renal impairment take
paracetamol regularly over a long period of time, signifi¬
cant accumulation of its polar metabolites would be ex¬
pected. Under these conditions it is possible that the
retained conjugates might undergo enterohepatic circu¬
lation, with some regeneration of the parent compound
by hydrolysis in the gastrointestinal tract [Verbeeck et al.
1981],
Little attention has been paid to the accumulation
of drugs and their metabolites during long-term treat¬
ment of patients with impaired renal function. We have
therefore compared the disposition of paracetamol and
its metabolites in healthy volunteers and in conservative¬
ly managed patients with chronic renal failure taking
1 g of paracetamol three times a day for 10 days. The
plasma concentrations of the glucuronide and sulphate
conjugates were compared with those expected on the




Studies were carried out in 6 healthy volunteers (3 men and
3 women), mean age 32 v (range 18-37 y) and mean weight 60 kg
(range 48-75 kg). They had no significant past medical history and
were not taking any regular medications. They did not smoke and
denied heavy consumption of alcohol. Physical examination and
routine biochemical and haematological screening were normal. We
also studied 6 patients (5 men. 1 women) on conservative manage¬
ment for chronic renal failure. Their clinical details are summarized
in Table 1. Their mean age and weight were 55 y (range 43-75 y) and
74 kg (range 52-97 kg). Apart from mild elevation of the alkaline
phosphatase in two of the patients, liver function tests were normal.
Both the patients and the volunteers were asked to avoid taking
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Table 1. Clinical details of the patients with chronic renal failure
U. Martin et al.: Paracetamol disposition in renal failure
Patient Age & Weight Medical & renal
sex (kg) diagnoses
Haemoglobin Albumin
(g dl ') (g I ')
Plasma Creatinine Drugs
creatinine clearance



























































paracetamol for 7 days before and for 4 days after the study. The
study was approved by the local Ethics Committee of Medical Re¬
search and all the subjects gave their informed consent before taking
part.
P <0.05. Correlations were determined using standard regression
analysis. The results are given as means (SD) and the concentrations
of the conjugates have been expressed as paracetamol equivalents.
Drug administration and blood sampling
The patients and volunteers took paracetamol 1 g (2 x 500 mg sol¬
uble Panadol® tablets) dissolved in approximately 100 ml of water,
at 10.00.16.00. and 22.00 h for 10 days. Food was avoided for 2 h be¬
fore and for 2 h after dosing. Venous blood was sampled at 09.00 h
on the first day of the study before starting paracetamol, at the
same time each morning for the next 10 days, and on the mornings
of the 2nd and 4th days after the last dose of paracetamol. The plas¬
ma was stored at - 20°C until assayed for paracetamol and its glu-
curonide. sulphate, cysteine, and mercapturate conjugates by




The mean daily pretreatment plasma concentrations of
paracetamol and its glucuronide and sulphate conjugates
are shown in Table 2. Each day the plasma concentrations
of paracetamol were higher in the renal failure patients
than in the volunteers. The mean values over the 10 days
of treatment of 3.1 (0.6) and 1.1 (0.3) mg -1"1 respectively
(P < 0.01).
Data analysis
Steady-state concentrations of paracetamol glucuronide and sul¬
phate conjugates were predicted from the relationship between the
degree of renal failure and the minimum steady-stale concentrations
calculated from data obtained in a previous single-dose study [Pres-
cott et al. 1989]. The data were fitted to a single exponential by the
'"SIPHAR" pharmacokinetic program, taking the "dose" as the
amount of conjugate formed from the administered paracetamol.
Using the derived coefficients and exponents the minimum steady-
state conjugate concentrations with the present repeated dose sche¬
dule were simulated according to the superimposition principle
[Wagner 1975]. These concentrations of glucuronide and sulphate
conjugates were closely related to the plasma creatinine concentra¬
tion (r = 0.89 and 0.95 respectively. P < 0.01). and the corresponding
regression equations were used to predict the minimum concentra¬
tions at steady-stale in the present study.
Statistical differences between the groups were determined by






Fig.l. Mean daily plasma concentrations of paracetamol ( □ ) and its
glucuronide (a) and sulphate (o) conjugates in 6 patients with
chronic renal failure taking paracetamol (1 g t.d.s.) for 10 days
□—□ Paracetamol A—A GlucuronideO—O Sulphate
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Table 2. Mean daily pre-dose plasma concentrations of paracetamol and of its glucuronide and sulphate metabolites (mg 1 ') in 6 healthy vol¬
unteers and 6 patients with chronic renal failure treated with paracetamol (1.0 g t.d.s.) for 10 days
Dav
1 2 3 4 5 6 7-10" 14
Paracetamol concentrations• (nig ■ I ■')
Healthy volunteers 1.3 (0.5) 1.4 (0.5) 1.2 (0.5) 1.2 (0.7) 1.7 (1.6) 1.5 (0.7) 0.8 (0.5) ND
Renal failure patients 2.4 (0.4) 2.7 (0-7) 3.1 (1.1) 2.9 (0.9) 2.7 (1.5) 4.7 (3.4) 3.1 (1.3) ND
Glucuronide concentrations (nig ■ /~j
Healthy volunteers 2.9 (0.8) 3.8 (1.3) 3.7 (0.9) 3.9 (1.4) 2.6 (1.5) 4.5 (1.3) 3.0 (0.5) 0.3 (0.6)
Renal failure patients 39 (19) 58 (36) 68 (47) 69 (51) 78 (61) 87 (67) 87 (69) 4.4 (7.0)
Sulphate concentrations (nig ■! ')
Healthy volunteers 1.7 (0.6) 1.6 (0.4) 1.4 (0.6) 1.4 (0.6) 1.7 (1.0) 1.9 (0.9) 1.1 (0.4) 0.5 (0.3)
Renal failure patients 22 (H) 25 (16) 26 (19) 24 (17) 25 (21) 27 (28) 25 (19) 1.4(1.9)
ND = not detectable
"
mean of concentrations on days 7-10
Glucuronide and sulphate conjugates
As expected the mean daily concentrations of the
conjugates were markedly higher in the patients than in
the volunteers, and mean values from the 7th to the 10th
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Fig. 2 a, b. Steady-slate plasma concentrations of (a) the glucuronide
and (b) the sulphate conjugate of paracetamol measured in patients
with chronic renal failure taking paracetamol (1 g t.d.s.) for 10 days
plotted against steady-state concentrations of the (A) glucuronide
and (B) the sulphate conjugate predicted from a previous single-
dose studv
The mean plasma concentration of the sulphate con¬
jugate in the renal failure patients was 21.7 (11.2) mg"1
after the first 24 hand24.5 (18.4) mg T'by the lOthdayof
treatment with little daily variation (Fig. 1). In contrast, the
mean plasma glucuronide concentrations increased pro¬
gressively to 87 (67) mgl"1 on day 6, afterwhich there was
no further accumulation. Thus, mean steady-state concen¬
trations were reached for the sulphate and glucuronide
conjugates by the 2nd and 6th days respectively. However,
there was considerable interindividual variation in the con¬
centrations of retained conjugates at steady state and in the
time taken to reach it. The means of the concentrations
measured on the 7th to 10th days were therefore taken to
represent steady-state values. The steady-state concentra¬
tion of the glucuronide conjugate were positively corre¬
lated with the plasma creatinine concentration (r = 0.97,
P <0.01, n = 6). However, the corresponding correlation
between the steady-state concentrations of the sulphate
conjugate and the plasma creatinine concentration was not
statistically significant (r = 0.74, P > 0.05, n = 6).
Predicted glucuronide and sulphate conjugate
concentrations
The minimum steady-state plasma concentrations of the
glucuronide conjugate predicted from the previous single-
dose studies were remarkably similar to the concentra¬
tions observed at steady state in the patients with renal
failure (Fig. 2 a). However, predictions of the steady-state
concentrations of the sulphate conjugate were accurate in
only 3 of the 6 patients, and were less than 50% of those
expected in the others (Fig.2b). In the patients in whom
the predicted and observed concentrations of sulphate
conjugates were similar the ratios of glucuronide to sul¬
phate conjugates were less than about 3.0, as expected
(2.1, 1.9. and 2.5). whereas in the other three the ratios
were much greater (5.7,4.4, and 5.3).
Cysteine andmercapturate conjugates
The cysteine and mercapturic acid conjugates of paraceta¬
mol were detected only in the plasma of the patientwith the
most severe renal failure and the concentrations were low.
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Plasma concentrations after stopping paracetamol
Paracetamol and its glucuronide and sulphate conjugates
disappeared rapidly from the plasma in both volunteers
and patients once paracetamol was discontinued
(Table 2). Only the two patients with the most severe
renal failure still had detectable amounts of retained con¬
jugates in the plasma 4 days after stopping the paraceta¬
mol.
Discussion
Oral paracetamol is metabolized extensively by conjuga¬
tion with glucuronic acid and sulphate. A small fraction of
the dose is converted to a reactive intermediate metabo¬
lite, which is then conjugated with glutathione and ex¬
creted as cysteine and mercapturate conjugates. Over
90% of a therapeutic dose is normally excreted in the
urine as metabolites within 24 h [Forrest et al. 1982]. In pa¬
tients with renal failure the ability of the kidney to elimi¬
nate polar metabolites is limited, and during repeated dos¬
ing significant accumulation of paracetamol conjugates
was expected.
When patients with chronic renal failure were given 1 g
of paracetamol 3 times daily for 10 days, plasma concen¬
trations of paracetamol were higher than in healthy volun¬
teers taking the same dose. This confirms similar findings
in a single-dose study of paracetamol disposition in pa¬
tients with renal failure [Prescott et al. 1989], The mecha¬
nisms are unknown, but it has been suggested that biliary
excretion of paracetamol conjugates may become more
important when their urinary excretion is reduced in renal
failure [Siegers and Klaassen 1984]. In such circumstances
tiie enterohepatic circulation of glucuronide and sulphate
metabolites may be increased and paracetamol may be re¬
generated by hydrolysis of the conjugates by gastrointesti¬
nal flora, with subsequent reabsorption of the parent drug
[Verbeeck et al. 1981].
The mean plasma concentrations of the sulphate and
glucuronide conjugates were markedly higher in the pa¬
tients with renal failure, and steady state was reached by
about the 2nd and 6th days respectively. The plasma con¬
centrations of the glucuronide conjugate at steady state
depended on the severity of the renal failure, but this rela¬
tionship did not hold for the sulphate conjugate. Similarly,
the steady-state concentration of the glucuronide con¬
jugate could be accurately predicted from single-dose
studies, but the accumulation of the sulphate conjugate
was much less than predicted in 3 of the 6 patients.
Long-term or high-dose paracetamol therapy is associ¬
ated with a reduced rate of formation of the sulphate con¬
jugate, which is due primarily to sulphate depletion [Levy
& Yamada 1971; Lin & Levy 1981; Clements et al. 1984],
although the serum concentrations of inorganic sulphate
are not invariably lower than normal [Hendrix-Treacy et
al. 1976], This may have limited the amount of sulphate
conjugates formed over the 10-day dosing period in some
of our patients. However, chronic renal failure is often as¬
sociated with sulphate retention [Freeman & Richards
U. Martin et al.: Paracetamol disposition in renal failure 1
1979], and so depletion is less likely to occur even with
large doses of paracetamol [Lin & Levy 1982]. The pa¬
tients were taking other medications and it is conceivable
that this might have influenced paracetamol metabolism.
Whatever the mechanism, it is clear that the sulphate
conjugation of paracetamol was limited in our patients.
Consequently, the concentrations of the glucuronide con¬
jugate were relatively higher, as shown by the increased
ratio of glucuronide:sulphate conjugates at steady slate.
Normally the ratio of glucuronide:su!phate conjugates
formed is about 2:1 [Forrest et al. 1982]. This relationship
was maintained in the three patients in whom the pre¬
dicted and observed steady-state concentration of sul¬
phate conjugate were similar, but not in the other three.
Further studies of the apparent non-linear sulphate con¬
jugation of paracetamol in patients with renal failure are
indicated, at a range of paracetamol doses, with simulta¬
neous measurement of the serum inorganic sulphate con¬
centrations.
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